{"ctNumber":"2024-515022-88-00","ctStatus":"Authorised","startDateEU":"2025-03-03","decisionDate":"2025-02-10T15:44:41.236","publishDate":"2026-11-17T02:37:36.477588261","ctPublicStatusCode":5,"authorizedApplication":{"authorizedPartI":{"id":142543,"rowSubjectCount":505,"rowCountriesInfo":[{"eutctId":100000000482,"name":"New Zealand","isoNumber":554,"isoAlpha2Code":"NZ","isoAlpha3Code":"NZL","current":true},{"eutctId":100000000557,"name":"United States","isoNumber":840,"isoAlpha2Code":"US","isoAlpha3Code":"USA","current":true},{"eutctId":100000000354,"name":"Canada","isoNumber":124,"isoAlpha2Code":"CA","isoAlpha3Code":"CAN","current":true},{"eutctId":100000000556,"name":"United Kingdom","isoNumber":826,"isoAlpha2Code":"GB","isoAlpha3Code":"GBR","current":true},{"eutctId":100000000329,"name":"Australia","isoNumber":36,"isoAlpha2Code":"AU","isoAlpha3Code":"AUS","current":true}],"products":[{"id":594731,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11576174","productPharmForm":"INJECTION","euMpNumber":"PRD11516336","prodAuthStatus":1,"prodName":"ANX007","pharmForm":"INJECTION","sponsorProductCode":"ANX007","activeSubstanceName":"ANX007","euSubstNumber":"SUB329239","nameOrg":"ANNEXON, INC.","productSubstances":[{"productPk":"11576174","substancePk":"329255","nameOrg":"ANNEXON, INC.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"ANX007","substanceEvCode":"SUB329239"}],"activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"000","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"000","maxTreatmentPeriod":24,"timeUnitCode":"3","evCode":"PRD11516336","sponsorProductCodeEdit":"ANX007","miaNumber":"104478","devices":[],"characteristics":["7"],"routes":["INTRAVITREAL USE"],"allSubstancesChemicals":false,"productName":"ANX007","jsonActiveSubstanceNames":"anx007","pharmaceuticalFormDisplay":"INJECTION"}],"trialDetails":{"clinicalTrialIdentifiers":{"fullTitle":"A Phase 3, Multicenter, Randomized, Parallel-Group, Double-Masked, 2-Arm, Sham Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Participants with  Dry Age-Related Macular Degeneration with Geographic Atrophy","fullTitleTranslations":[{"id":12069926,"uuid":"462cb649-f77d-4a21-a282-147ece9c538e","attributeTranslation":"Estudio de fase 3, multicéntrico, aleatorizado, doble enmascarado, controlado con tratamiento simulado y con 2 grupos paralelos sobre la eficacia, la seguridad y la tolerabilidad de ANX007 administrado mediante inyección intravítrea en  participantes con degeneración macular asociada a la edad seca con atrofia geográfica.","language":7,"languageDescription":"Spanish"},{"id":12069930,"uuid":"462cb649-f77d-4a21-a282-147ece9c538e","attributeTranslation":"Een gerandomiseerd, dubbelblind, multicenter, met nepbehandeling gecontroleerd fase 3-onderzoek met 2 groepen naar de werkzaamheid, veiligheid en verdraagbaarheid van ANX007, toegediend via intravitreale injectie bij patiënten met droge leeftijdsgerelateerde maculadegeneratie met geografische atrofie","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12069929,"uuid":"462cb649-f77d-4a21-a282-147ece9c538e","attributeTranslation":"Eine multizentrische, randomisierte, doppelblinde, zweiarmige, scheinkontrollierte \nParallelgruppenstudie der Phase III zur Wirksamkeit, Sicherheit und \nVerträglichkeit von ANX007, das durch intravitreale Injektion verabreicht wird, \nbei Teilnehmern mit einer trockenen altersbedingten\nMakuladegeneration mit geografischer Atrophie","language":27,"languageDescription":"German (Austria)"},{"id":12069927,"uuid":"462cb649-f77d-4a21-a282-147ece9c538e","attributeTranslation":"Wieloośrodkowe, randomizowane badanie fazy III, prowadzone metodą podwójnie ślepej próby w grupach równoległych, z dwiema grupami terapeutycznymi, z grupą kontrolną otrzymującą leczenie pozorowane, mające na celu ocenę skuteczności, bezpieczeństwa stosowania i tolerancji ANX007 podawanego we wstrzyknięciu doszklistkowym u uczestników z  suchą postacią zwyrodnienia plamki żółtej związanego z wiekiem z zanikiem geograficznym","language":19,"languageDescription":"Polish"},{"id":12069928,"uuid":"462cb649-f77d-4a21-a282-147ece9c538e","attributeTranslation":"III. fázisú, többközpontú, randomizált, párhuzamos csoportos, kettős maszkolású, kétkaros, színlelt beavatkozással kontrollált vizsgálat az intravitreális injekció formájában alkalmazott ANX007 hatásosságáról, biztonságosságáról és tolerálhatóságáról az geografikus atrofiával társuló időskori száraz makuladegenerációban szenvedő résztvevőknél","language":13,"languageDescription":"Hungarian"},{"id":12069931,"uuid":"462cb649-f77d-4a21-a282-147ece9c538e","attributeTranslation":"Étude de phase 3, multicentrique, randomisée, en groupes parallèles, en double aveugle, à 2 bras, versus procédure factice, visant à évaluer l’efficacité, la sécurité d'emploi et la tolérabilité de l’ANX007 administré par injection intravitréenne chez des participatients atteints de dégénérescence maculaire liée à l’âge sèche avec atrophie géographique","language":10,"languageDescription":"French"}],"publicTitle":"A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Participants with Dry Age-Related Macular Degeneration with Geographic Atrophy","publicTitleTranslations":[{"id":12069988,"uuid":"f1b1513a-9e19-4041-b030-fa6a36199305","attributeTranslation":"Étude visant à évaluer l’efficacité et la sécurité d’emploi des injections intravitréennes (IVT) d’ANX007 chez des participants atteints de dégénérescence maculaire liée à l’âge sèche avec atrophie géographique (AG)","language":10,"languageDescription":"French"},{"id":12069987,"uuid":"f1b1513a-9e19-4041-b030-fa6a36199305","attributeTranslation":"Badanie mające na celu ocenę skuteczności i bezpieczeństwa stosowania wstrzyknięć doszklistkowych ANX007 u  uczesntików z suchą postacią zwyrodnienia plamki żółtej związanego z wiekiem z zanikiem geograficznym","language":19,"languageDescription":"Polish"},{"id":12069991,"uuid":"f1b1513a-9e19-4041-b030-fa6a36199305","attributeTranslation":"Een onderzoek naar de werkzaamheid en veiligheid van injecties met ANX007 in het oog bij patiënten met droge leeftijdsgerelateerde \nmaculadegeneratiemet met geografische atrofie","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12069989,"uuid":"f1b1513a-9e19-4041-b030-fa6a36199305","attributeTranslation":"Eine Studie zur Untersuchung der Wirksamkeit und Sicherheit intravitrealer (IVT) Injektionen von ANX007 bei Teilnehmern mit einer trockenen altersbedingten Makuladegeneration mit geografischer Atrophie","language":27,"languageDescription":"German (Austria)"},{"id":12069990,"uuid":"f1b1513a-9e19-4041-b030-fa6a36199305","attributeTranslation":"Vizsgálat, amely az ANX007 intravitreális injekcióinak hatékonyságát és biztonságosságát vizsgálja geografikus atrófiával társuló időskori száraz makuladegenerációban szenvedő résztvevőknél","language":13,"languageDescription":"Hungarian"},{"id":12069986,"uuid":"f1b1513a-9e19-4041-b030-fa6a36199305","attributeTranslation":"Un estudio que investiga la eficacia y seguridad de ANX007 administrado mediante inyección intravítrea  en  participantes con degeneración macular asociada a la edad seca con atrofia geográfica","language":7,"languageDescription":"Spanish"}],"shortTitle":"ANX007-GA-02","secondaryIdentifyingNumbers":{"nctNumber":{"id":576905,"number":"NCT06510816"},"additionalRegistries":[]}},"trialInformation":{"trialCategory":{"isLowIntervention":false,"trialPhase":"5","trialCategory":"2","justificationForTrialCategory":"This is a phase III trial","trialCategoryId":131857},"medicalCondition":{"partIMedicalConditions":[{"id":149401,"medicalCondition":"Dry Age-Related Macular Degeneration (AMD) with geographic atrophy (GA)","medicalConditionTranslations":[{"id":12069800,"uuid":"cda98b0c-c3eb-40ee-89d4-1500c69764ac","attributeTranslation":"dégénérescence maculaire liée à l’âge sèche avec atrophie géographique","language":10,"languageDescription":"French"},{"id":12069802,"uuid":"cda98b0c-c3eb-40ee-89d4-1500c69764ac","attributeTranslation":"Sucha postać  zwyrodnienia plamki żółtej związanego z wiekiem z zanikiem geograficznym","language":19,"languageDescription":"Polish"},{"id":12069804,"uuid":"cda98b0c-c3eb-40ee-89d4-1500c69764ac","attributeTranslation":"a geografikus atrófiával (GA) társuló  időskori száraz makuladegeneráció (AMD)","language":13,"languageDescription":"Hungarian"},{"id":12069803,"uuid":"cda98b0c-c3eb-40ee-89d4-1500c69764ac","attributeTranslation":"Degeneración macular asociada a la edad seca (DMAE) con atrofia geográfica (GA)","language":7,"languageDescription":"Spanish"},{"id":12069801,"uuid":"cda98b0c-c3eb-40ee-89d4-1500c69764ac","attributeTranslation":"Trockene altersbedingten Makuladegeneration (AMD) mit geografischer Atrophie","language":27,"languageDescription":"German (Austria)"},{"id":12069805,"uuid":"cda98b0c-c3eb-40ee-89d4-1500c69764ac","attributeTranslation":"Droge leeftijdsgerelateerde maculadegeneratie (AMD) met geografische atrofie (GA)","language":37,"languageDescription":"Dutch (Netherlands)"}],"isConditionRareDisease":false}],"meddraConditionTerms":[{"termId":100000070107,"version":"20.1","level":"LLT","termName":"Geographic atrophy","classificationCode":"10063947","organClass":10015919,"active":false}]},"trialObjective":{"trialScopes":[{"code":"4","trialScopeId":433645},{"code":"13","otherDescription":"Tolerability","trialScopeId":433644},{"code":"5","trialScopeId":433643}],"mainObjective":"To evaluate efficacy of intravitreal (IVT) injections of ANX007 on visual function and visual acuity","mainObjectiveTranslations":[{"id":12069980,"uuid":"f1967912-4a5b-4951-a5d4-f76dbf690e01","attributeTranslation":"Az ANX007 intravitreális (IVT) injekcióinak látásfunkcióra és látásélességre gyakorolt hatásosságának értékelése","language":13,"languageDescription":"Hungarian"},{"id":12069984,"uuid":"f1967912-4a5b-4951-a5d4-f76dbf690e01","attributeTranslation":"Evaluar la eficacia de las inyecciones intravítreas (IVT) de ANX007 sobre la función y agudeza visuales.","language":7,"languageDescription":"Spanish"},{"id":12069983,"uuid":"f1967912-4a5b-4951-a5d4-f76dbf690e01","attributeTranslation":"Ocena skuteczności wstrzyknięć doszklistkowych (IVT) ANX007 w zakresie poprawy czynności narządu wzroku i ostrości widzenia","language":19,"languageDescription":"Polish"},{"id":12069982,"uuid":"f1967912-4a5b-4951-a5d4-f76dbf690e01","attributeTranslation":"Het beoordelen van de werkzaamheid van intravitreale (IVT) injecties met ANX007 op visuele functie en gezichtsscherpte","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12069981,"uuid":"f1967912-4a5b-4951-a5d4-f76dbf690e01","attributeTranslation":"Évaluer l’efficacité des injections intravitréennes (IVT) d’ANX007 sur la fonction visuelle et l’acuité visuelle","language":10,"languageDescription":"French"},{"id":12069985,"uuid":"f1967912-4a5b-4951-a5d4-f76dbf690e01","attributeTranslation":"Beurteilung der Wirksamkeit von intravitrealen (IVT) Injektionen von ANX007 auf die Sehfunktion und die Sehschärfe","language":27,"languageDescription":"German (Austria)"}],"secondaryObjectives":[{"id":510704,"number":1,"secondaryObjective":"1. To evaluate efficacy of IVT injections of ANX007 on secondary measures of visual function and visual acuity","secondaryObjectiveTranslations":[{"id":12069993,"uuid":"6b4a6990-57d0-40cd-aba1-83a5f5a3d866","attributeTranslation":"Ocena skuteczności wstrzyknięć IVT ANX007 w zakresie  drugorzędowych miar czynności narządu wzroku i ostrości widzenia","language":19,"languageDescription":"Polish"},{"id":12069996,"uuid":"6b4a6990-57d0-40cd-aba1-83a5f5a3d866","attributeTranslation":"Beurteilung der Wirksamkeit von IVT-Injektionen von ANX007 auf  sekundäre Messungen der Sehfunktion und der Sehschärfe","language":27,"languageDescription":"German (Austria)"},{"id":12069994,"uuid":"6b4a6990-57d0-40cd-aba1-83a5f5a3d866","attributeTranslation":"Evaluar la eficacia de las inyecciones IVT de ANX007 sobre mediciones secundarias de la función y agudeza visuales.","language":7,"languageDescription":"Spanish"},{"id":12069995,"uuid":"6b4a6990-57d0-40cd-aba1-83a5f5a3d866","attributeTranslation":"Évaluer l’efficacité des injections IVT d’ANX007 sur des mesures secondaires de la fonction visuelle et de l’acuité visuelle","language":10,"languageDescription":"French"},{"id":12069992,"uuid":"6b4a6990-57d0-40cd-aba1-83a5f5a3d866","attributeTranslation":"Az ANX007 IVT injekcióinak a látásfunkcióra és látásélességre vonatkozó  másodlagos mutatókra gyakorolt hatásosságának értékelése","language":13,"languageDescription":"Hungarian"},{"id":12069997,"uuid":"6b4a6990-57d0-40cd-aba1-83a5f5a3d866","attributeTranslation":"Het beoordelen van de werkzaamheid van IVT-injecties met ANX007 op secundaire metingen van visuele functie en gezichtsscherpte","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":510705,"number":2,"secondaryObjective":"2. To compare the change in total loss of the ellipsoid zone (EZ) layer with IVT injections of ANX007 vs Sham control","secondaryObjectiveTranslations":[{"id":12069998,"uuid":"371fd3f5-036a-4c9e-b113-7e4906537b98","attributeTranslation":"Porównanie zmiany w zakresie całkowitej utraty warstwy fotoreceptorów strefy elipsoidalnej (EZ)  pomiędzy grupą otrzymującą wstrzyknięcia IVT ANX007 a grupą poddawaną leczeniu pozorowanemu","language":19,"languageDescription":"Polish"},{"id":12070003,"uuid":"371fd3f5-036a-4c9e-b113-7e4906537b98","attributeTranslation":"Comparer le changement de la perte totale de la couche de la zone ellipsoïde (ellipsoid zone, EZ) avec des injections IVT d’ANX007 par rapport à la procédure témoin factice","language":10,"languageDescription":"French"},{"id":12070001,"uuid":"371fd3f5-036a-4c9e-b113-7e4906537b98","attributeTranslation":"Az ellipszoid zóna (EZ) rétegben bekövetkező teljes csökkenés  változásának összehasonlítása az ANX007 IVT injekciók, illetve a színlelt kontroll között","language":13,"languageDescription":"Hungarian"},{"id":12070002,"uuid":"371fd3f5-036a-4c9e-b113-7e4906537b98","attributeTranslation":"Vergleich der Veränderung von totalem Verlust der Ellipsoidzonen(EZ)-Schicht  mit IVT-Injektionen von ANX007 versus Scheinkontrolle","language":27,"languageDescription":"German (Austria)"},{"id":12070000,"uuid":"371fd3f5-036a-4c9e-b113-7e4906537b98","attributeTranslation":"Het vergelijken van de  verandering in totaal verlies van de ellipsoïde zone (EZ)-laag met IVT-injecties met ANX007 vs. nepbehandeling","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12069999,"uuid":"371fd3f5-036a-4c9e-b113-7e4906537b98","attributeTranslation":"Comparar el cambio en la pérdida total de la capa de la zona elipsoide (ZE) con las inyecciones IVT de ANX007 frente al tratamiento simulado de control.","language":7,"languageDescription":"Spanish"}]},{"id":510706,"number":3,"secondaryObjective":"3. To compare the change in [CCI] IVT injections of ANX007 vs Sham control","secondaryObjectiveTranslations":[{"id":12070007,"uuid":"0e4a331a-e335-40f2-b5d0-a39a83c3b52c","attributeTranslation":"Comparer le changement [CCI] avec des injections IVT d’ANX007 et une procédure témoin factice","language":10,"languageDescription":"French"},{"id":12070008,"uuid":"0e4a331a-e335-40f2-b5d0-a39a83c3b52c","attributeTranslation":"Vergleich der Veränderung [CCI]  mit IVT-Injektionen von ANX007 versus Scheinkontrolle","language":27,"languageDescription":"German (Austria)"},{"id":12070006,"uuid":"0e4a331a-e335-40f2-b5d0-a39a83c3b52c","attributeTranslation":"[CCI] csökkenés változásának összehasonlítása az ANX007 IVT injekciók, illetve a színlelt kontroll között","language":13,"languageDescription":"Hungarian"},{"id":12070009,"uuid":"0e4a331a-e335-40f2-b5d0-a39a83c3b52c","attributeTranslation":"Comparar el cambio en [CCI] con las inyecciones IVT de ANX007 frente al tratamiento simulado de control.","language":7,"languageDescription":"Spanish"},{"id":12070004,"uuid":"0e4a331a-e335-40f2-b5d0-a39a83c3b52c","attributeTranslation":"Het vergelijken van de verandering in [CCI] met IVT-injecties met ANX007 vs. nepbehandeling","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12070005,"uuid":"0e4a331a-e335-40f2-b5d0-a39a83c3b52c","attributeTranslation":"Porównanie zmiany [CCI] otrzymującą wstrzyknięcia IVT ANX007 a grupą poddawaną leczeniu pozorowanemu","language":19,"languageDescription":"Polish"}]},{"id":510707,"number":4,"secondaryObjective":"4. To assess the safety and tolerability of IVT injections of ANX007","secondaryObjectiveTranslations":[{"id":12070013,"uuid":"92365d7b-fa94-4406-a573-1cfe28d26099","attributeTranslation":"Az ANX007 IVT injekciók biztonságosságának és tolerálhatóságának felmérése","language":13,"languageDescription":"Hungarian"},{"id":12070012,"uuid":"92365d7b-fa94-4406-a573-1cfe28d26099","attributeTranslation":"Evaluar la seguridad y la tolerabilidad de las inyecciones IVT de ANX007.","language":7,"languageDescription":"Spanish"},{"id":12070011,"uuid":"92365d7b-fa94-4406-a573-1cfe28d26099","attributeTranslation":"Beurteilung der Sicherheit und Verträglichkeit von IVT-Injektionen von ANX007","language":27,"languageDescription":"German (Austria)"},{"id":12070015,"uuid":"92365d7b-fa94-4406-a573-1cfe28d26099","attributeTranslation":"Het beoordelen van de veiligheid en verdraagbaarheid van IVT-injecties met ANX007","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12070010,"uuid":"92365d7b-fa94-4406-a573-1cfe28d26099","attributeTranslation":"Évaluer la sécurité d’emploi et la tolérabilité des injections IVT d’ANX007","language":10,"languageDescription":"French"},{"id":12070014,"uuid":"92365d7b-fa94-4406-a573-1cfe28d26099","attributeTranslation":"Ocena bezpieczeństwa i tolerancji wstrzyknięć IVT ANX007","language":19,"languageDescription":"Polish"}]},{"id":510708,"number":5,"secondaryObjective":"5. To assess patient reported outcomes","secondaryObjectiveTranslations":[{"id":12070018,"uuid":"858aa933-89b5-4959-9808-08c6b2950b2e","attributeTranslation":"Het beoordelen van door de patiënt gerapporteerde resultaten","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12070016,"uuid":"858aa933-89b5-4959-9808-08c6b2950b2e","attributeTranslation":"Evaluar los resultados comunicados por los pacientes.","language":7,"languageDescription":"Spanish"},{"id":12070019,"uuid":"858aa933-89b5-4959-9808-08c6b2950b2e","attributeTranslation":"A betegek által jelentett kimenetelek értékelése","language":13,"languageDescription":"Hungarian"},{"id":12070020,"uuid":"858aa933-89b5-4959-9808-08c6b2950b2e","attributeTranslation":"Ocena wyników na podstawie opinii pacjentów","language":19,"languageDescription":"Polish"},{"id":12070017,"uuid":"858aa933-89b5-4959-9808-08c6b2950b2e","attributeTranslation":"Évaluer les résultats rapportés par les patients","language":10,"languageDescription":"French"},{"id":12070021,"uuid":"858aa933-89b5-4959-9808-08c6b2950b2e","attributeTranslation":"Beurteilung der subjektiv von Patienten angegebenen Ergebnisse","language":27,"languageDescription":"German (Austria)"}]}]},"eligibilityCriteria":{"principalInclusionCriteria":[{"id":971509,"number":1,"principalInclusionCriteria":"1.\tFellow eyes treated with an approved anti-complement drug or other locally-administered treatment for GA that was initiated at least 4 weeks prior to randomization may continue treatment with no washout. Fellow eyes treated with an approved therapy for GA for fewer than 4 weeks should not be randomized in the study. GA -treatment-naive fellow eyes should, in the opinion of the Investigator, be unlikely to need treatment for GA in the fellow eye for at least the first year of the study.","principalInclusionCriteriaTranslations":[{"id":12069935,"uuid":"8721b903-a8e4-4f2b-b723-edb06be35531","attributeTranslation":"1.\tSe podrá continuar el tratamiento del otro ojo tratado con un fármaco anti-complemento aprobado u otro tratamiento administrado localmente para la AG que se hubiera iniciado  al menos 4 semanas antes de la  aleatorización sin requerir un período de reposo farmacológico. El otro ojo tratado con un tratamiento aprobado para la AG durante menos de 4 semanas no debe  aleatorizarse en el estudio. El otro ojo sin tratamiento previo para la AG, según la opinión del investigador,  no debería necesitar tratamiento para la AG en el otro ojo, al menos durante el primer año del estudio.","language":7,"languageDescription":"Spanish"},{"id":12069933,"uuid":"8721b903-a8e4-4f2b-b723-edb06be35531","attributeTranslation":"\"1.\tPartneraugen, die seit mindestens 4 Wochen vor Randomisierung zum ersten Mal mit einem zugelassenen Anti-Komplement-Medikament oder anderen lokal verabreichten Behandlung gegen GA behandelt wurden, können die Behandlung ohne Washout fortsetzen. Partneraugen, die über weniger als 4 Wochen mit einerm zugelassenen Therapie gegen GA behandelt wurden, sollten nicht in die Studie randomisiert werden. Nicht GA-vorbehandelte Partneraugen sollten nach Ansicht des Prüfarztes mindestens im ersten Jahr der Studie wahrscheinlich keine Behandlung für GA im Partnerauge benötigen.\"","language":27,"languageDescription":"German (Austria)"},{"id":12069936,"uuid":"8721b903-a8e4-4f2b-b723-edb06be35531","attributeTranslation":"1. Un traitement de l’autre œil par un médicament anti-complément approuvé ou un autre traitement administré localement pour \nl’AG qui a été instauré au moins 4 semaines avant la randomisation t de l’étude peut se poursuivre sans \nnécessiter une période sans traitement. Les participants dont l’autre œil est traité par \nun traitement approuvé pour l’AG depuis moins de 4 semaine \nne doivent pas être randomisés dans l’étude. Les participants dont l’autre œil est naïf de \ntraitement contre l’AG doivent, de l’avis de l’investigateur, être peu susceptibles\nde nécessiter un traitement pour une AG dans l’autre œil pendant au moins la \npremière année de l’étude.","language":10,"languageDescription":"French"},{"id":12069937,"uuid":"8721b903-a8e4-4f2b-b723-edb06be35531","attributeTranslation":"1.     A randomizálást megelőzően legalább  4 héttel korábban indított, GA-ra jóváhagyott komplementerellenes gyógyszerrel vagy más, helyileg alkalmazott terápiával kezelt másik szem esetén a kezelés kimosás nélkül folytatható. A terápiával kezelt másik szem esetén a beteg nem randomizálható a vizsgálatban. A GA-kezelésben még nem részesült másik szem esetén a vizsgálatvezető véleménye szerint a betegnek valószínűleg nem lesz szüksége kezelésre a másik szemet érintő GA miatt legalább a vizsgálat első évében.","language":13,"languageDescription":"Hungarian"},{"id":12069934,"uuid":"8721b903-a8e4-4f2b-b723-edb06be35531","attributeTranslation":"1.\tVoor de andere ogen die ten minste 4 weken voorafgaand aan de randomisatie zijn behandeld met een goedgekeurd anti-complement-geneesmiddel of een andere lokaal toegediende behandeling voor GA, kan de behandeling worden voortgezet zonder uitwassing. De andere ogen die minder dan 4 weken zijn behandeld met een goedgekeurde behandeling  voor GA mogen niet in het onderzoek worden gerandomiseerd. Andere ogen die GA-behandelingsnaïef zijn, zouden naar het oordeel van de onderzoeker waarschijnlijk niet behandeld moeten worden voor GA gedurende ten minste het eerste jaar van het onderzoek.","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12069932,"uuid":"8721b903-a8e4-4f2b-b723-edb06be35531","attributeTranslation":"1.\tUczestnicy, których drugie oko jest leczone dopuszczonym do stosowania lekiem przeciwko składowym dopełniacza lub innym podawanym miejscowo lekiem z powodu GA od co najmniej 4 tygodni przed randomizacją, mogą kontynuować leczenie bez zachowania okresu wypłukiwania. W ramach badania nie należy randomizować osób, których drugie oko jest poddawane dopuszczalnemu leczeniu z powodu GA przez okres krótszy niż 4 tygodnie Jeżeli drugie oko nie było poddawane leczeniu z powodu GA, w ocenie badacza nie powinno ono wymagać leczenia GA przez co najmniej pierwszy rok badania.","language":19,"languageDescription":"Polish"}]},{"id":971510,"number":2,"principalInclusionCriteria":"2.\tParticipant must be at least 50 years of age at the time of signing the informed consent.","principalInclusionCriteriaTranslations":[{"id":12069941,"uuid":"141e87f6-67a3-40e7-a48d-031973faa63a","attributeTranslation":"2.\tDer Teilnehmer muss zum Zeitpunkt der Unterzeichnung der Teilnehmerinformation und Einwilligungserklärung mindestens 50 Jahre alt sein.","language":27,"languageDescription":"German (Austria)"},{"id":12069939,"uuid":"141e87f6-67a3-40e7-a48d-031973faa63a","attributeTranslation":"2. Le/La participant(e) doit être âgé(e) d’au moins 50 ans au moment de la signature \ndu consentement éclairé.","language":10,"languageDescription":"French"},{"id":12069943,"uuid":"141e87f6-67a3-40e7-a48d-031973faa63a","attributeTranslation":"\"2.\tDe deelnemer moet ten minste 50 jaar oud zijn op het moment van ondertekening van de geïnformeerde toestemming.\"","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12069942,"uuid":"141e87f6-67a3-40e7-a48d-031973faa63a","attributeTranslation":"2. El participante debe tener al menos 50 años en el momento de firmar el consentimiento informado.","language":7,"languageDescription":"Spanish"},{"id":12069938,"uuid":"141e87f6-67a3-40e7-a48d-031973faa63a","attributeTranslation":"2.\tUczestnik w wieku co najmniej 50 lat w momencie podpisywania formularza świadomej zgody.","language":19,"languageDescription":"Polish"},{"id":12069940,"uuid":"141e87f6-67a3-40e7-a48d-031973faa63a","attributeTranslation":"2.\tA résztvevőknek a tájékoztatás utáni beleegyező nyilatkozat aláírásának időpontjában legalább 50 évesnek kell lennie","language":13,"languageDescription":"Hungarian"}]},{"id":971511,"number":3,"principalInclusionCriteria":"3.\t Able and willing to participate in a 24-month study with monthly visits.","principalInclusionCriteriaTranslations":[{"id":12069946,"uuid":"4cf6b313-3dc0-4042-bc68-5bd8012cfea5","attributeTranslation":"3.\tFähigkeit und Bereitschaft zur Teilnahme an einer 24-monatigen Studie mit monatlichen Besuchsterminen.","language":27,"languageDescription":"German (Austria)"},{"id":12069948,"uuid":"4cf6b313-3dc0-4042-bc68-5bd8012cfea5","attributeTranslation":"3.\tIn staat en bereid zijn om deel te nemen aan een 24 maanden durend onderzoek met maandelijkse bezoeken.","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12069949,"uuid":"4cf6b313-3dc0-4042-bc68-5bd8012cfea5","attributeTranslation":"3. Capacité et volonté de participer à une étude de 24 mois impliquant des visites \nmensuelles.","language":10,"languageDescription":"French"},{"id":12069944,"uuid":"4cf6b313-3dc0-4042-bc68-5bd8012cfea5","attributeTranslation":"3. Ser capaz y estar dispuesto a participar en un estudio de 24 meses con visitas.","language":7,"languageDescription":"Spanish"},{"id":12069945,"uuid":"4cf6b313-3dc0-4042-bc68-5bd8012cfea5","attributeTranslation":"Képes és hajlandó részt venni egy 24 hónapos, havi vizitekkel járó vizsgálatban","language":13,"languageDescription":"Hungarian"},{"id":12069947,"uuid":"4cf6b313-3dc0-4042-bc68-5bd8012cfea5","attributeTranslation":"3.\tZdolność i chęć udziału w trwającym 24 miesiące badaniu obejmującym comiesięczne wizyty.","language":19,"languageDescription":"Polish"}]},{"id":971512,"number":4,"principalInclusionCriteria":"4.\tDiagnosis of dry AMD with GA as determined by the Investigator and confirmed by the independent Central Reading Center.","principalInclusionCriteriaTranslations":[{"id":12069954,"uuid":"b6bec0a5-94e9-4387-9d90-090b4a108c24","attributeTranslation":"\"4.\tRozpoznanie suchej postaci AMD z GA, stwierdzone przez badacza i potwierdzone przez niezależny Centralny Ośrodek Odczytów.\"","language":19,"languageDescription":"Polish"},{"id":12069951,"uuid":"b6bec0a5-94e9-4387-9d90-090b4a108c24","attributeTranslation":"\"4.\tDiagnose van  droge AMD met GA, zoals bepaald door de onderzoeker en bevestigd door het onafhankelijke CRC (Centraal leescentrum).\"","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12069950,"uuid":"b6bec0a5-94e9-4387-9d90-090b4a108c24","attributeTranslation":"\"4.\tDiagnóstico de  DMAE seca con GA según la determinación del investigador y confirmado por el centro independiente de lecturas centralizadas.\"","language":7,"languageDescription":"Spanish"},{"id":12069952,"uuid":"b6bec0a5-94e9-4387-9d90-090b4a108c24","attributeTranslation":"4. A GA-hoz társuló száraz AMD diagnózisa, a vizsgáló által megállapítva és a független központi leletezőközpont által megerősítve.","language":13,"languageDescription":"Hungarian"},{"id":12069953,"uuid":"b6bec0a5-94e9-4387-9d90-090b4a108c24","attributeTranslation":"\"4. Diagnostic de DMLA sèche avec d’AG, tel que déterminé par \nl’investigateur et confirmé par le centre de lecture central indépendant.\"","language":10,"languageDescription":"French"},{"id":12069955,"uuid":"b6bec0a5-94e9-4387-9d90-090b4a108c24","attributeTranslation":"\"4.\tDiagnose  von trockener AMD mit GA, bestimmt durch den Prüfarzt und bestätigt durch das unabhängige zentrale Auswertungszentrum.\"","language":27,"languageDescription":"German (Austria)"}]},{"id":971513,"number":5,"principalInclusionCriteria":"5. The GA lesion must have the following characteristics as determined by the independent Central Reading Center based on assessment of FAF imaging at screening. If both eyes are confirmed to be eligible by the independent Central Reading Center, the determination of the study eye selection is in the opinion of the Investigator. a.\tWell-demarcated GA with a total area (baseline lesion size) ≥2.5 mm2 and ≤ 17.5 mm2. b.\tIf GA is multifocal, at least one focal lesion must measure ≥1.25 mm2 with the overall aggregate area of GA as specified above in 5a. c.\tPresence of hyper autofluorescence, any pattern, in the junctional zone of the GA. Absence of hyper autofluorescence (ie., pattern = none) is exclusionary. d.\tThe entire GA lesion must be completely visualized on the macula centered image and must be able to be imaged in its entirety and not contiguous with any peripapillary atrophy.","principalInclusionCriteriaTranslations":[{"id":12069957,"uuid":"3ad639e8-6db6-4af7-9f4a-cbe73a583ea1","attributeTranslation":"5.\tZmiana GA musi mieć następujące cechy określone przez niezależny Centralny Ośrodek Odczytów w oparciu o analizę obrazu FAF podczas badań przesiewowych. Jeżeli niezależny Centralny Ośrodek Odczytów potwierdzi, że oboje oczu kwalifikuje się do udziału w badaniu, decyzja o wyborze badanego oka należy do badacza.\na.\tDobrze odgraniczony GA obejmujący całkowity obszar (rozmiar zmiany wyjściowej) ≥2,5 mm2 i ≤ 17,5 mm2.\nb.\tJeśli GA jest wieloogniskowy, co najmniej jedna zmiana ogniskowa musi mierzyć ≥1,25 mm2 , zaś ogólny obszar objęty GA musi mieć wielkość określoną powyżej w punkcie 5a.\nc.\tObecność zmian hiperautofluorescencyjnych o dowolnym wzorze w strefie przejściowej GA. Brak zmian hiperautofluorescencyjnych (tj. wzór = brak zmian) jest czynnikiem wykluczającym.\nd.\tCała zmiana GA musi być w pełni widoczna na obrazie z wyśrodkowaną plamką, musi być możliwa do zobrazowania w całości i nie może przylegać do żadnego obszaru zaniku okołotarczowego.","language":19,"languageDescription":"Polish"},{"id":12069956,"uuid":"3ad639e8-6db6-4af7-9f4a-cbe73a583ea1","attributeTranslation":"5.\tDe GA-laesie moet de volgende kenmerken hebben, zoals bepaald door het onafhankelijke CRC op basis van beoordeling van FAF-beeldvorming bij de screening. Als het onafhankelijke CRC bevestigt dat beide ogen in aanmerking komen, is het de onderzoeker die beslist welk oog het onderzoeksoog wordt.\na.\tGoed afgebakende GA met een totaal gebied (laesiegrootte bij baseline) van ≥ 2,5 mm2 en ≤ 17,5 mm2.\nb.\tAls GA multifocaal is, moet ten minste één focale laesie ≥ 1,25 mm2 groot zijn met het totale geaggregeerde GA-gebied zoals hierboven gespecificeerd in 5a.\nc.\tAanwezigheid van hyperautofluorescentie, elk patroon, in de junctionele zone van de GA. Afwezigheid van hyperautofluorescentie (d.w.z. patroon = geen) is een exclusiecriterium.\nd.\tDe gehele GA-laesie moet volledig zichtbaar zijn op het gecentreerde beeld van de macula en moet in zijn geheel kunnen worden afgebeeld, zonder dat er sprake is van peripapillaire atrofie.","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12069960,"uuid":"3ad639e8-6db6-4af7-9f4a-cbe73a583ea1","attributeTranslation":"5.\tLa lesión por AG debe presentar las siguientes características de acuerdo con la determinación del centro independiente de lecturas centralizadas, en función de la evaluación de las imágenes de la AFF durante la selección. Si el centro de lectura central independiente confirma que ambos ojos son aptos, la asignación como ojo del estudio queda a discreción del investigador.\na.\tAG bien delimitada, con un área total (tamaño basal de la lesión) ≥2,5 mm2 y ≤17,5 mm2.\nb.\tSi la AG es multifocal, al menos una lesión focal debe medir ≥1,25 mm2, con el área total acumulada de AG como se especifica anteriormente en 5a.\nc.\tPresencia de hiperautofluorescencia, cualquier patrón, en la zona de unión de la AG. La ausencia de hiperautofluorescencia (es decir, patrón = ninguno) es excluyente.\nd.\tToda la lesión por AG debe visualizarse por completo en la imagen centrada en la mácula y debe poder visualizarse en su totalidad y no estar contigua a ninguna atrofia peripapilar.","language":7,"languageDescription":"Spanish"},{"id":12069959,"uuid":"3ad639e8-6db6-4af7-9f4a-cbe73a583ea1","attributeTranslation":"5.\tDie GA-Läsion muss die folgenden Merkmale aufweisen, die vom unabhängigen zentralen Auswertungszentrum basierend auf der Beurteilung der FAF-Bildgebung beim Screening bestimmt werden. Wenn vom unabhängigen zentralen Auswertungszentrum bestätigt wird, dass beide Augen geeignet sind, bestimmt der Prüfarzt die Auswahl des Studienauges.\na.\tGut abgegrenztes GA mit einer Gesamtfläche (Baselinegröße der Läsion) ≥ 2,5 mm2 und ≤ 17,5 mm2.\nb.\tWenn es sich um eine multifokale GA handelt, muss mindestens eine fokale Läsion ein Maß von ≥ 1,25 mm2 mit der aggregierten GA-Gesamtfläche wie oben in 5a angegeben besitzen.\nc.\tVorhandensein von Hyperautofluoreszenz, beliebiges Muster, in der Übergangszone des GA. Das Fehlen einer Hyperautofluoreszenz (d. h. Muster = keines) ist ein Ausschlusskriterium.\nd.\tDie gesamte GA-Läsion muss auf dem Makula-zentrierten Bild vollständig visualisiert sein und muss vollständig und nicht an eine peripapilläre Atrophie angrenzend abgebildet werden können.","language":27,"languageDescription":"German (Austria)"},{"id":12069958,"uuid":"3ad639e8-6db6-4af7-9f4a-cbe73a583ea1","attributeTranslation":"5.\tA GA-léziónak a következő jellemzőkkel kell rendelkeznie, amelyet a független központi leletezőközpontnak kell a szűrés során végzett FAF-képalkotás értékelése alapján megállapítania. Ha a független központi leletezőközpont mindkét szem alkalmasságát megerősíti, a vizsgált szem kiválasztása a vizsgálatvezető véleménye szerint történik.\na.\tJól körülhatárolt GA, melynek teljes területe (a lézió kiindulási mérete) ≥2,5 mm2 és ≤17,5 mm2.\nb.\tHa a GA multifokális, legalább egy fokális léziónak ≥1,25 mm2-es méretűnek kell lennie, és a GA teljes összesített területének a fenti 5a. pontban meghatározottaknak kell megfelelnie.\nc.\tHiperautofluoreszcencia jelenléte, bármilyen mintázatban, a GA junkciós zónájában. A hiperautofluoreszcencia hiánya (vagyis ha a mintázat =vagy nincs) kizáró tényező.\nd.\tA teljes GA-léziónak maradéktalanul láthatónak kell lennie makula-központú képen, teljes egészében leképezhetőnek kell lennie, és nem érhet össze peripapilláris atrófiával.","language":13,"languageDescription":"Hungarian"},{"id":12069961,"uuid":"3ad639e8-6db6-4af7-9f4a-cbe73a583ea1","attributeTranslation":"5. La lésion AG doit avoir les caractéristiques suivantes, telles que déterminées \npar le centre de lecture central indépendant sur la base de l’évaluation de \nl’imagerie de la FAF au moment de la sélection. Si l’éligibilité des deux yeux \nest confirmée par le centre de lecture centralisée indépendant, le choix de l’œil à \nl’étude est laissé à l’appréciation de l’investigateur.\na. AG bien délimitée avec une surface totale (taille de la lésion à la \nréférence) ≥ 2,5 mm2\net ≤ 17,5 mm2\n.\nb. Si l’AG est multifocale, au moins une lésion focale doit \nmesurer ≥ 1,25 mm2\navec la surface globale de l’AG comme spécifiée \nci-dessus au point 5a.\nc. Présence d’hyper-autofluorescence, quel que soit le type de halo, au \nniveau de la zone jonctionnelle de l’AG. L’absence d’hyperautofluorescence (c.-à-d. halo = aucun) constitue un critère \nd’exclusion.\nd. L’ensemble de la lésion AG doit être complètement visualisé sur \nl’image centrée sur la macula et doit pouvoir être imagée dans son \nintégralité et ne pas être contiguë à une atrophie péripapillaire.","language":10,"languageDescription":"French"}]},{"id":971514,"number":6,"principalInclusionCriteria":"6.\tNormal luminance BCVA of 45 to 83 letters using ETDRS methodology(20/25 to 20/100 Snellen equivalent, inclusive).  a.\t[CCI]","principalInclusionCriteriaTranslations":[{"id":12069965,"uuid":"ce6a88c4-d6bd-42ac-a35a-24d8ec066de5","attributeTranslation":"\"6.\tMAVC con luminosidad normal de 45 a 83 letras utilizando la metodología del ETDRS (equivalente a unos valores de 20/25 a 20/100 en el test de Snellen, ambos inclusive).\na.\t[CCI]\"","language":7,"languageDescription":"Spanish"},{"id":12069962,"uuid":"ce6a88c4-d6bd-42ac-a35a-24d8ec066de5","attributeTranslation":"\"6.\tBCVA w typowym oświetleniu musi wynosić od 45 do 83 liter za pomocą metodologii ETDRS (co odpowiada od 20/25 do 20/100 dla tablic Snellena, włącznie). \na.\t[CCI]\n\"","language":19,"languageDescription":"Polish"},{"id":12069967,"uuid":"ce6a88c4-d6bd-42ac-a35a-24d8ec066de5","attributeTranslation":"\"6.\tBCVA met normale luminantie van 45 tot en met 83 letters aan de hand van ETDRS-methodologie (20/25 tot en met 20/100 Snellen-equivalent). \na.\t[CCI]\"","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12069966,"uuid":"ce6a88c4-d6bd-42ac-a35a-24d8ec066de5","attributeTranslation":"\"6.\tBCVA bei normaler Leuchtdichte von 45 bis 83 Buchstaben unter Verwendung der ETDRS-Methode (Snellen-Äquivalent von 20/25 bis 20/100 einschließlich). \na.\t[CCI]\"","language":27,"languageDescription":"German (Austria)"},{"id":12069964,"uuid":"ce6a88c4-d6bd-42ac-a35a-24d8ec066de5","attributeTranslation":"\"6. MAVC en luminance normale de 45 à 83 lettres sur la base de la \nméthodologie ETDRS (équivalent Snellen de 20/25 à 20/100 inclus).\na. [CCI]\"","language":10,"languageDescription":"French"},{"id":12069963,"uuid":"ce6a88c4-d6bd-42ac-a35a-24d8ec066de5","attributeTranslation":"\"6. Normál fénysűrűség melletti BCVA 45–83 betű az ETDRS  módszer alapján (20/25–20/100 Snellen-egyenérték, a szélsőértékeket is beleértve).\na.\t[CCI]\n\"","language":13,"languageDescription":"Hungarian"}]},{"id":971515,"number":7,"principalInclusionCriteria":"7.\tA female participant is eligible if she is not pregnant or breastfeeding, and one of the following conditions applies: o\tIs a woman of non-childbearing potential (WONCBP) (defined as having undergone surgical sterilization or being postmenopausal [ie, greater than 50 years old with amenorrhea for at least 12 months without an alternative medical cause]). OR o\tIs a WOCBP using an acceptable contraceptive method during the study intervention period and for at least 30 days after the last dose of study intervention. •\tWOCBP must have a negative pregnancy test (PT) within 24 hours before the first dose of study intervention. •\tThe Investigator has reviewed medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.","principalInclusionCriteriaTranslations":[{"id":12069968,"uuid":"8e0d5ef6-2183-45bb-a383-b2e7bbbaeb74","attributeTranslation":"\"7. Une participante de sexe féminin est éligible si elle n’est pas enceinte, si elle \nn’allaite pas et si elle remplit au moins l’une des conditions suivantes :\no Est une femme n’étant pas en âge de procréer (FNAP) (définie \ncomme ayant subi une stérilisation chirurgicale ou étant \nménopausée [c.-à-d. âgée de plus de 50 ans avec une aménorrhée \ndepuis au moins 12 mois sans autre cause médicale]).\nOU\no Est une FAP utilisant une méthode contraceptive acceptable pendant la période \nd’intervention de l’étude et pendant au moins 30 jours après la \ndernière dose d’intervention de l’étude.\n• Les FAP doivent présenter un test de grossesse (TG) négatif dans les \n24 heures précédant la première dose de l’intervention de l’étude.\n• L’investigateur revu les antécédents médicaux, les\nantécédents menstruels et l’activité sexuelle récente de la participante, afin \nde réduire le risque de recruter une femme dont la grossesse précoce n’a \npas été détectée.\"","language":10,"languageDescription":"French"},{"id":12069969,"uuid":"8e0d5ef6-2183-45bb-a383-b2e7bbbaeb74","attributeTranslation":"7.\tEen vrouwelijke deelnemer komt in aanmerking voor deelname als ze niet zwanger is, geen borstvoeding geeft en ten minste 1 van de volgende voorwaarden van toepassing is:\no\tEen vrouw die niet zwanger kan worden (gedefinieerd als een vrouw die een chirurgische sterilisatie heeft ondergaan of postmenopauzaal is [d.w.z. ouder dan 50 jaar met amenorroe gedurende ten minste 12 maanden zonder een alternatieve medische oorzaak]).\nOF\no\tEen vrouw die zwanger kan worden en die een aanvaardbare anticonceptiemethode gebruikt tijdens de onderzoeksinterventieperiode en gedurende ten minste 30 dagen na de laatste dosis onderzoeksinterventie.\n•\tEen vrouw die zwanger kan worden moet een negatieve zwangerschapstest hebben binnen 24 uur vóór de eerste dosis van de onderzoeksinterventie.\n•\tDe onderzoeker heeft de medische voorgeschiedenis, menstruatiegeschiedenis en recente seksuele activiteit bekeken om het risico te verkleinen op inclusie van een vrouw met een vroege, niet-gedetecteerde zwangerschap.","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12069971,"uuid":"8e0d5ef6-2183-45bb-a383-b2e7bbbaeb74","attributeTranslation":"7.\tEgy női résztvevő akkor alkalmas a részvételre, ha nem terhes, nem szoptat, illetve a következő feltételek közül egy teljesül:\no\tNem fogamzóképes nő (műtéti sterilizáláson esett át vagy posztmenopauzális [azaz 50 évesnél idősebb, legalább 12 hónapja tartó amenorrhoeával, amelynek nincs más orvosi oka]).\nVAGY\nO\tFogamzóképes nő, aki elfogadható fogamzásgátló módszert használ a vizsgálati beavatkozási időszak alatt és a vizsgálati beavatkozás utolsó adagját követően még legalább 30 napig.\n•  A fogamzóképes nőknek a vizsgálati beavatkozás első adagja előtti 24 órán belül végzett, negatív eredményű terhességi teszttel kell rendelkezniük. \n• A vizsgáló  áttekinti az orvosi kórtörténetet, a menstruációs történetet, valamint a közelmúltbeli szexuális aktivitást, hogy csökkentse az olyan nők bevonásának kockázatát, akiknek korai fel nem ismert terhességük van.","language":13,"languageDescription":"Hungarian"},{"id":12069970,"uuid":"8e0d5ef6-2183-45bb-a383-b2e7bbbaeb74","attributeTranslation":"7.\t Uczestniczka kwalifikuje się do udziału w badaniu, jeśli nie jest w ciąży ani nie karmi piersią i spełnia jeden z poniższych warunków:\no\tjest niezdolna do posiadania potomstwa (WONCBP) (przez co rozumie się, że została poddana sterylizacji chirurgicznej lub jest w okresie pomenopauzalnym [tj. ma ponad 50 lat i nie ma miesiączki od co najmniej 12 miesięcy bez alternatywnej przyczyny medycznej]);\nLUB\no\tjest zdolna do posiadania potomstwa (WOCBP) i stosuje akceptowalną metodę antykoncepcji w okresie przyjmowania badanego leku i przez co najmniej 30 dni po przyjęciu ostatniej dawki badanego leku.\n•\tKobiety WOCBP muszą uzyskać ujemny wynik testu ciążowego w ciągu 24 godzin przed podaniem pierwszej dawki badanego leku.\n•\tBadacz przeprowadził analizę wywiadu lekarskiego, wywiadu dotyczącego miesiączek i niedawnej aktywności seksualnej w celu obniżenia ryzyka włączenia kobiety z wczesną niewykrytą ciążą.","language":19,"languageDescription":"Polish"},{"id":12069972,"uuid":"8e0d5ef6-2183-45bb-a383-b2e7bbbaeb74","attributeTranslation":"7.\tEn el estudio podrán participar mujeres que no estén embarazadas ni en período de lactancia y que cumplan al menos una de las condiciones siguientes:\no\tSer una mujer sin capacidad reproductiva (MSCR) (esto es, que se haya sometido a esterilización quirúrgica o sea posmenopáusica [es decir, mayor de 50 años con amenorrea durante al menos 12 meses, sin una causa médica alternativa]).\nO BIEN\no\tSer una MCR y utilizar un método anticonceptivo aceptable, durante el período de intervención del estudio y durante al menos 30 días después de la última dosis de la intervención del estudio.\n•\tLas MCR deben presentar un resultado negativo en una prueba de embarazo (PE)  que se realice en el transcurso de las 24 horas anteriores a la primera dosis de la intervención del estudio.\n•\tEl investigador ha revisado los antecedentes médicos, los antecedentes menstruales y la actividad sexual reciente, para reducir el riesgo de incluir a una mujer con un embarazo al comienzo de la gestación no detectado.","language":7,"languageDescription":"Spanish"},{"id":12069973,"uuid":"8e0d5ef6-2183-45bb-a383-b2e7bbbaeb74","attributeTranslation":"7.\tEine Teilnehmerin ist geeignet, wenn sie nicht schwanger ist oder stillt und eine der folgenden Bedingungen zutrifft:\no\tSie ist eine nicht gebärfähige Frau (woman of non-childbearing potential, WONCBP) (definiert als Frauen, die sich einer chirurgischen Sterilisation unterzogen haben oder postmenopausal sind [d. h. älter als 50 Jahre mit Amenorrhö seit mindestens 12 Monaten ohne alternative medizinische Ursache]).\nODER\no\tSie ist eine gebärfähige Frau und verwendet während des Interventionszeitraums und noch mindestens 30 Tage nach der letzten Dosis der Studienintervention eine akzeptable Verhütungsmethode\n•\tBei einer gebärfähigen Frau muss innerhalb von 24 Stunden vor der ersten Dosis der Studienintervention ein Schwangerschaftstest (PT) durchgeführt werden, der negativ ausfallen muss.\n•\tDer Prüfarzt hat die Krankengeschichte, der Menstruationsanamnese und der letzten sexuellen Aktivität überprüft, um das Risiko, dass Frauen mit einer unentdeckten Schwangerschaft im Frühstadium aufgenommen werden, zu verringern.","language":27,"languageDescription":"German (Austria)"}]},{"id":971516,"number":8,"principalInclusionCriteria":"8.\tCapable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the Informed Consent Form (ICF) and in this protocol.","principalInclusionCriteriaTranslations":[{"id":12069975,"uuid":"5f59a5c8-96aa-44a5-89cf-ff70c1760980","attributeTranslation":"8.\tCapacidad para otorgar el consentimiento informado firmado, lo que incluye el cumplimiento de los requisitos y las restricciones que se recogen en el documento de consentimiento informado (DCI) y en este protocolo.","language":7,"languageDescription":"Spanish"},{"id":12069977,"uuid":"5f59a5c8-96aa-44a5-89cf-ff70c1760980","attributeTranslation":"8. A résztvevő képes tájékoztatáson alapuló írásos beleegyezést adni, amibe beletartozik, hogy betartja a tájékoztatáson alapuló beleegyező nyilatkozatban, valamint az ebben a protokollban szereplő követelményeket és korlátozásokat.","language":13,"languageDescription":"Hungarian"},{"id":12069978,"uuid":"5f59a5c8-96aa-44a5-89cf-ff70c1760980","attributeTranslation":"8.\tIn staat om ondertekende geïnformeerde toestemming te geven, inclusief naleving van de vereisten en beperkingen die in het toestemmingsformulier (ICF) en dit protocol worden vermeld.","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12069979,"uuid":"5f59a5c8-96aa-44a5-89cf-ff70c1760980","attributeTranslation":"8. Capacité et volonté de donner son consentement éclairé, ce qui inclut de se \nconformer aux exigences et restrictions énoncées dans la notice d’information et \nle formulaire de consentement (NIFC) et dans ce protocole","language":10,"languageDescription":"French"},{"id":12069976,"uuid":"5f59a5c8-96aa-44a5-89cf-ff70c1760980","attributeTranslation":"\"8.\tFähigkeit, schriftlich einzuwilligen. Dies schließt die Einhaltung der in der Teilnehmerinformation und Einwilligungserklärung (Informed Consent Form, ICF) sowie in diesem Prüfplan aufgeführten Anforderungen und Einschränkungen ein.\"","language":27,"languageDescription":"German (Austria)"},{"id":12069974,"uuid":"5f59a5c8-96aa-44a5-89cf-ff70c1760980","attributeTranslation":"8.\tUczestnicy są zdolni do udzielenia świadomej zgody na piśmie i tym samym do przestrzegania wymogów badania oraz stosowania się do ograniczeń wskazanych w Formularzu świadomej zgody (ICF) oraz w protokole badania.","language":19,"languageDescription":"Polish"}]}],"principalExclusionCriteria":[{"id":1658095,"number":1,"principalExclusionCriteria":"1.\tGeographic atrophy due to other causes than AMD such as Stargardt disease, cone-rod dystrophy, pathologic myopia, or toxic maculopathies (eg, plaquenil maculopathy) in either eye.","principalExclusionCriteriaTranslations":[{"id":12069818,"uuid":"a9473bd9-8aa5-484e-9c33-bb70aaa8e09e","attributeTranslation":"1. Atrophie géographique due à d’autres causes que la DMLA, comme la maladie \nde Stargardt, une dystrophie des cônes et des bâtonnets, une myopie \npathologique ou des maculopathies toxiques (p. ex., maculopathie à \nl'hydroxychloroquine) dans l’un ou l’autre œil.","language":10,"languageDescription":"French"},{"id":12069821,"uuid":"a9473bd9-8aa5-484e-9c33-bb70aaa8e09e","attributeTranslation":"1.\tGeographische Atrophie aufgrund anderer Ursachen als AMD wie Morbus Stargardt, Kegel-Stäbchen-Dystrophie, pathologische Myopie oder toxische Makulopathien (z. B. Plaque-Stäbchen-Makulopathie) in einem der beiden Augen.","language":27,"languageDescription":"German (Austria)"},{"id":12069820,"uuid":"a9473bd9-8aa5-484e-9c33-bb70aaa8e09e","attributeTranslation":"1. Az AMD-n kívül más okok, például Stargardt-kór, csap-pálcika disztrófia, kóros rövidlátás vagy toxikus makulopátiák (pl. Plaquenil okozta makulopátia) miatti geográfiai atrófia bármelyik szemben","language":13,"languageDescription":"Hungarian"},{"id":12069823,"uuid":"a9473bd9-8aa5-484e-9c33-bb70aaa8e09e","attributeTranslation":"1.\tAtrofia geográfica debida a otras causas distintas de la DMAE, como la enfermedad de Stargardt, la distrofia de conos y bastones, la miopía patológica o las maculopatías tóxicas (p. ej., maculopatía provocada por Plaquenil) en cualquiera de los ojos.","language":7,"languageDescription":"Spanish"},{"id":12069819,"uuid":"a9473bd9-8aa5-484e-9c33-bb70aaa8e09e","attributeTranslation":"1.\tGeografische atrofie als gevolg van andere oorzaken dan AMD, zoals de ziekte van Stargardt, kegel-staafdystrofie, pathologische myopie of toxische maculopathieën (bijv. maculopathie door Plaquenil) in een van de ogen.","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12069822,"uuid":"a9473bd9-8aa5-484e-9c33-bb70aaa8e09e","attributeTranslation":"1.\tZanik geograficzny wywołany innymi przyczynami niż AMD, takimi jak choroba Stargardta, dystrofia czopkowo-pręcikowa, patologiczna krótkowzroczność lub makulopatie toksyczne (np. makulopatia wywołana hydroksychlorochiną) w dowolnym z oczu.","language":19,"languageDescription":"Polish"}]},{"id":1658096,"number":10,"principalExclusionCriteria":"10.\tHistory of idiopathic, autoimmune-associated, or other uveitis in either eye.\"","principalExclusionCriteriaTranslations":[{"id":12069829,"uuid":"eb9d0ead-10ed-4651-964b-b05acde2e201","attributeTranslation":"\"10.\tVoorgeschiedenis van idiopathische, auto-immuungeassocieerde of andere uveïtis in een van de ogen.\"","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12069827,"uuid":"eb9d0ead-10ed-4651-964b-b05acde2e201","attributeTranslation":"\"10.\tAntecedentes de uveítis autoinmunitaria, idiopática  o de otro tipo en cualquier ojo.\"","language":7,"languageDescription":"Spanish"},{"id":12069826,"uuid":"eb9d0ead-10ed-4651-964b-b05acde2e201","attributeTranslation":"\"10.\tA kórtörténetben szereplő, bármelyik szemet érintő idiopátiás  autoimmun eredetű vagy más eredetű uveitisz.\"","language":13,"languageDescription":"Hungarian"},{"id":12069824,"uuid":"eb9d0ead-10ed-4651-964b-b05acde2e201","attributeTranslation":"\"10.\tIdiopatyczne,  autoimmunologiczne lub inne zapalenie błony naczyniowej któregokolwiek z oczu w wywiadzie.\"","language":19,"languageDescription":"Polish"},{"id":12069825,"uuid":"eb9d0ead-10ed-4651-964b-b05acde2e201","attributeTranslation":"10. Antécédents d’uvéite idiopathique,  auto-immune ou autre dans l’un ou l’autre œil.","language":10,"languageDescription":"French"},{"id":12069828,"uuid":"eb9d0ead-10ed-4651-964b-b05acde2e201","attributeTranslation":"\"10.\tIdiopathische, autoimmun-assoziierte oder andere Uveitis in einem der beiden Augen in der Vorgeschichte.\"","language":27,"languageDescription":"German (Austria)"}]},{"id":1658097,"number":11,"principalExclusionCriteria":"11.\tAny current or prior ocular condition, other than dry AMD with GA, that in the opinion of the Investigator could interfere with the conduct of the study (including, but not limited to, insufficient pupil dilation, retinal or optic nerve disease, media opacity, or aphakia in the study eye).","principalExclusionCriteriaTranslations":[{"id":12069835,"uuid":"35df3112-0c58-4a0b-b822-53ff41cb5082","attributeTranslation":"\"11.\tWszelkie trwające lub wcześniej występujące  schorzenia oczu inne niż sucha postać AMD z  GA, które zdaniem badacza mogą zakłócać przebieg badania, w tym, między innymi, niewystarczające rozszerzenie źrenic, choroba siatkówki lub nerwu wzrokowego, utrata przezierności lub afakia badanego oka.\"","language":19,"languageDescription":"Polish"},{"id":12069834,"uuid":"35df3112-0c58-4a0b-b822-53ff41cb5082","attributeTranslation":"\"11.\tBármely jelenlegi vagy korábbi szembetegség, a GA mellett társuló száraz AMD kivételével, amely a vizsgáló véleménye szerint zavarhatja a vizsgálat lefolytatását, ( beleértve, de nem kizárólagosan, az elégtelen pupillatágulást, a retina vagy a látóideg betegségét, a közeg opacitását vagy afákiát a vizsgált szem esetében).\"","language":13,"languageDescription":"Hungarian"},{"id":12069832,"uuid":"35df3112-0c58-4a0b-b822-53ff41cb5082","attributeTranslation":"11. Cualquier afección ocular actual o previa, distinta de la DMAE seca con AG, que en opinión del investigador pueda interferir en la realización del estudio, (incluidas, entre otras, dilatación insuficiente de la pupila, enfermedad de la retina o del nervio óptico, opacidad de los medios o afaquia en el ojo en estudio).","language":7,"languageDescription":"Spanish"},{"id":12069831,"uuid":"35df3112-0c58-4a0b-b822-53ff41cb5082","attributeTranslation":"\"11. Toute affection oculaire actuelle ou antérieure, autre que la DMLA sèche avec l’AG, qui, de l’avis de \nl’investigateur, pourrait interférer avec la conduite de l’étude (, y compris, mais \nsans s’y limiter, une dilatation insuffisante de la pupille, une maladie de la rétine \nou du nerf optique, une opacification du cristallin ou une aphakie dans l’œil à \nl’étude).\"","language":10,"languageDescription":"French"},{"id":12069830,"uuid":"35df3112-0c58-4a0b-b822-53ff41cb5082","attributeTranslation":"\"11.\tJede aktuelle oder frühere Augenerkrankung außer trockener AMD mit GA, die nach Ansicht des Prüfarztes die Durchführung der Studie beeinträchtigen könnte, (insbesondere unzureichende Pupillenerweiterung, Netzhaut- oder Sehnerverkrankung, Medientrübung oder Aphakie im Studienauge).\"","language":27,"languageDescription":"German (Austria)"},{"id":12069833,"uuid":"35df3112-0c58-4a0b-b822-53ff41cb5082","attributeTranslation":"\"11.\tElke huidige of eerdere oogaandoening, anders dan droge AMD met GA, die naar het oordeel van de onderzoeker de uitvoering van het onderzoek zou kunnen verstoren, (inclusief, maar niet beperkt tot, onvoldoende pupilverwijding, retinale of optische zenuwziekte, opaciteit van de oculaire media of afakie in het onderzoeksoog).\"","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1658098,"number":12,"principalExclusionCriteria":"12.\tHistory of any prior IVT treatment for any indication in the study eye.","principalExclusionCriteriaTranslations":[{"id":12069839,"uuid":"09996661-a656-481c-ae3b-54b3328a2046","attributeTranslation":"12.\tWcześniejsze leczenie IVT badanego oka z jakiegokolwiek wskazania.","language":19,"languageDescription":"Polish"},{"id":12069836,"uuid":"09996661-a656-481c-ae3b-54b3328a2046","attributeTranslation":"12.\tVorgeschichte einer früheren IVT-Behandlung für eine beliebige Indikation im Studienauge.","language":27,"languageDescription":"German (Austria)"},{"id":12069838,"uuid":"09996661-a656-481c-ae3b-54b3328a2046","attributeTranslation":"12.\tVoorgeschiedenis van een eerdere IVT-behandeling voor welke indicatie dan ook in het onderzoeksoog.","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12069840,"uuid":"09996661-a656-481c-ae3b-54b3328a2046","attributeTranslation":"12.\tA vizsgált szemet érintő, bármilyen indikáció miatt alkalmazott bármilyen korábbi IVT kezelés a kórtörténetben.","language":13,"languageDescription":"Hungarian"},{"id":12069841,"uuid":"09996661-a656-481c-ae3b-54b3328a2046","attributeTranslation":"12.\tAntecedentes de un tratamiento IVT previo para cualquier indicación en el ojo en estudio.","language":7,"languageDescription":"Spanish"},{"id":12069837,"uuid":"09996661-a656-481c-ae3b-54b3328a2046","attributeTranslation":"12. Antécédents de tout traitement antérieur par IVT dans l’œil à l’étude, toutes \nindications confondues.","language":10,"languageDescription":"French"}]},{"id":1658099,"number":13,"principalExclusionCriteria":"13.\tAny prior treatment for AMD in the study eye ( including investigational treatments, eg, pharmacological, surgical, radiation, thermotherapeutic, light therapy, or laser intervention), or systemic anti-GA or anti-complement treatment (including investigational treatments). NOTE: Oral supplements  (multivitamins/minerals, eg, AREDS vitamins) are permitted during the study.","principalExclusionCriteriaTranslations":[{"id":12069842,"uuid":"3ae8a7ed-8cdf-4726-a9a5-673d0f649636","attributeTranslation":"\"13.\tJegliche vorherige Behandlung der AMD im Studienauge ( einschließlich Studienbehandlungen, z. B. pharmakologische, chirurgische, Strahlen-, thermotherapeutische Intervention, Lichttherapie oder Laserintervention) oder systemische anti-GA oder antikomplementäre Behandlung (einschließlich Studienbehandlungen). HINWEIS: Orale Nahrungsergänzungsmittel (Multivitamine Mineralstoffe, z. B. AREDS-Vitamine) sind während der Studie zulässig.\"","language":27,"languageDescription":"German (Austria)"},{"id":12069846,"uuid":"3ae8a7ed-8cdf-4726-a9a5-673d0f649636","attributeTranslation":"\"13.\tWszelkie wcześniejsze leczenie AMD w badanym oku w tym terapie eksperymentalne,  np. leczenie farmakologiczne, chirurgiczne, radioterapia, termoterapia, terapia światłem lub laseroterapia), lub ogólnoustrojowe leczenie GA lub skierowane przeciwko składowym dopełniacza (w tym terapie eksperymentalne). UWAGA:  w ramach badania dopuszczalne jest stosowanie doustnych  suplementów diety (preparatów wielowitaminowych/mineralnych, np. witamin AREDS) \"","language":19,"languageDescription":"Polish"},{"id":12069844,"uuid":"3ae8a7ed-8cdf-4726-a9a5-673d0f649636","attributeTranslation":"\"13.\tA vizsgált szemet érintő, AMD elleni bármilyen korábbi kezelés (többek között vizsgálati kezelések, pl. gyógyszeres, sebészeti, sugárkezelés, hőterápiás, fényterápiás vagy lézeres beavatkozás),  vagy szisztémás anti-GA vagy antikomplementer kezelés (beleértve a vizsgálati jellegű kezeléseket is). MEGJEGYZÉS: Orális étrend-kiegészítők (multivitaminok/ ásványi anyagok pl. AREDS vitaminok) megengedettek a vizsgálat során.\"","language":13,"languageDescription":"Hungarian"},{"id":12069845,"uuid":"3ae8a7ed-8cdf-4726-a9a5-673d0f649636","attributeTranslation":"13.\tEerdere behandeling voor AMD in het onderzoeksoog (inclusief onderzoeksbehandelingen, bijv. farmacologische, chirurgische, bestralings-, thermotherapeutische, lichttherapie- of laserinterventie) of systemische anti-GA- of anti-complementbehandeling (inclusief onderzoeksbehandelingen). OPMERKING: orale supplementen (multivitaminen/mineralen, bijv. AREDS-vitaminen) zijn toegestaan tijdens het onderzoek.","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12069843,"uuid":"3ae8a7ed-8cdf-4726-a9a5-673d0f649636","attributeTranslation":"\"13.\tUn tratamiento previo para la DMAE en el ojo en estudio (incluidos los tratamientos en investigación, p. ej., intervención farmacológica, quirúrgica, radioterápica, termoterápica, con fototerapioa o con láser), o un tratamiento sistémico contra la AG o un anticomplemento\n(incluidos los tratamientos en investigación). NOTA: se permiten los\n suplementos orales o (multivitaminas/minerales, p.e., vitaminas AREDS) durante el estudio.\"","language":7,"languageDescription":"Spanish"},{"id":12069847,"uuid":"3ae8a7ed-8cdf-4726-a9a5-673d0f649636","attributeTranslation":"\"13. Tout traitement antérieur pour une DMLA dans l’œil à l’étude ( compris,\ntraitements expérimentaux, intervention pharmacologique, chirurgicale, \nradiologique, thermothérapeutique, luminothérapie ou intervention au laser), \nou traitement systémique anti-AG ou anti-complémentaire (y compris les \ntraitements expérimentaux). REMARQUE :les compléments \npar voie orale (multivitamines/minéraux, p. ex., vitamines formule AREDS)\npar voie oralesont autorisés pendant l’étude.\"","language":10,"languageDescription":"French"}]},{"id":1658100,"number":14,"principalExclusionCriteria":"14.\tPrevious participation in any studies of investigational medications not already prohibited by Exclusions 12 and 13, within 3 months or 5 half-lives of the active ingredient (whichever is longer) prior to the start of study treatment.","principalExclusionCriteriaTranslations":[{"id":12069851,"uuid":"12eadd88-1390-4f35-a30e-6d4d854d44c4","attributeTranslation":"\"14.\tEerdere deelname aan onderzoeken naar onderzoeksmiddelen die nog niet zijn verboden door exclusiecriteria 12 en 13, binnen 3 maanden of 5 halfwaardetijden van het actieve bestanddeel (afhankelijk van wat langer is) voorafgaand aan de start van de onderzoeksbehandeling.\"","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12069852,"uuid":"12eadd88-1390-4f35-a30e-6d4d854d44c4","attributeTranslation":"\"14.\tParticipación previa en cualquier estudio de medicamentos en investigación, que no se hayan prohibido ya en los criterios de \nexclusión 12 y 13,  en el plazo de los 3 meses o 5 semividas del principio activo (el período más largo) anteriores al inicio del tratamiento del estudio.\"","language":7,"languageDescription":"Spanish"},{"id":12069853,"uuid":"12eadd88-1390-4f35-a30e-6d4d854d44c4","attributeTranslation":"\"14. Participation antérieure à des études sur des médicaments expérimentaux qui \nne sont pas déjà interdits par les exclusions 12 et 13 dans \nles 3  mois ou 5  demi-vies du principe actif (selon la période la plus longue) avant le début du traitement à l’étude.\nRemarque : la participation à des études cliniques impliquant uniquement une \nobservation, des vitamines ou des compléments en vente libre, ou des régimes \nalimentaires ne constitue pas un critère d’exclusion.\n\"","language":10,"languageDescription":"French"},{"id":12069849,"uuid":"12eadd88-1390-4f35-a30e-6d4d854d44c4","attributeTranslation":"\"14.\tFrühere Teilnahme an Studien mit Prüfpräparaten, die nicht bereits aufgrund von Ausschlusspunkten 12 und 13 unzulässig sind, innerhalb von 3 Monaten oder 5 Halbwertszeiten des Wirkstoffs (je nachdem, welcher Zeitraum länger ist) vor Beginn der Studienbehandlung.\"","language":27,"languageDescription":"German (Austria)"},{"id":12069848,"uuid":"12eadd88-1390-4f35-a30e-6d4d854d44c4","attributeTranslation":"14 A Kizárási kritériumok 12 és 13. pontjában nem felsorolt  vizsgálati gyógyszerekkel kapcsolatos bármilyen vizsgálatban való korábbi részvétel a vizsgálati kezelés megkezdése előtt hónapon vagy a hatóanyag 5 felezési idején belül (amelyik hosszabb).","language":13,"languageDescription":"Hungarian"},{"id":12069850,"uuid":"12eadd88-1390-4f35-a30e-6d4d854d44c4","attributeTranslation":"14.\tWcześniejszy udział w jakichkolwiek badaniach nad lekami eksperymentalnymi innymi niż wskazane jako niedopuszczalne w kryteriach wyłączenia 12 i 13  w ciągu 3 miesięcy lub 5 okresów półtrwania substancji czynnej (w zależności od tego, który okres jest dłuższy) przed rozpoczęciem leczenia w ramach badania.","language":19,"languageDescription":"Polish"}]},{"id":1658101,"number":15,"principalExclusionCriteria":"15.\tKnown hypersensitivity to ANX007 or any of the excipients in the ANX007 solution (as described in the ANX007 Investigator’s Brochure or other ANX molecules (eg ANX005).","principalExclusionCriteriaTranslations":[{"id":12069856,"uuid":"d6b7eb35-7718-4407-a917-eba427cd3b3a","attributeTranslation":"\"15.\tStwierdzona nadwrażliwość na ANX007 lub którąkolwiek substancję pomocniczą znajdującą się w roztworze ANX007 (zgodnie z opisem w Broszurze badacza [BB] dla ANX007), lub na inne cząsteczki z serii ANX (np. ANX005).\"","language":19,"languageDescription":"Polish"},{"id":12069854,"uuid":"d6b7eb35-7718-4407-a917-eba427cd3b3a","attributeTranslation":"\"15.\tBekende overgevoeligheid voor ANX007 of een van de hulpstoffen in de ANX007-oplossing (zoals beschreven in het onderzoekersdossier [Investigator’s Brochure, IB]) van ANX007 of andere ANX-moleculen (bijv. ANX005).\"","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12069858,"uuid":"d6b7eb35-7718-4407-a917-eba427cd3b3a","attributeTranslation":"\"15. Hypersensibilité connue à l’ANX007 ou à l’un des excipients de la solution \nd’ANX007 (telle que décrite dans la Brochure de l’investigateur \n[BI] de l’ANX007) ou à d’autres molécules d’ANX (p. ex., ANX005).\"","language":10,"languageDescription":"French"},{"id":12069855,"uuid":"d6b7eb35-7718-4407-a917-eba427cd3b3a","attributeTranslation":"\"15.\tBekannte Überempfindlichkeit gegen ANX007 oder einen der sonstigen Bestandteile der ANX007-Lösung (wie in der ANX007-Prüfarztbroschüre [Investigator’s Brochure, IB] beschrieben) oder gegen andere ANX-Moleküle (z. B. ANX005).\"","language":27,"languageDescription":"German (Austria)"},{"id":12069857,"uuid":"d6b7eb35-7718-4407-a917-eba427cd3b3a","attributeTranslation":"\"15.\tIsmert túlérzékenység az ANX007 készítménnyel vagy az ANX007 oldat bármely segédanyagával (az ANX007 vizsgálói kézikönyv  [IB] 1. táblázatában leírtak szerint) vagy más ANX molekulákkal (pl. ANX005) szemben.\"","language":13,"languageDescription":"Hungarian"},{"id":12069859,"uuid":"d6b7eb35-7718-4407-a917-eba427cd3b3a","attributeTranslation":"\"15.\tHipersensibilidad conocida a ANX007 o alguno de los excipientes de la solución de ANX007 (según se detalla en el manual del investigador [MI] de ANX007) u otras moléculas de ANX (p. ej., ANX005).\"","language":7,"languageDescription":"Spanish"}]},{"id":1658102,"number":16,"principalExclusionCriteria":"16.\tKnown hypersensitivity to fluorescein","principalExclusionCriteriaTranslations":[{"id":12069862,"uuid":"7ed51459-98e2-40ee-9a26-58dded70bbf3","attributeTranslation":"16.\tBekende overgevoeligheid voor fluoresceïne","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12069865,"uuid":"7ed51459-98e2-40ee-9a26-58dded70bbf3","attributeTranslation":"16.\tHipersensibilidad conocida a la fluoresceína.","language":7,"languageDescription":"Spanish"},{"id":12069863,"uuid":"7ed51459-98e2-40ee-9a26-58dded70bbf3","attributeTranslation":"16. Bekannte Überempfindlichkeit gegen Fluorescein","language":27,"languageDescription":"German (Austria)"},{"id":12069860,"uuid":"7ed51459-98e2-40ee-9a26-58dded70bbf3","attributeTranslation":"16. Hypersensibilité connue à la fluorescéine.","language":10,"languageDescription":"French"},{"id":12069861,"uuid":"7ed51459-98e2-40ee-9a26-58dded70bbf3","attributeTranslation":"16.\tFluoreszceinnel szembeni ismert túlérzékenység.","language":13,"languageDescription":"Hungarian"},{"id":12069864,"uuid":"7ed51459-98e2-40ee-9a26-58dded70bbf3","attributeTranslation":"16.\tStwierdzona nadwrażliwość na fluoresceinę.","language":19,"languageDescription":"Polish"}]},{"id":1658103,"number":17,"principalExclusionCriteria":"17.\tActive alcohol or substance abuse/dependence or any other reason that makes it unlikely that the participant will comply with study procedures.","principalExclusionCriteriaTranslations":[{"id":12069867,"uuid":"301953c1-3bbc-464d-96ba-85dbe9c14e4c","attributeTranslation":"\"17.\tCzynne nadużywanie/uzależnienie od alkoholu lub substancji psychoaktywnych lub jakikolwiek inny powód, który sprawia, że jest mało prawdopodobne, aby uczestnik przestrzegał procedur badania.\"","language":19,"languageDescription":"Polish"},{"id":12069868,"uuid":"301953c1-3bbc-464d-96ba-85dbe9c14e4c","attributeTranslation":"\"17. Consommation abusive ou dépendance active à l’alcool ou aux substances, ou \ntoute autre raison rendant peu probable que le/la participant(e) se conforme aux \nprocédures de l’étude.\"","language":10,"languageDescription":"French"},{"id":12069869,"uuid":"301953c1-3bbc-464d-96ba-85dbe9c14e4c","attributeTranslation":"\"17.\tActief misbruik of afhankelijkheid van alcohol of drugs of enig andere reden waardoor het onwaarschijnlijk is dat de deelnemer zich zal houden aan de onderzoeksprocedures.\"","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12069870,"uuid":"301953c1-3bbc-464d-96ba-85dbe9c14e4c","attributeTranslation":"\"17.\tAlkohollal vagy más szerekkel való aktív visszaélés/függőség vagy bármilyen más ok, amely valószínűtlenné teszi, hogy a résztvevő betartsa a vizsgálati eljárásokat.\"","language":13,"languageDescription":"Hungarian"},{"id":12069866,"uuid":"301953c1-3bbc-464d-96ba-85dbe9c14e4c","attributeTranslation":"\"17.\tAktive(r) Alkohol- oder Substanzmissbrauch/-abhängigkeit oder ein anderer Grund, der es unwahrscheinlich macht, dass der Teilnehmer die Studienverfahren einhält.\"","language":27,"languageDescription":"German (Austria)"},{"id":12069871,"uuid":"301953c1-3bbc-464d-96ba-85dbe9c14e4c","attributeTranslation":"\"17.\tAbuso o dependencia activa de alcohol o drogas o cualquier otra razón que haga improbable que el participante cumpla con los procedimientos del estudio.\"","language":7,"languageDescription":"Spanish"}]},{"id":1658104,"number":18,"principalExclusionCriteria":"18.\tHistory of current systemic medical or psychiatric conditions or any other reason, including laboratory findings, that may, in the opinion of the Investigator, contraindicate the use of an investigational medication, affect interpretation of study results, preclude adherence to the study visit schedule, or safe participation in the study.","principalExclusionCriteriaTranslations":[{"id":12069872,"uuid":"c63df656-0a5b-402d-a898-53c8a40cfb19","attributeTranslation":"18. Jelenlegi vagy korábbi szisztémás egészségügyi vagy pszichiátriai állapot, vagy bármely egyéb ok, beleértve a laboratóriumi leleteket is, amely miatt a vizsgáló véleménye szerint a vizsgálati készítmény alkalmazása ellenjavallt, illetve amely befolyásolhatja a vizsgálati eredmények értelmezését, megakadályozza a vizsgálati vizitek ütemtervének betartását vagy a biztonságos részvételt a vizsgálatban.","language":13,"languageDescription":"Hungarian"},{"id":12069876,"uuid":"c63df656-0a5b-402d-a898-53c8a40cfb19","attributeTranslation":"18.\tAntecedentes de afecciones psiquiátricas o médicas sistémicas o presencia de estas enfermedades en la actualidad, o cualquier otro motivo, incluidos los hallazgos analíticos, que puedan, en opinión del investigador, contraindicar la administración de un medicamento en investigación, afectar a la interpretación de los resultados del estudio, impedir el cumplimiento del calendario de visitas del estudio o la participación segura en el estudio.","language":7,"languageDescription":"Spanish"},{"id":12069875,"uuid":"c63df656-0a5b-402d-a898-53c8a40cfb19","attributeTranslation":"18.\tVorgeschichte aktueller systemischer medizinischer oder psychiatrischer Erkrankungen oder anderer Gründe, einschließlich Laborbefunde, die nach Ansicht des Prüfarztes die Anwendung eines Prüfpräparats kontraindizieren, die Interpretation der Studienergebnisse beeinträchtigen, die Einhaltung des Studienbesuchsplans ausschließen oder eine sichere Teilnahme an der Studie verhindern können.","language":27,"languageDescription":"German (Austria)"},{"id":12069877,"uuid":"c63df656-0a5b-402d-a898-53c8a40cfb19","attributeTranslation":"18.\tVoorgeschiedenis van huidige systemische medische of psychiatrische aandoeningen of enige andere reden, waaronder laboratoriumbevindingen, die, naar het oordeel van de onderzoeker, het gebruik van een onderzoeksmiddel contra-indiceren, de interpretatie van de onderzoeksresultaten beïnvloeden, naleving van het onderzoeksbezoekschema of veilige deelname aan het onderzoek uitsluiten.","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12069873,"uuid":"c63df656-0a5b-402d-a898-53c8a40cfb19","attributeTranslation":"18. Antécédents de troubles médicaux systémiques ou psychiatriques ou pour toute \nautre raison, y compris des résultats de laboratoire pouvant, de l’avis de \nl’investigateur, représenter une contre-indication à l’utilisation d’un médicament \nexpérimental, affecter l’interprétation des résultats de l’étude, empêcher le \nrespect du calendrier des visites de l’étude ou la participation en toute sécurité à \nl’étude.","language":10,"languageDescription":"French"},{"id":12069874,"uuid":"c63df656-0a5b-402d-a898-53c8a40cfb19","attributeTranslation":"18.\tStwierdzone w wywiadzie choroby ogólnoustrojowe lub choroby psychiczne lub jakikolwiek inny powód, w tym wyniki badań laboratoryjnych, które, zdaniem badacza, mogą stanowić przeciwwskazanie do stosowania leku eksperymentalnego, wpływać na interpretację wyników badania, wykluczać przestrzeganie harmonogramu wizyt w ramach badania lub wpływać na bezpieczeństwo podczas udziału w badaniu.","language":19,"languageDescription":"Polish"}]},{"id":1658105,"number":2,"principalExclusionCriteria":"2.\tAny evidence of CNV in the study eye: a.\tAny history of CNV of any cause based on medical history. b.\tEvidence of prior or active CNV or related findings (eg, retinal pigment epithelial rips or tears) based on FAF, SD-OCT imaging, intravenous fluorescein angiography (IVFA), and color fundus photo as assessed by the Central Reading Center.","principalExclusionCriteriaTranslations":[{"id":12069882,"uuid":"c485da09-f9c8-4171-bba0-eca738e51fc2","attributeTranslation":"\"2.\tJeglicher Nachweis einer CNV im Studienauge:\na.\tEine Vorgeschichte von CNV jeglicher Ursache in der Krankengeschichte.\nb.\tNachweis früherer oder aktiver CNV- oder verwandter Befunde (z. B. retinale Pigmentepithelrisse) basierend auf FAF, SD-OCT Bildgebung, intravenöser Fluoreszein-Angiographie (IVFA) und Farbfundusfoto, beurteilt durch das zentrale Auswertungszentrum.\"","language":27,"languageDescription":"German (Austria)"},{"id":12069883,"uuid":"c485da09-f9c8-4171-bba0-eca738e51fc2","attributeTranslation":"\"2.\tWszelkie dowody obecności CNV w badanym oku:\na.\tWystępowanie w przeszłości CNV z dowolnej przyczyny w oparciu o wywiad lekarski.\nb.\tDowody wcześniejszej obecności lub aktywnej postaci CNV albo powiązanych zdarzeń (np. odwarstwienie lub przerwanie ciągłości nabłonka barwnikowego siatkówki) stwierdzone w oparciu o obrazowanie metodą FAF, SD-OCT, dożylnej angiografii fluoresceinowej (IVFA) i kolorowego zdjęcia dna oka, zgodnie z oceną dokonaną przez Centralny Ośrodek Odczytów.","language":19,"languageDescription":"Polish"},{"id":12069880,"uuid":"c485da09-f9c8-4171-bba0-eca738e51fc2","attributeTranslation":"\"2.\tA CNV-re utaló bármilyen bizonyíték a vizsgált szemben:\na.\tBármilyen okból kialakult korábbi CNV a kórtörténet alapján.\nb.\tKorábbi vagy aktív CNV bizonyítéka vagy ezzel összefüggő leletek (pl. a retina pigmentepitéliumának repedése vagy szakadása) az FAF, spektrális domén optikai koherencia tomográfia (SD-OCT) képalkotás, intravénás fluoreszcein angiográfia (IVFA) és színes szemfenéki fotó alapján a központi leletezőközpont által értékelve.\"","language":13,"languageDescription":"Hungarian"},{"id":12069879,"uuid":"c485da09-f9c8-4171-bba0-eca738e51fc2","attributeTranslation":"\"2.\tBewijs van CNV in het onderzoeksoog:\na.\tElke voorgeschiedenis van CNV, ongeacht de oorzaak, op basis van medische voorgeschiedenis.\nb.\tBewijs van eerdere of actieve CNV of gerelateerde bevindingen (bijv. scheurtjes in het retinale pigmentepitheel) op basis van FAF, SD-OCT, intraveneuze fluoresceïne-angiografie (IVFA) en fundusfoto in kleur, zoals beoordeeld door het CRC.\"","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12069878,"uuid":"c485da09-f9c8-4171-bba0-eca738e51fc2","attributeTranslation":"\"2. Tout signe de NVC dans l’œil à l’étude :\na. Tout antécédent de NVC, quelle qu’en soit la cause, d’après les \nantécédents médicaux. \nb. Signes d’une NVC antérieure ou active ou signes connexes (p. ex., \ndécollement ou déchirure de l’épithélium pigmentaire rétinien) sur la \nbase de la FAF, de l’imagerie de SD-OCT, de l’angiographie à la fluorescéine \npar injection intraveineuse (AFIV) et de la photo couleur du fond \nd’œil évaluée par le centre de lecture central.\"","language":10,"languageDescription":"French"},{"id":12069881,"uuid":"c485da09-f9c8-4171-bba0-eca738e51fc2","attributeTranslation":"\"2.\tCualquier signo de NVC en el ojo en estudio:\na.\tCualquier antecedente de NVC por cualquier causa según los antecedentes médicos.\nb.\tSignos de NVC activa o previa o hallazgos relacionados (p. ej., desgarros o roturas del epitelio pigmentario de la retina) determinados en una prueba de AFF, una TCO-DE, una angiografía con fluoresceína intravenosa (AFIV) y una fotografía en color del fondo de ojo, según el criterio del centro de lecturas centralizadas.","language":7,"languageDescription":"Spanish"}]},{"id":1658106,"number":3,"principalExclusionCriteria":"3.\tSpherical equivalent of -8.00 diopters (D) myopia or higher in the study eye.","principalExclusionCriteriaTranslations":[{"id":12069888,"uuid":"d23bbecb-fb82-458b-827e-233820f00f90","attributeTranslation":"3.\tSphärisches Äquivalent einer Myopie von -8,00 Dioptrien (D) oder höher im Studienauge.","language":27,"languageDescription":"German (Austria)"},{"id":12069885,"uuid":"d23bbecb-fb82-458b-827e-233820f00f90","attributeTranslation":"3.\tEquivalente esférico de −8,00 o más dioptrías (D) de miopía en el ojo en estudio.","language":7,"languageDescription":"Spanish"},{"id":12069886,"uuid":"d23bbecb-fb82-458b-827e-233820f00f90","attributeTranslation":"3.\tWada sferycznie równoważna -8,00 dioptrii (D) lub większa w badanym oku.","language":19,"languageDescription":"Polish"},{"id":12069887,"uuid":"d23bbecb-fb82-458b-827e-233820f00f90","attributeTranslation":"8,00 dioptriás (D) vagy annál súlyosabb rövidlátásnak megfelelő szférikus egyenérték a vizsgált szemben.","language":13,"languageDescription":"Hungarian"},{"id":12069884,"uuid":"d23bbecb-fb82-458b-827e-233820f00f90","attributeTranslation":"3. Myopie avec équivalent sphérique de -8,00 dioptries (D) ou plus dans l’œil à \nl’étude.","language":10,"languageDescription":"French"},{"id":12069889,"uuid":"d23bbecb-fb82-458b-827e-233820f00f90","attributeTranslation":"3.\tSferisch equivalent van myopie van -8,00 dioptrie (D) of hoger in het onderzoeksoog.","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1658107,"number":4,"principalExclusionCriteria":"4.\tUncontrolled glaucoma in the study eye (Intraocular pressure (IOP) >25 mmHg despite treatment with anti-glaucoma medication) or history of neovascular glaucoma.","principalExclusionCriteriaTranslations":[{"id":12069891,"uuid":"dbaa72a7-ae84-41dd-9efc-b08b4a58a03a","attributeTranslation":"\"4.\tUnkontrolliertes Glaukom im Studienauge (Intraokulardruck [IOP] > 25 mmHg trotz Behandlung mit Anti-Glaukom-Medikamenten) oder neovaskuläres Glaukom in der Vorgeschichte.\"","language":27,"languageDescription":"German (Austria)"},{"id":12069892,"uuid":"dbaa72a7-ae84-41dd-9efc-b08b4a58a03a","attributeTranslation":"4.\tGlaucoma sin controlar en el ojo en estudio (presión intraocular [PIO]) >25 mm Hg a pesar de recibir tratamiento con medicamentos antiglaucomatosos) o antecedentes de glaucoma neovascular.","language":7,"languageDescription":"Spanish"},{"id":12069894,"uuid":"dbaa72a7-ae84-41dd-9efc-b08b4a58a03a","attributeTranslation":"4.\tNiekontrolowana jaskra w badanym oku (ciśnienie wewnątrzgałkowe (IOP) >25 mmHg pomimo leczenia lekami przeciwjaskrowymi) lub jaskra neowaskularna w wywiadzie.","language":19,"languageDescription":"Polish"},{"id":12069895,"uuid":"dbaa72a7-ae84-41dd-9efc-b08b4a58a03a","attributeTranslation":"4. Glaucome non contrôlé dans l’œil à l’étude (pression intraoculaire \n[PIO] > 25 mmHg malgré un traitement avec des médicaments contre le \nglaucome) ou antécédents de glaucome néovasculaire.","language":10,"languageDescription":"French"},{"id":12069893,"uuid":"dbaa72a7-ae84-41dd-9efc-b08b4a58a03a","attributeTranslation":"4.\tOngecontroleerd glaucoom in het onderzoeksoog (intraoculaire druk [IOP] > 25 mmHg ondanks behandeling met anti-glaucoommedicatie) of voorgeschiedenis van neovasculair glaucoom.","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12069890,"uuid":"dbaa72a7-ae84-41dd-9efc-b08b4a58a03a","attributeTranslation":"4.\tNem kontrollált gglaukóma a vizsgált szemben (az intraokuláris nyomás (IOP) >25 Hgmm a glaukóma elleni gyógyszeres kezelés ellenére) vagy a kórtörténetben szereplő neovaszkuláris glaukóma.","language":13,"languageDescription":"Hungarian"}]},{"id":1658108,"number":5,"principalExclusionCriteria":"5.\tHistory of incisional glaucoma surgery (eg, glaucoma filtration surgery, minimally invasive glaucoma surgery  implantation of a drainage device); vitrectomy surgery; or other procedure in the study eye that could affect drug distribution and/or clearance.","principalExclusionCriteriaTranslations":[{"id":12069896,"uuid":"9734360f-4ad5-43c1-9691-568d7470f2df","attributeTranslation":"\"5.\tAnamnestisch bekannte inzisionale Glaukomoperation (z. B. Glaukomfiltrationsoperation, minimalinvasive Glaukomoperation Einsetzen eines Drainage-Implantats);Vitrektomie; oder ein anderes Verfahren im Studienauge, das die Medikamentenverteilung und/oder Clearance beeinträchtigen könnte.\"","language":27,"languageDescription":"German (Austria)"},{"id":12069898,"uuid":"9734360f-4ad5-43c1-9691-568d7470f2df","attributeTranslation":"\"5.\tPrzebyty w przeszłości chirurgiczny zabieg leczenia jaskry (np.  utworzenie przetok filtracyjnych minimalnie inwazyjna operacja jaskry, wszczepienie implantu drenującego), zabieg witrektomii lub inny zabieg przeprowadzany w badanym oku, który może wpłynąć na dystrybucję leku i/lub jego klirens.\"","language":19,"languageDescription":"Polish"},{"id":12069897,"uuid":"9734360f-4ad5-43c1-9691-568d7470f2df","attributeTranslation":"\"5.\tA kórtörténetben  a vizsgált szemet érintő, vágással végzett glaukóma (pl. glaukóma filtrációs műtét, minimálisan invazív, implantátumot alkalmazó műtét,  eszközzel módosított trabulektómia;  vitrektómiás műtét,; vagy egyéb olyan eljárás, amely befolyásolhatja a gyógyszer eloszlását és/vagy kiürülését.\"","language":13,"languageDescription":"Hungarian"},{"id":12069901,"uuid":"9734360f-4ad5-43c1-9691-568d7470f2df","attributeTranslation":"\"5.\tAntecedentes de cirugía incisional de glaucoma (p. ej. cirugía de filtración del glaucoma, cirugía del glaucoma mínimamente invasiva, implante, de un dispositivo de drenaje); cirugía de vitrectomía u otro procedimiento en el ojo en estudio que podría afectar la distribución y/o la eliminación del fármaco.\"","language":7,"languageDescription":"Spanish"},{"id":12069900,"uuid":"9734360f-4ad5-43c1-9691-568d7470f2df","attributeTranslation":"\"5.\tVoorgeschiedenis van incisie-glaucoomoperatie (bijv. glaucoomfiltratie, minimaal invasieve glaucoomoperatie, implantatie van een drainageapparaat);  vitrectomie; of een andere ingreep in het onderzoeksoog die de distributie en/of klaring van het onderzoeksmiddel kan beïnvloeden.\"","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12069899,"uuid":"9734360f-4ad5-43c1-9691-568d7470f2df","attributeTranslation":"\"5. Antécédents de chirurgie incisionnelle du glaucome (p. ex., chirurgie \nfiltrante du glaucome, chirurgie mini-invasive du \nglaucome, implantation \nd’un dispositif de drainage)  vitrectomie, ou autre procédure dans \nl’œil à l’étude susceptible d’affecter la distribution et/ou la clairance du \nmédicament.\"","language":10,"languageDescription":"French"}]},{"id":1658109,"number":6,"principalExclusionCriteria":"6.\tHistory of cataract surgery less than 3 months prior to dosing in the study eye (cataract surgery should have been uncomplicated to be considered eligible).","principalExclusionCriteriaTranslations":[{"id":12069903,"uuid":"1bb8be74-0d3e-4fa6-bd23-4ec7f143461a","attributeTranslation":"\"6.\tHaberse sometido a cirugía de cataratas  menos de 3 meses antes de la administración en el ojo en estudio (para\nconsiderar al participante apto, la cirugía de cataratas no debe haber\ntenido complicaciones). \"","language":7,"languageDescription":"Spanish"},{"id":12069905,"uuid":"1bb8be74-0d3e-4fa6-bd23-4ec7f143461a","attributeTranslation":"\"6. Antécédents de chirurgie de la cataracte datant de moins de \n 3 mois avant l’administration du médicament dans l’œil à l’étude (la \nchirurgie de la cataracte doit avoir été effectuée sans complications pour être \nconsidérée comme éligible).\"","language":10,"languageDescription":"French"},{"id":12069904,"uuid":"1bb8be74-0d3e-4fa6-bd23-4ec7f143461a","attributeTranslation":"\"6.\tA vizsgált szemet érintő szürkehályogműtét a kórtörténetben, kevesebb mint 3 hónappal az adagolás előtt  (a szürkehályogműtétnek szövődménymentesnek kellett lennie ahhoz, hogy megfelelőnek minősüljön).\"","language":13,"languageDescription":"Hungarian"},{"id":12069907,"uuid":"1bb8be74-0d3e-4fa6-bd23-4ec7f143461a","attributeTranslation":"\"6.\t Operacja zaćmy w wywiadzie wcześniej niż 3 miesiące przed podaniem dawki leku do badanego oka (operacyjne leczenie zaćmy powinno zostać przeprowadzone bez powikłań, aby uczestnik mógł kwalifikować się do badania).\"","language":19,"languageDescription":"Polish"},{"id":12069902,"uuid":"1bb8be74-0d3e-4fa6-bd23-4ec7f143461a","attributeTranslation":"\"6.\tAnamnestisch bekannte  Kataraktoperation weniger als 3 Monate vor der Dosierung im Studienauge (Kataraktoperation sollte unkompliziert verlaufen sein, um geeignet zu sein).\"","language":27,"languageDescription":"German (Austria)"},{"id":12069906,"uuid":"1bb8be74-0d3e-4fa6-bd23-4ec7f143461a","attributeTranslation":"\"6.\tVoorgeschiedenis van staaroperatie in het onderzoeksoog, minder dan 3 maanden voorafgaand aan toediening (staaroperatie moet zonder complicaties zijn geweest om in aanmerking te komen).\"","language":37,"languageDescription":"Dutch (Netherlands)"}]},{"id":1658110,"number":7,"principalExclusionCriteria":"7.\tAny ophthalmic condition that may require surgery during the study period in the study eye","principalExclusionCriteriaTranslations":[{"id":12069909,"uuid":"12d12a94-85a8-438d-9f2d-183603b22b72","attributeTranslation":"7.\tKażdy stan okulistyczny, który może wymagać operacji badanego oka w trakcie badania.","language":19,"languageDescription":"Polish"},{"id":12069908,"uuid":"12d12a94-85a8-438d-9f2d-183603b22b72","attributeTranslation":"7. Bármilyen szemészeti betegség, amely műtétet igényelhet a vizsgálati időszakban a vizsgált szemen.","language":13,"languageDescription":"Hungarian"},{"id":12069911,"uuid":"12d12a94-85a8-438d-9f2d-183603b22b72","attributeTranslation":"7. Toute affection ophtalmique pouvant nécessiter une opération de l’œil à l’étude \npendant la période d’étude","language":10,"languageDescription":"French"},{"id":12069913,"uuid":"12d12a94-85a8-438d-9f2d-183603b22b72","attributeTranslation":"7.\tJegliche ophthalmologische Erkrankung, die während des Studienzeitraums im Studienauge eine Operation erforderlich machen könnte.","language":27,"languageDescription":"German (Austria)"},{"id":12069910,"uuid":"12d12a94-85a8-438d-9f2d-183603b22b72","attributeTranslation":"7.\tElke oogaandoening in het onderzoeksoog waarvoor een operatie nodig kan zijn tijdens de onderzoeksperiode.","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12069912,"uuid":"12d12a94-85a8-438d-9f2d-183603b22b72","attributeTranslation":"7.\tCualquier afección oftálmica que pueda requerir cirugía durante el período del estudio en el ojo en estudio.","language":7,"languageDescription":"Spanish"}]},{"id":1658111,"number":8,"principalExclusionCriteria":"8.\tOcular trauma in the study eye within the preceding 6 months.","principalExclusionCriteriaTranslations":[{"id":12069915,"uuid":"3fb5f1c1-410c-4606-b771-68d71620f227","attributeTranslation":"8.\tA vizsgált szemet érintő szemsérülés az elmúlt 6 hónapban.","language":13,"languageDescription":"Hungarian"},{"id":12069919,"uuid":"3fb5f1c1-410c-4606-b771-68d71620f227","attributeTranslation":"8. Traumatisme oculaire dans l’œil à l’étude au cours des 6 derniers mois.","language":10,"languageDescription":"French"},{"id":12069914,"uuid":"3fb5f1c1-410c-4606-b771-68d71620f227","attributeTranslation":"8.\tTraumatismo ocular en el ojo en estudio en el transcurso de los 6 meses anteriores.","language":7,"languageDescription":"Spanish"},{"id":12069916,"uuid":"3fb5f1c1-410c-4606-b771-68d71620f227","attributeTranslation":"8.\tOculair trauma in het onderzoeksoog in de voorafgaande 6 maanden.","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12069917,"uuid":"3fb5f1c1-410c-4606-b771-68d71620f227","attributeTranslation":"8.\tUraz badanego oka w ciągu ostatnich 6 miesięcy.","language":19,"languageDescription":"Polish"},{"id":12069918,"uuid":"3fb5f1c1-410c-4606-b771-68d71620f227","attributeTranslation":"8.\tAugentrauma im Studienauge innerhalb der vorangegangenen 6 Monate.","language":27,"languageDescription":"German (Austria)"}]},{"id":1658112,"number":9,"principalExclusionCriteria":"9.\tAny active ocular/intraocular infection or inflammation in either eye (e.g., blepharitis, infectious conjunctivitis, keratitis, scleritis, endophthalmitis, uveitis).","principalExclusionCriteriaTranslations":[{"id":12069924,"uuid":"998c98d0-86aa-45e1-b57d-bd5e84843d3b","attributeTranslation":"9.\tCzynne zakażenie lub zapalenie oka lub wewnątrzgałkowe (np. zapalenie powiek, zakaźne zapalenie spojówek, zapalenie rogówki, zapalenie twardówki, zapalenie wnętrza gałki ocznej, zapalenie błony naczyniowej oka).","language":19,"languageDescription":"Polish"},{"id":12069925,"uuid":"998c98d0-86aa-45e1-b57d-bd5e84843d3b","attributeTranslation":"9.\tCualquier infección o inflamación ocular o intraocular activa en cualquiera de los ojos (p. ej., blefaritis, conjuntivitis infecciosa, queratitis, escleritis, endoftalmitis, uveítis).","language":7,"languageDescription":"Spanish"},{"id":12069921,"uuid":"998c98d0-86aa-45e1-b57d-bd5e84843d3b","attributeTranslation":"9.\tEen actieve oculaire/intraoculaire infectie of ontsteking in een van de ogen (bijv. blefaritis, infectieuze conjunctivitis, keratitis, scleritis, endoftalmitis, uveïtis).","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12069920,"uuid":"998c98d0-86aa-45e1-b57d-bd5e84843d3b","attributeTranslation":"9.\tBármely aktív okuláris/intraokuláris fertőzés vagy gyulladás bármelyik szemben (pl. blefaritisz, fertőző kötőhártya-gyulladás, keratitisz, szkleritisz, endoftalmitisz, uveitisz).","language":13,"languageDescription":"Hungarian"},{"id":12069923,"uuid":"998c98d0-86aa-45e1-b57d-bd5e84843d3b","attributeTranslation":"9. Toute infection ou inflammation oculaire/intraoculaire active dans l’un ou \nl’autre œil (p. ex., blépharite, conjonctivite infectieuse, kératite, sclérite, \nendophtalmie, uvéite).","language":10,"languageDescription":"French"},{"id":12069922,"uuid":"998c98d0-86aa-45e1-b57d-bd5e84843d3b","attributeTranslation":"9.\tJede aktive okuläre/intraokuläre Infektion oder Entzündung in einem der beiden Augen (z. B. Blepharitis, infektiöse Konjunktivitis, Keratitis, Skleritis, Endophthalmitis, Uveitis).","language":27,"languageDescription":"German (Austria)"}]}]},"endPoint":{"primaryEndPoints":[{"id":1135949,"number":1,"endPoint":"Confirmed best corrected visual acuity (BCVA) ≥15-letter loss from baseline through Month 15 as assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) method.","isPrimary":true,"endPointTranslations":[{"id":12069811,"uuid":"e838e83c-aaa7-49d7-89d4-62b275dea2e4","attributeTranslation":"A legjobb korrigált látásélességben (BCVA) megerősítetten bekövetkező ≥15 betűnyi veszteség a kiindulástól kezdve 15. hónapig, a diabéteszes retinopátia korai kezelésének vizsgálata (Early Treatment Diabetic Retinopathy Study, ETDRS) módszeralapján.","language":13,"languageDescription":"Hungarian"},{"id":12069809,"uuid":"e838e83c-aaa7-49d7-89d4-62b275dea2e4","attributeTranslation":"Perte confirmée de la meilleure acuité visuelle corrigée (MAVC) ≥ 15 lettres entre la référence et le Mois 15, telle qu’évaluée par la méthode de l’étude sur le traitement précoce de la rétinopathie diabétique (Early Treatment Diabetic Retinopathy Study, ETDRS).","language":10,"languageDescription":"French"},{"id":12069808,"uuid":"e838e83c-aaa7-49d7-89d4-62b275dea2e4","attributeTranslation":"Bestätigter Verlust von ≥ 15 Buchstaben gegenüber der Baseline bei der bestkorrigierten Sehschärfe (best corrected visual acuity, BCVA) bis Monat 15, beurteilt anhand der ETDRS-Tabelle (Early Treatment Diabetic Retinopathy Study) Methode .","language":27,"languageDescription":"German (Austria)"},{"id":12069810,"uuid":"e838e83c-aaa7-49d7-89d4-62b275dea2e4","attributeTranslation":"Bevestigd verlies van ≥ 15 letters op best gecorrigeerde gezichtsscherpte (BCVA) ervaart vanaf de baseline tot en met maand 15, zoals beoordeeld aan de hand van de vroege behandeling van diabetische retinopathie (ETDRS)-methode.","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12069807,"uuid":"e838e83c-aaa7-49d7-89d4-62b275dea2e4","attributeTranslation":"Potwierdzona utrata ≥15 liter w ramach najlepszej skorygowanej ostrości wzroku (BCVA) w miesiącu 15 względem punktu wyjściowego, zgodnie z oceną za pomocą metody Badania wczesnego leczenia retinopatii cukrzycowej (ETDRS) .","language":19,"languageDescription":"Polish"},{"id":12069806,"uuid":"e838e83c-aaa7-49d7-89d4-62b275dea2e4","attributeTranslation":"Pérdida confirmada de ≥15 letras en la mejor agudeza visual corregida (MAVC) desde el momento basal hasta el mes 15 conforme al método del Estudio del Tratamiento Temprano de la Retinopatía Diabética (ETDRS).","language":7,"languageDescription":"Spanish"}]},{"id":1135992,"number":2,"endPoint":"Confirmed BCVA ≥15-letter loss from baseline through Month 24 as assessed by the ETDRS method.","isPrimary":true,"endPointTranslations":[{"id":12070310,"uuid":"eaee30b9-2c8a-410a-9298-3c1395d6d16c","attributeTranslation":"Bevestigd verlies van ≥15 letters vanaf de baseline tot en met maand 24, zoals beoordeeld aan de hand van de ETDRS-methode.","language":37,"languageDescription":"Dutch (Netherlands)"},{"id":12070307,"uuid":"eaee30b9-2c8a-410a-9298-3c1395d6d16c","attributeTranslation":"Bestätigter BCVA-Verlust von ≥ 15 Buchstaben gegenüber der Baseline bis Monat 24, ermittelt nach der ETDRS-Methode.","language":27,"languageDescription":"German (Austria)"},{"id":12070312,"uuid":"eaee30b9-2c8a-410a-9298-3c1395d6d16c","attributeTranslation":"Pérdida confirmada de MAVC de ≥15 letras desde el inicio hasta el mes 24, según la evaluación realizada mediante el método ETDRS.","language":7,"languageDescription":"Spanish"},{"id":12070308,"uuid":"eaee30b9-2c8a-410a-9298-3c1395d6d16c","attributeTranslation":"Perte confirmée de ≥ 15 lettres de la MAVC par rapport à la valeur initiale jusqu'au mois 24, évaluée selon la méthode ETDRS.","language":10,"languageDescription":"French"},{"id":12070309,"uuid":"eaee30b9-2c8a-410a-9298-3c1395d6d16c","attributeTranslation":"A kiinduláshoz képest a 24. hónapig bekövetkező megerősített BCVA ≥15 betűnyi veszteség az ETDRS módszerrel meghatározva.","language":13,"languageDescription":"Hungarian"},{"id":12070311,"uuid":"eaee30b9-2c8a-410a-9298-3c1395d6d16c","attributeTranslation":"Potwierdzona utrata ≥15 liter w BCVA względem punktu wyjściowego, utrzymująca się do 24. miesiąca, zgodnie z oceną za pomocą metody ETDRS.","language":19,"languageDescription":"Polish"}]}],"secondaryEndPoints":[{"id":1135950,"number":1,"endPoint":"Incidence and severity of ocular and systemic treatment-emergent adverse events (TEAEs) and adverse events of special interest (AESI)","isPrimary":false,"endPointTranslations":[{"id":12069817,"uuid":"91b4bb5c-adc7-405c-820d-fedf1f405e73","attributeTranslation":"Az okuláris és szisztémás kezelés miatt kialakult nemkívánatos események (TEAE) és a különleges figyelmet érdemlő nemkívánatos események (AESI) előfordulása és súlyossága","language":13,"languageDescription":"Hungarian"},{"id":12069813,"uuid":"91b4bb5c-adc7-405c-820d-fedf1f405e73","attributeTranslation":"Inzidenz und Schwere von okulären und systemischen therapieassoziierten unerwünschten Ereignissen (TEAEs) sowie unerwünschten Ereignissen von\nbesonderem Interesse (AESI)","language":27,"languageDescription":"German (Austria)"},{"id":12069816,"uuid":"91b4bb5c-adc7-405c-820d-fedf1f405e73","attributeTranslation":"Incidencia e intensidad de los acontecimientos adversos  surgidos durante el tratamiento (AAST) y los acontecimientos adversos de especial interés (AAEI) oculares\ny sistémicos.","language":7,"languageDescription":"Spanish"},{"id":12069812,"uuid":"91b4bb5c-adc7-405c-820d-fedf1f405e73","attributeTranslation":"Incidence et \ngravité des événements indésirables \noculaires et systémiques liés au\ntraitement (EILT)  et des événements indésirables d’intérêt particulier (EIIP)","language":10,"languageDescription":"French"},{"id":12069815,"uuid":"91b4bb5c-adc7-405c-820d-fedf1f405e73","attributeTranslation":"Częstość występowania i nasilenie pojawiających się w trakcie leczenia zdarzeń niepożądanych (TEAE) związanych z narządem wzroku i ogólnoustrojowych (TEAE) oraz zdarzeń niepożądanych o szczególnym znaczeniu (AESI)","language":19,"languageDescription":"Polish"},{"id":12069814,"uuid":"91b4bb5c-adc7-405c-820d-fedf1f405e73","attributeTranslation":"Incidentie en ernst van oculaire en systemische, door  de behandeling veroorzaakte  bijwerkingen (treatment emergent adverse events, TEAE’s) en bijwerkingen van bijzonder belang (adverse events of special interest AESI's).","language":37,"languageDescription":"Dutch (Netherlands)"}]}]},"trialDuration":{"estimatedGlobalEndDate":"2028-02-29","estimatedEndDate":"2028-02-29","estimatedRecruitmentStartDate":"2025-03-03"},"sourceOfMonetarySupport":[{"id":105062,"organisationName":"Annexon, Inc."}],"populationOfTrialSubjects":{"ageRanges":[{"id":391702,"ageRangeCategoryCode":"4","ageRangeCategory":"4"},{"id":391701,"ageRangeCategoryCode":"3","ageRangeCategory":"3"}],"ageRangeSecondaryIds":[{"id":391703,"ageRangeCategoryCode":"4","ctAgeRangeCode":"8","ageRangeCategory":"4","ctAgeRange":"8"},{"id":391704,"ageRangeCategoryCode":"4","ctAgeRangeCode":"7","ageRangeCategory":"4","ctAgeRange":"7"}],"clinicalTrialGroups":[{"code":"2","name":"Patients"}],"isFemaleSubjects":true,"isMaleSubjects":true,"isVulnerablePopulationSelected":true},"individualParticipantData":{"planToShareIPD":"3","planDescription":"IPD sharing plan not yet established. The CTIS IPD information will be updated at the later stage after IPD sharing plan is established."}},"protocolInformation":{"studyDesign":{"periodDetails":[{"id":203120,"businessKey":"1","title":"Screening","description":"The entire screening period (i.e., from the date of the first screening procedure until Day -1 [day prior to the first dose]), should not exceed 30 days for any given patient. This period will cover screening evaluations described in schedule of events, and assignment of a patient screening number.","blindingMethodCode":"3","blindedRoles":[],"armDetails":[],"allocationMethod":"3"},{"id":203121,"businessKey":"2","title":"Treatment","description":"Participants will visit the clinic each month during the 24-month treatment period for ANX007 or Sham administrations and safety assessments as detailed in the protocol","blindingMethodCode":"2","blindedRoles":[{"id":203123,"code":3,"name":"Monitor"},{"id":203124,"code":1,"name":"Subject"},{"id":203122,"code":4,"name":"Analyst"}],"blindingDetails":"All participants, study site personnel the evaluating physician, the  Sponsor,  Sponsor representatives (eg, Contract Research Organization [CRO], and the independent Central Reading Center personnel will be masked to treatment assignment (ANX007 or Sham control) except for:\n-The injecting physician and those assisting the injecting physician  \n-Site pharmacy team \n-Drug reconciliation clinical research associate (CRA)  \n-Data Safety Monitoring Committee (DSMC; see Section 11.6).) and firewalled team preparing unmasked reports \n-Clinical pharmacologist \nA list of the names and roles of the unmasked individuals is maintained in the investigator site files. Once a masked physician performs unmasked study evaluations (eg for emergency safety reasons), she/he cannot continue in the masked role.\n\nAt least 2 study physicians are required at each study site. A masked evaluating physician conducts routine study visits, which include safety assessments and eye examinations. An unmasked injecting physician performs all injections (ANX007 and Sham) and the immediate post-injection management. The unmasked injecting physician does not discuss any study-related observations with the masked members of the team.\nTreatment-revealing data, including PK and pharmacodynamics (PD) results, are not provided to the masked team until participant data have been cleaned (up to Month 24), the database has been locked, and the study is unmasked for the primary analysis. The Sponsor and Sponsor representatives involved with the analysis of the results will be unmasked after database lock to perform the primary analysis. The masked individuals involved with the conduct of the study will remain masked until after the database is locked for final analysis and unmasked.","armDetails":[{"description":"ANX007 once EM for 24 months (24 doses)","title":"ANX007 arm","id":112809},{"description":"Sham injection EM for 24 months","title":"Sham arm","id":112810}],"allocationMethod":"1"},{"id":203125,"businessKey":"3","title":"Month 24 / Early Termination (ET)","description":"All participants return to the clinic at Month 24/ET for\nsafety and efficacy follow-up assessments. Participants who discontinue from the treatment prior to completing the assigned treatment regimen will continue in the study and return to the clinic for follow-up assessments as scheduled","blindingMethodCode":"2","blindedRoles":[{"id":203126,"code":3,"name":"Monitor"},{"id":203127,"code":4,"name":"Analyst"},{"id":203128,"code":2,"name":"Investigator"}],"blindingDetails":"All participants, study site personnel  the evaluating physician, the Sponsor, Sponsor representatives (eg, Contract Research Organization [CRO], and the independent Central Reading Center personnel will be masked to treatment assignment (ANX007 or Sham control) except for:\n-The injecting physician and those assisting the injecting physician  \n-Site pharmacy team \n-Drug reconciliation clinical research associate (CRA)  \n-Data Safety Monitoring Committee (DSMC; see Section 11.6).) and firewalled team preparing unmasked reports \n-Clinical pharmacologist \nA list of the names and roles of the unmasked individuals is maintained in the investigator site files. Once a masked physician performs unmasked study evaluations (eg, for emergency safety reasons), she/he cannot continue in the masked role.\n\nAt least 2 study physicians are required at each study site. A masked evaluating physician conducts routine study visits, which include safety assessments and eye examinations. An unmasked injecting physician performs all injections (ANX007 and Sham) and the immediate post-injection management. The unmasked injecting physician  does not discuss any study-related observations with the masked members of the team.\nTreatment-revealing data, including PK and pharmacodynamics (PD) results, are not provided to the masked team until participant data have been cleaned (up to Month 24), the database has been locked, and the study is unmasked for the primary analysis. The Sponsor and Sponsor representatives involved with the analysis of the results will be unmasked after database lock to perform the primary analysis. The masked individuals involved with the conduct of the study will remain masked until after the database is locked for final analysis and unmasked.","armDetails":[{"description":"ANX007 once EM for 24 months (24 doses)","title":"ANX007 arm","id":112811},{"description":"Sham injection EM for 24 months","title":"Sham arm","id":112812}],"allocationMethod":"1"}]}},"scientificAdviceAndPip":{"scientificAdvices":[{"id":62253,"competentAuthority":{"id":595765,"organisation":{"id":628578,"type":"EEA National Competent authority","typeCode":"16","name":"Swedish Medical Products Agency","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100003944","organisationLocationStatus":"Active"},"address":{"addressId":643001,"oneLine":"Dag Hammarskjolds Vag 42, Uppsala Science Park","addressLine1":"Dag Hammarskjolds Vag 42","addressLine2":"Uppsala Science Park","addressLine3":"","addressLine4":"","city":"Uppsala","postcode":"752 37","country":2028,"countryName":"Sweden"},"isBusinessKeyValidated":true,"businessKey":"ORG-100003944"}},{"id":62255,"competentAuthority":{"id":595764,"organisation":{"id":628577,"type":"EU Institution/Body/Agency","typeCode":"14","name":"European Medicines Agency","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100013412","organisationLocationStatus":"Active"},"address":{"addressId":643000,"oneLine":"Domenico Scarlattilaan 6","addressLine1":"Domenico Scarlattilaan 6","addressLine2":"","addressLine3":"","addressLine4":"","city":"Amsterdam","postcode":"1083 HS","country":2029,"countryName":"Netherlands"},"isBusinessKeyValidated":true,"businessKey":"ORG-100013412"}},{"id":62254,"competentAuthority":{"id":595767,"organisation":{"id":628580,"type":"EEA National Competent authority","typeCode":"16","name":"Spanish Agency For Medicines And Health Products","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100003943","organisationLocationStatus":"Active"},"address":{"addressId":643003,"oneLine":"Edificio 8, Calle Campezo Nº 1","addressLine1":"Edificio 8","addressLine2":"Calle Campezo Nº 1","addressLine3":"","addressLine4":"","city":"Madrid","postcode":"28022","country":2027,"countryName":"Spain"},"isBusinessKeyValidated":true,"businessKey":"ORG-100003943"}}],"paediatricInvestigationPlan":[]},"associatedClinicalTrials":[],"references":[],"pubmedCode":[],"pubmedUrl":[]},"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-11-09","conclusionDate":"2026-11-09","therapeuticAreas":[{"code":"11","name":"Diseases [C] - Eye Diseases [C11]"}],"medicalConditions":[{"id":149401,"medicalCondition":"Dry Age-Related Macular Degeneration (AMD) with geographic atrophy (GA)","isConditionRareDisease":false}],"sponsors":[{"id":162489,"primary":true,"publicContacts":[{"id":479684,"type":"Public","functionalName":"AJ Acker","functionalEmailAddress":"aacker@annexonbio.com","telephone":"16508225500","organisation":{"id":502523,"type":"Pharmaceutical company","typeCode":"10","name":"Annexon Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100014540","organisationLocationStatus":"Active"}}],"scientificContacts":[{"id":479685,"type":"Scientific","functionalName":"Jamie Dananberg, MD.","functionalEmailAddress":"jdananberg@annexonbio.com","telephone":"13178748450","organisation":{"id":502523,"type":"Pharmaceutical company","typeCode":"10","name":"Annexon Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100014540","organisationLocationStatus":"Active"}}],"thirdParties":[{"id":743251,"organisationAddress":{"id":597474,"organisation":{"id":630297,"type":"Laboratory/Research/Testing facility","typeCode":"9","name":"Labconnect LLC","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100042800","organisationLocationStatus":"Active"},"address":{"addressId":644926,"oneLine":"2304 Silverdale Drive Suite 100","addressLine1":"2304 Silverdale Drive Suite 100","addressLine2":"","addressLine3":"","addressLine4":"","city":"Johnson City","postcode":"37601-2590","country":840,"countryName":"United States"},"phone":"14235248500","email":"jmedas@labconnect.com","isBusinessKeyValidated":true,"businessKey":"ORG-100042800"},"sponsorDuties":[{"id":1151498,"code":"15","value":"central lab"}],"phoneNumber":"14235248500","email":"jmedas@labconnect.com"},{"id":743255,"organisationAddress":{"id":597494,"organisation":{"id":630317,"type":"Pharmaceutical company","typeCode":"10","name":"Transperfect Translations International Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100043494","organisationLocationStatus":"Active"},"address":{"addressId":644948,"oneLine":"1250 Broadway Fl 32th","addressLine1":"1250 Broadway Fl 32th","addressLine2":"","addressLine3":"","addressLine4":"","city":"New York","postcode":"10001-3749","country":840,"countryName":"United States"},"phone":"16502551241","email":"tala.husary@transperfect.com","isBusinessKeyValidated":true,"businessKey":"ORG-100043494"},"sponsorDuties":[{"id":1151516,"code":"15","value":"Translation services"}],"phoneNumber":"16502551241","email":"tala.husary@transperfect.com"},{"id":743254,"organisationAddress":{"id":597464,"organisation":{"id":630287,"type":"Pharmaceutical company","typeCode":"10","name":"PPD Development LP","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100011560","organisationLocationStatus":"Active"},"address":{"addressId":644916,"oneLine":"3151 South 17th Street","addressLine1":"3151 South 17th Street","addressLine2":"","addressLine3":"","addressLine4":"","city":"Wilmington","postcode":"28412-6461","country":840,"countryName":"United States"},"phone":"+33182392401","email":"EUCTRInquiry.sm@ppd.com","isBusinessKeyValidated":true,"businessKey":"ORG-100011560"},"sponsorDuties":[{"id":1151502,"code":"1"},{"id":1151503,"code":"10"},{"id":1151504,"code":"11"},{"id":1151505,"code":"12"},{"id":1151506,"code":"13"},{"id":1151507,"code":"14"},{"id":1151508,"code":"2"},{"id":1151509,"code":"3"},{"id":1151510,"code":"4"},{"id":1151511,"code":"5"},{"id":1151512,"code":"6"},{"id":1151513,"code":"7"},{"id":1151514,"code":"8"},{"id":1151515,"code":"9"}],"phoneNumber":"+33182392401","email":"EUCTRInquiry.sm@ppd.com"},{"id":743257,"organisationAddress":{"id":597484,"organisation":{"id":630307,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Scout Clinical","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100042228","organisationLocationStatus":"Active"},"address":{"addressId":644937,"oneLine":"15770 Dallas Pkwy Ste 1075","addressLine1":"15770 Dallas Pkwy Ste 1075","addressLine2":"","addressLine3":"","addressLine4":"","city":"Dallas","postcode":"75248-3331","country":840,"countryName":"United States"},"phone":"19725036119","email":"clientcompliance@meetingprotocol.com","isBusinessKeyValidated":true,"businessKey":"ORG-100042228"},"sponsorDuties":[{"id":1151518,"code":"15","value":"Transportation/reimbursement"}],"phoneNumber":"19725036119","email":"clientcompliance@meetingprotocol.com"},{"id":743250,"organisationAddress":{"id":597477,"organisation":{"id":630300,"type":"Educational Institution","typeCode":"1","name":"Duke University","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100051387","organisationLocationStatus":"Active"},"address":{"addressId":644930,"oneLine":"2200 West Main Street Floor 10 Suite 1000","addressLine1":"2200 West Main Street Floor 10 Suite 1000","addressLine2":"","addressLine3":"","addressLine4":"","city":"Durham","postcode":"27705-1104","country":840,"countryName":"United States"},"phone":"19196133640","email":"patricia.phinney@duke.edu","isBusinessKeyValidated":true,"businessKey":"ORG-100051387"},"sponsorDuties":[{"id":1151497,"code":"15","value":"reading center"}],"phoneNumber":"19196133640","email":"patricia.phinney@duke.edu"},{"id":743256,"organisationAddress":{"id":597487,"organisation":{"id":630310,"type":"Pharmaceutical company","typeCode":"10","name":"Mapi Research Trust","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100028753","organisationLocationStatus":"Active"},"address":{"addressId":644941,"oneLine":"27 Rue De La Villette","addressLine1":"27 Rue De La Villette","addressLine2":"","addressLine3":"","addressLine4":"","city":"Lyon","postcode":"69003","country":2012,"countryName":"France"},"phone":"330472136666","email":"magdalena.heluszka@mapi-trust.org","isBusinessKeyValidated":true,"businessKey":"ORG-100028753"},"sponsorDuties":[{"id":1151517,"code":"15","value":"Clinical Outcome Assessment provider"}],"phoneNumber":"330472136666","email":"magdalena.heluszka@mapi-trust.org"},{"id":743248,"organisationAddress":{"id":782209,"organisation":{"id":820999,"type":"Pharmaceutical company","typeCode":"10","name":"Charles River Laboratories Montreal ULC","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100041009","organisationLocationStatus":"Active"},"address":{"addressId":863736,"oneLine":"445 Armand-Frappier Blvd","addressLine1":"445 Armand-Frappier Blvd","addressLine2":"","addressLine3":"","addressLine4":"","city":"Laval","postcode":"H7V 4B3","country":124,"countryName":"Canada"},"phone":"4509732240","email":"Marilyne.Blain@crl.com","isBusinessKeyValidated":true,"businessKey":"ORG-100041009"},"sponsorDuties":[{"id":1151495,"code":"15","value":"Specialty lab"}],"phoneNumber":"4509732240","email":"Marilyne.Blain@crl.com"},{"id":743253,"organisationAddress":{"id":597486,"organisation":{"id":630309,"type":"Pharmaceutical company","typeCode":"10","name":"Icon Public Limited Company","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100042517","organisationLocationStatus":"Active"},"address":{"addressId":644940,"oneLine":"South County Business Park","addressLine1":"South County Business Park","addressLine2":"","addressLine3":"","addressLine4":"","city":"Dublin 18","postcode":"D18 X5R3","country":2017,"countryName":"Ireland"},"phone":"35312912000","email":"Lynne.Abell@iconplc.com","isBusinessKeyValidated":true,"businessKey":"ORG-100042517"},"sponsorDuties":[{"id":1151500,"code":"15","value":"Pharmacovigilance/SAE reporting"},{"id":1151501,"code":"8"}],"phoneNumber":"35312912000","email":"Lynne.Abell@iconplc.com"},{"id":743247,"organisationAddress":{"id":597500,"organisation":{"id":630323,"type":"Non-Pharmaceutical company","typeCode":"11","name":"Medidata Solutions Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100016256","organisationLocationStatus":"Active"},"address":{"addressId":644954,"oneLine":"350 Hudson Street","addressLine1":"350 Hudson Street","addressLine2":"","addressLine3":"","addressLine4":"","city":"New York","postcode":"10014-4504","country":840,"countryName":"United States"},"phone":"7142354818","email":"michelle.mckenzie@3ds.com","isBusinessKeyValidated":true,"businessKey":"ORG-100016256"},"sponsorDuties":[{"id":1151493,"code":"15","value":"EDC/RTSM"},{"id":1151494,"code":"7"}],"phoneNumber":"7142354818","email":"michelle.mckenzie@3ds.com"},{"id":743252,"organisationAddress":{"id":786576,"organisation":{"id":825394,"type":"Pharmaceutical company","typeCode":"10","name":"Charles River Laboratories Montreal ULC","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100041009","organisationLocationStatus":"Active"},"address":{"addressId":868986,"oneLine":"22022 Aut Felix-Leclerc","addressLine1":"22022 Aut Felix-Leclerc","addressLine2":"","addressLine3":"","addressLine4":"","city":"Senneville","postcode":"H9X 3R3","country":124,"countryName":"Canada"},"phone":"5146308200","email":"Jamie.Dubois@crl.com","isBusinessKeyValidated":true,"businessKey":"ORG-100041009"},"sponsorDuties":[{"id":1151499,"code":"15","value":"Specialty lab"}],"phoneNumber":"5146308200","email":"Jamie.Dubois@crl.com"},{"id":743249,"organisationAddress":{"id":597471,"organisation":{"id":630294,"type":"Laboratory/Research/Testing facility","typeCode":"9","name":"Optymedge LLC","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100045359","organisationLocationStatus":"Active"},"address":{"addressId":644923,"oneLine":"401 North Washington Street Suite 700","addressLine1":"401 North Washington Street Suite 700","addressLine2":"","addressLine3":"","addressLine4":"","city":"Rockville","postcode":"20850-1785","country":840,"countryName":"United States"},"phone":"3012511161","email":"cforee@optymedge.com","isBusinessKeyValidated":true,"businessKey":"ORG-100045359"},"sponsorDuties":[{"id":1151496,"code":"15","value":"Visual Acuity Certification"}],"phoneNumber":"3012511161","email":"cforee@optymedge.com"}],"organisation":{"id":502523,"type":"Pharmaceutical company","typeCode":"10","name":"Annexon Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100014540","organisationLocationStatus":"Active"},"addresses":[{"id":470153,"organisation":{"id":502523,"type":"Pharmaceutical company","typeCode":"10","name":"Annexon Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100014540","organisationLocationStatus":"Active"},"address":{"addressId":504083,"oneLine":"1400 Sierra Point Parkway","addressLine1":"1400 Sierra Point Parkway","addressLine2":"","addressLine3":"","addressLine4":"","city":"Brisbane","postcode":"94005-1808","country":840,"countryName":"United States"},"isBusinessKeyValidated":true,"businessKey":"ORG-100014540"}],"isCommercial":true,"commercial":"Commercial"}],"trialCategoryCode":"2","trialCategoryJustificationComment":"This is a phase III trial","partOneTherapeuticAreas":[{"id":1238658,"therapeuticArea":{"code":"11","name":"Diseases [C] - Eye Diseases [C11]"}}],"productRoleGroupInfos":[{"id":441088,"comments":"ANX007","miaNumber":"104478","productRoleCode":"1","productRoleName":"Test","products":[{"id":594731,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11576174","productPharmForm":"INJECTION","euMpNumber":"PRD11516336","prodAuthStatus":1,"prodName":"ANX007","pharmForm":"INJECTION","sponsorProductCode":"ANX007","activeSubstanceName":"ANX007","euSubstNumber":"SUB329239","nameOrg":"ANNEXON, INC.","productSubstances":[{"productPk":"11576174","substancePk":"329255","nameOrg":"ANNEXON, INC.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"ANX007","substanceEvCode":"SUB329239"}],"activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"000","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"000","maxTreatmentPeriod":24,"timeUnitCode":"3","evCode":"PRD11516336","sponsorProductCodeEdit":"ANX007","miaNumber":"104478","devices":[],"characteristics":["7"],"routes":["INTRAVITREAL USE"],"allSubstancesChemicals":false,"productName":"ANX007","jsonActiveSubstanceNames":"anx007","pharmaceuticalFormDisplay":"INJECTION"}]}],"isLowIntervention":false},"authorizedPartsII":[{"id":238639,"mscId":39620,"mscInfo":{"id":39620,"clinicalTrialId":15935,"countryOrganisationId":2029,"reportingStatusCode":"Authorised","fromDate":"2025-01-15","toDate":"2025-01-15","isProposedRms":true,"expressDecision":"unwilling","countryName":"Netherlands","organisationInfo":{},"firstDecisionDate":"2025-02-10","trialStatus":"Authorised","trialPeriod":[{"id":57250,"trialStartDate":"2025-05-21","fromDate":"2025-05-22"},{"id":57265,"trialStartDate":"2025-05-21","fromDate":"2025-05-22"}],"trialRecruitmentPeriod":[{"id":77230,"recruitmentStartDate":"2025-05-21","fromDate":"2025-05-22"},{"id":82049,"recruitmentStartDate":"2025-05-21","recruitmentEndDate":"2025-06-25","fromDate":"2025-07-10"},{"id":82050,"recruitmentStartDate":"2025-05-21","recruitmentEndDate":"2025-06-25","fromDate":"2025-07-10"},{"id":82002,"recruitmentStartDate":"2025-05-21","recruitmentEndDate":"2025-06-25","fromDate":"2025-07-10"},{"id":77606,"recruitmentStartDate":"2025-05-21","fromDate":"2025-05-27"},{"id":77607,"recruitmentStartDate":"2025-05-21","fromDate":"2025-05-27"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":83728,"trialStartDate":"2025-05-21","fromDate":"2025-05-22"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2025-05-21","recruitmentEndDate":"2025-06-25"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":55162,"mscId":39620,"trialStatus":"Under evaluation","trialStatusDate":"2024-10-03T20:03:11.654"},{"id":75995,"mscId":39620,"trialStatus":"Authorised","trialStatusDate":"2025-02-10T15:44:39.608"}],"applicationTypeMsc":"1","mscName":"Netherlands","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-09-29","decision":"authorized","decisionDate":"2025-02-10"},"decisionDate":"2025-02-10","recruitmentSubjectCount":4,"trialSites":[{"id":1620361,"organisationAddressInfo":{"id":611862,"organisation":{"id":649428,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Stichting Elisabeth-Tweesteden Ziekenhuis","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100031075","organisationLocationStatus":"Active"},"address":{"addressId":661122,"oneLine":"Dr. Deelenlaan 5","addressLine1":"Dr. Deelenlaan 5","addressLine2":"","addressLine3":"","addressLine4":"","city":"Tilburg","postcode":"5042 AD","country":2029,"countryName":"Netherlands"},"phone":"+31132100000","email":"j.vanlith-verhoeven@etz.nl","isBusinessKeyValidated":true,"businessKey":"ORG-100031075"},"personInfo":{"id":1801686,"firstName":"Janneke","lastName":"van Lith-Verhoeven","telephone":"+31132100000","email":"j.vanlith-verhoeven@etz.nl","title":"1"},"departmentName":"Ophthalmology"}],"applicationStatusCode":"Authorised"},{"id":236365,"mscId":39621,"mscInfo":{"id":39621,"clinicalTrialId":15935,"countryOrganisationId":2031,"reportingStatusCode":"Authorised","fromDate":"2025-01-13","toDate":"2025-01-13","isProposedRms":false,"expressDecision":"unwilling","countryName":"Poland","organisationInfo":{},"firstDecisionDate":"2025-02-17","trialStatus":"Authorised","trialPeriod":[{"id":54774,"trialStartDate":"2025-04-07","fromDate":"2025-04-11"},{"id":54775,"trialStartDate":"2025-04-07","fromDate":"2025-04-11"}],"trialRecruitmentPeriod":[{"id":73652,"recruitmentStartDate":"2025-04-07","fromDate":"2025-04-11"},{"id":73653,"recruitmentStartDate":"2025-04-07","fromDate":"2025-04-11"},{"id":82001,"recruitmentStartDate":"2025-04-07","recruitmentEndDate":"2025-06-25","fromDate":"2025-07-10"},{"id":82047,"recruitmentStartDate":"2025-04-07","recruitmentEndDate":"2025-06-25","fromDate":"2025-07-10"},{"id":82048,"recruitmentStartDate":"2025-04-07","recruitmentEndDate":"2025-06-25","fromDate":"2025-07-10"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":78979,"trialStartDate":"2025-04-07","fromDate":"2025-04-11"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2025-04-07","recruitmentEndDate":"2025-06-25"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":55163,"mscId":39621,"trialStatus":"Under evaluation","trialStatusDate":"2024-10-03T20:03:11.665"},{"id":76600,"mscId":39621,"trialStatus":"Authorised","trialStatusDate":"2025-02-17T14:19:04.347"}],"applicationTypeMsc":"1","mscName":"Poland","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-09-27","decision":"authorized","decisionDate":"2025-02-17"},"decisionDate":"2025-02-17","recruitmentSubjectCount":11,"trialSites":[{"id":1604118,"organisationAddressInfo":{"id":612553,"organisation":{"id":650123,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Oftalmika Sp. z o.o.","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100044391","organisationLocationStatus":"Active"},"address":{"addressId":661892,"oneLine":"Ul. Modrzewiowa 15","addressLine1":"Ul. Modrzewiowa 15","addressLine2":"","addressLine3":"","addressLine4":"","city":"Bydgoszcz","postcode":"85-631","country":2031,"countryName":"Poland"},"phone":"+48606616655","email":"bartka@by.onet.pl","isBusinessKeyValidated":true,"businessKey":"ORG-100044391"},"personInfo":{"id":1783713,"firstName":"Bartlomiej","lastName":"Kaluzny","telephone":"+48606616655","email":"bartka@by.onet.pl","title":"2"},"departmentName":"n/a"},{"id":1604119,"organisationAddressInfo":{"id":612562,"organisation":{"id":650132,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Osrodek Chirurgii Oka Prof.Zagorskiego Sp. z o.o.","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100047117","organisationLocationStatus":"Active"},"address":{"addressId":661901,"oneLine":"Ul. Stanislawa Moniuszki 8","addressLine1":"Ul. Stanislawa Moniuszki 8","addressLine2":"","addressLine3":"","addressLine4":"","city":"Rzeszow","postcode":"35-015","country":2031,"countryName":"Poland"},"phone":"+48607760370","email":"jsamela@ocho.pl","isBusinessKeyValidated":true,"businessKey":"ORG-100047117"},"personInfo":{"id":1783714,"firstName":"Justyna","lastName":"Mazur- Samela","telephone":"+48607760370","email":"jsamela@ocho.pl","title":"1"},"departmentName":"n/a"},{"id":1604117,"organisationAddressInfo":{"id":612557,"organisation":{"id":650127,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Uniwersyteckie Centrum Kliniczne Im. Prof. K. Gibinskiego Slaskiego Uniwersytetu Medycznego W Katowicach","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100044004","organisationLocationStatus":"Active"},"address":{"addressId":661896,"oneLine":"Ul. Ceglana 35","addressLine1":"Ul. Ceglana 35","addressLine2":"","addressLine3":"","addressLine4":"","city":"Katowice","postcode":"40-514","country":2031,"countryName":"Poland"},"phone":"+48698751950","email":"mrukwa@uck.katowice.pl","isBusinessKeyValidated":true,"businessKey":"ORG-100044004"},"personInfo":{"id":1783712,"firstName":"Ewa","lastName":"Mrukwa- Kominek","telephone":"+48698751950","email":"mrukwa@uck.katowice.pl","title":"2"},"departmentName":"Oddzial Okulistyki Dorosłych"},{"id":1604120,"organisationAddressInfo":{"id":612554,"organisation":{"id":650124,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Centrum Diagnostyki I Mikrochirurgii Oka Lens Sp. z o.o.","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100045015","organisationLocationStatus":"Active"},"address":{"addressId":661893,"oneLine":"Ul. Budowlana 3a","addressLine1":"Ul. Budowlana 3a","addressLine2":"","addressLine3":"","addressLine4":"","city":"Olsztyn","postcode":"10-424","country":2031,"countryName":"Poland"},"phone":"48691463680","email":"domizal@gmail.com","isBusinessKeyValidated":true,"businessKey":"ORG-100045015"},"personInfo":{"id":1783715,"firstName":"Dominik","lastName":"Zalewski","telephone":"48691463680","email":"domizal@gmail.com","title":"1"},"departmentName":"n/a"},{"id":1604116,"organisationAddressInfo":{"id":612563,"organisation":{"id":650133,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Caminomed Sp. z o.o.","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100052129","organisationLocationStatus":"Active"},"address":{"addressId":661902,"oneLine":"Ul. Kardynala Stefana Wyszynskiego 3a","addressLine1":"Ul. Kardynala Stefana Wyszynskiego 3a","addressLine2":"","addressLine3":"","addressLine4":"","city":"Tarnowskie Gory","postcode":"42-600","country":2031,"countryName":"Poland"},"phone":"+48322710400","email":"caminomed.zatorska@gmail.com","isBusinessKeyValidated":true,"businessKey":"ORG-100052129"},"personInfo":{"id":1783711,"firstName":"Barbara","lastName":"Zatorska","telephone":"+48322710400","email":"caminomed.zatorska@gmail.com","title":"1"},"departmentName":"n/a"},{"id":1604121,"organisationAddressInfo":{"id":612556,"organisation":{"id":650126,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Warszawski Szpital Okulistyczny Sp. z o.o.","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100044696","organisationLocationStatus":"Active"},"address":{"addressId":661895,"oneLine":"Ul. Wolska 165/u7","addressLine1":"Ul. Wolska 165/u7","addressLine2":"","addressLine3":"","addressLine4":"","city":"Warsaw","postcode":"01-258","country":2031,"countryName":"Poland"},"phone":"48505976069","email":"nowosielska.aga@gmail.com","isBusinessKeyValidated":true,"businessKey":"ORG-100044696"},"personInfo":{"id":1783716,"firstName":"Agnieszka","lastName":"Nowosielska","telephone":"48505976069","email":"nowosielska.aga@gmail.com","title":"1"},"departmentName":"n/a"}],"applicationStatusCode":"Authorised"},{"id":233559,"mscId":39616,"mscInfo":{"id":39616,"clinicalTrialId":15935,"countryOrganisationId":2015,"reportingStatusCode":"Authorised","fromDate":"2025-01-07","toDate":"2025-01-07","isProposedRms":false,"expressDecision":"unwilling","countryName":"Hungary","organisationInfo":{},"firstDecisionDate":"2025-02-13","trialStatus":"Authorised","trialPeriod":[{"id":54772,"trialStartDate":"2025-04-01","fromDate":"2025-04-11"},{"id":54773,"trialStartDate":"2025-04-01","fromDate":"2025-04-11"}],"trialRecruitmentPeriod":[{"id":73650,"recruitmentStartDate":"2025-04-01","fromDate":"2025-04-11"},{"id":73651,"recruitmentStartDate":"2025-04-01","fromDate":"2025-04-11"},{"id":82005,"recruitmentStartDate":"2025-04-01","recruitmentEndDate":"2025-06-26","fromDate":"2025-07-10"},{"id":82055,"recruitmentStartDate":"2025-04-01","recruitmentEndDate":"2025-06-26","fromDate":"2025-07-10"},{"id":82056,"recruitmentStartDate":"2025-04-01","recruitmentEndDate":"2025-06-26","fromDate":"2025-07-10"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":78977,"trialStartDate":"2025-04-01","fromDate":"2025-04-11"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2025-04-01","recruitmentEndDate":"2025-06-26"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":55159,"mscId":39616,"trialStatus":"Under evaluation","trialStatusDate":"2024-10-03T20:03:11.618"},{"id":76320,"mscId":39616,"trialStatus":"Authorised","trialStatusDate":"2025-02-13T14:44:42.108"}],"applicationTypeMsc":"1","mscName":"Hungary","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-09-29","decision":"authorized","decisionDate":"2025-02-13"},"decisionDate":"2025-02-13","recruitmentSubjectCount":6,"trialSites":[{"id":1583837,"organisationAddressInfo":{"id":613891,"organisation":{"id":651722,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Nozologen Kft.","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100043044","organisationLocationStatus":"Active"},"address":{"addressId":663403,"oneLine":"Varady Antal Utca 10 Fszt. 5","addressLine1":"Varady Antal Utca 10 Fszt. 5","addressLine2":"","addressLine3":"","addressLine4":"","city":"Pecs","postcode":"7621","country":2015,"countryName":"Hungary"},"phone":"3672951130","email":"varsanyi.balazs@ganglion.hu","isBusinessKeyValidated":true,"businessKey":"ORG-100043044"},"personInfo":{"id":1761202,"firstName":"Balázs","lastName":"Varsányi","telephone":"3672951130","email":"varsanyi.balazs@ganglion.hu","title":"1"},"departmentName":"n/a"},{"id":1583838,"organisationAddressInfo":{"id":663382,"organisation":{"id":701424,"type":"Educational Institution","typeCode":"1","name":"Semmelweis University","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100023482","organisationLocationStatus":"Active"},"address":{"addressId":721689,"oneLine":"Rokk Szilard Utca 13","addressLine1":"Rokk Szilard Utca 13","addressLine2":"","addressLine3":"","addressLine4":"","city":"Budapest VIII","postcode":"1085","country":2015,"countryName":"Hungary"},"phone":"3614591500","email":"andras.papp.md@gmail.com","isBusinessKeyValidated":true,"businessKey":"ORG-100023482"},"personInfo":{"id":1761203,"firstName":"András","lastName":"Papp","telephone":"3614591500","email":"andras.papp.md@gmail.com","title":"1"},"departmentName":"n/a"},{"id":1583836,"organisationAddressInfo":{"id":720187,"organisation":{"id":758448,"type":"Educational Institution","typeCode":"1","name":"University Of Debrecen","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100000129","organisationLocationStatus":"Active"},"address":{"addressId":789385,"oneLine":"Nagyerdei Korut 98","addressLine1":"Nagyerdei Korut 98","addressLine2":"","addressLine3":"","addressLine4":"","city":"Debrecen","postcode":"4032","country":2015,"countryName":"Hungary"},"phone":"+3652255456","email":"vajasa@gmail.com","isBusinessKeyValidated":true,"businessKey":"ORG-100000129"},"personInfo":{"id":1761201,"firstName":"Attila","lastName":"Vajas","telephone":"+3652255456","email":"vajasa@gmail.com","title":"1"},"departmentName":"Szemklinika"},{"id":1583841,"organisationAddressInfo":{"id":720172,"organisation":{"id":758433,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Central Hospital Of Northern Pest Military Hospital","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100029054","organisationLocationStatus":"Active"},"address":{"addressId":789369,"oneLine":"Podmaniczky Utca 109","addressLine1":"Podmaniczky Utca 109","addressLine2":"","addressLine3":"","addressLine4":"","city":"Budapest VI","postcode":"1062","country":2015,"countryName":"Hungary"},"phone":"+3614752525","email":"gabor.vogt@tosho.hu","isBusinessKeyValidated":true,"businessKey":"ORG-100029054"},"personInfo":{"id":1761206,"firstName":"Vogt","lastName":"Gábor","telephone":"+3614752525","email":"gabor.vogt@tosho.hu","title":"1"},"departmentName":"Szemészeti Osztály"},{"id":1583839,"organisationAddressInfo":{"id":720188,"organisation":{"id":758449,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Budapesti Bajcsy-Zsilinszky Korhaz Es Rendelointezet","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100042048","organisationLocationStatus":"Active"},"address":{"addressId":789387,"oneLine":"Maglodi Ut 89-91, Kerulet","addressLine1":"Maglodi Ut 89-91","addressLine2":"Kerulet","addressLine3":"","addressLine4":"","city":"Budapest","postcode":"1106","country":2015,"countryName":"Hungary"},"phone":"+36203396557","email":"agneskerenyi@gmail.com","isBusinessKeyValidated":true,"businessKey":"ORG-100042048"},"personInfo":{"id":1761204,"firstName":"Ágnes","lastName":"Kerényi","telephone":"+36203396557","email":"agneskerenyi@gmail.com","title":"1"},"departmentName":"Szemészeti Osztály"},{"id":1583840,"organisationAddressInfo":{"id":720286,"organisation":{"id":758547,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Budapest Retina Associates Kft.","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100045536","organisationLocationStatus":"Active"},"address":{"addressId":789497,"oneLine":"Vaci Ut 76, Kerulet","addressLine1":"Vaci Ut 76","addressLine2":"Kerulet","addressLine3":"","addressLine4":"","city":"Budapest XIII","postcode":"1133","country":2015,"countryName":"Hungary"},"phone":"+36307912014","email":"seres@budapestretina.hu","isBusinessKeyValidated":true,"businessKey":"ORG-100045536"},"personInfo":{"id":1761205,"firstName":"András","lastName":"Seres","telephone":"+36307912014","email":"seres@budapestretina.hu","title":"1"},"departmentName":"Szemészeti Osztály"}],"applicationStatusCode":"Authorised"},{"id":232320,"mscId":39623,"mscInfo":{"id":39623,"clinicalTrialId":15935,"countryOrganisationId":2012,"reportingStatusCode":"Authorised","fromDate":"2024-12-09","toDate":"2024-12-09","isProposedRms":false,"expressDecision":"unwilling","countryName":"France","organisationInfo":{},"firstDecisionDate":"2025-03-31","trialStatus":"Authorised","trialPeriod":[{"id":56007,"trialStartDate":"2025-04-28","fromDate":"2025-05-05"},{"id":55855,"trialStartDate":"2025-04-28","fromDate":"2025-05-01"}],"trialRecruitmentPeriod":[{"id":75471,"recruitmentStartDate":"2025-04-28","fromDate":"2025-05-06"},{"id":75472,"recruitmentStartDate":"2025-04-28","fromDate":"2025-05-06"},{"id":75349,"recruitmentStartDate":"2025-04-28","fromDate":"2025-05-05"},{"id":81998,"recruitmentStartDate":"2025-04-28","recruitmentEndDate":"2025-06-26","fromDate":"2025-07-10"},{"id":82045,"recruitmentStartDate":"2025-04-28","recruitmentEndDate":"2025-06-26","fromDate":"2025-07-10"},{"id":82046,"recruitmentStartDate":"2025-04-28","recruitmentEndDate":"2025-06-26","fromDate":"2025-07-10"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":81048,"trialStartDate":"2025-04-28","fromDate":"2025-05-05"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2025-04-28","recruitmentEndDate":"2025-06-26"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":55157,"mscId":39623,"trialStatus":"Under evaluation","trialStatusDate":"2024-10-03T20:03:11.594"},{"id":76344,"mscId":39623,"trialStatus":"Authorised","trialStatusDate":"2025-02-13T15:55:26.46"}],"applicationTypeMsc":"1","mscName":"France","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-08-14","decision":"authorized","decisionDate":"2025-03-31"},"decisionDate":"2025-03-31","recruitmentSubjectCount":8,"trialSites":[{"id":1574080,"organisationAddressInfo":{"id":720781,"organisation":{"id":759044,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Pole Vision Val D'Ouest","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100048563","organisationLocationStatus":"Active"},"address":{"addressId":790065,"oneLine":"39 Chemin De La Vernique","addressLine1":"39 Chemin De La Vernique","addressLine2":"","addressLine3":"","addressLine4":"","city":"Ecully","postcode":"69130","country":2012,"countryName":"France"},"phone":"+330637753072","email":"gonzalez_flore@yahoo.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100048563"},"personInfo":{"id":1750516,"firstName":"Flore","lastName":"De Bats","telephone":"+330637753072","email":"gonzalez_flore@yahoo.fr","title":"1"},"departmentName":"N/A"},{"id":1574076,"organisationAddressInfo":{"id":613507,"organisation":{"id":651181,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Centre Hospitalier Universitaire De Nice","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008529","organisationLocationStatus":"Active"},"address":{"addressId":662981,"oneLine":"30 Voie Romaine","addressLine1":"30 Voie Romaine","addressLine2":"","addressLine3":"","addressLine4":"","city":"Nice","postcode":"06000","country":2012,"countryName":"France"},"phone":"+33492038025","email":"Baillif.s@chu-nice.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100008529"},"personInfo":{"id":1750512,"firstName":"Stéphanie","lastName":"Baillif","telephone":"+33492038025","email":"Baillif.s@chu-nice.fr","title":"2"},"departmentName":"Ophthalmology Department"},{"id":1574079,"organisationAddressInfo":{"id":720780,"organisation":{"id":759043,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Centre Monticelli Paradis D Ophtalmologie","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100045317","organisationLocationStatus":"Active"},"address":{"addressId":790064,"oneLine":"433 Rue Paradis","addressLine1":"433 Rue Paradis","addressLine2":"","addressLine3":"","addressLine4":"","city":"Marseille","postcode":"13008","country":2012,"countryName":"France"},"phone":"+330491162232","email":"fdbm.retine@gmail.com","isBusinessKeyValidated":true,"businessKey":"ORG-100045317"},"personInfo":{"id":1750515,"firstName":"François","lastName":"Devin","telephone":"+330491162232","email":"fdbm.retine@gmail.com","title":"1"},"departmentName":"Ophtalmologie"},{"id":1574073,"organisationAddressInfo":{"id":613554,"organisation":{"id":651228,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Ophtalmologie Maison Rouge S.C.M.","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100046554","organisationLocationStatus":"Active"},"address":{"addressId":663032,"oneLine":"6 Rue De L Eglise","addressLine1":"6 Rue De L Eglise","addressLine2":"","addressLine3":"","addressLine4":"","city":"Strasbourg","postcode":"67000","country":2012,"countryName":"France"},"phone":"0033388321903","email":"bwolff@hotmail.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100046554"},"personInfo":{"id":1750509,"firstName":"Benjamin","lastName":"Wolff","telephone":"0033388321903","email":"bwolff@hotmail.fr","title":"1"},"departmentName":"Ophthalmology Department"},{"id":1574075,"organisationAddressInfo":{"id":613636,"organisation":{"id":651463,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Assistance Publique Hopitaux De Paris","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100004082","organisationLocationStatus":"Active"},"address":{"addressId":663124,"oneLine":"2 Rue Ambroise Pare","addressLine1":"2 Rue Ambroise Pare","addressLine2":"","addressLine3":"","addressLine4":"","city":"Paris Cedex 10","postcode":"75475","country":2012,"countryName":"France"},"phone":"0033149956489","email":"Aude.couturier@aphp.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100004082"},"personInfo":{"id":1750511,"firstName":"Aude","lastName":"Couturier","telephone":"0033149956489","email":"Aude.couturier@aphp.fr","title":"2"},"departmentName":"Ophthalmology Department"},{"id":1574072,"organisationAddressInfo":{"id":613599,"organisation":{"id":651273,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Quinze-Vingts National Ophthalmology Hospital","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100009504","organisationLocationStatus":"Active"},"address":{"addressId":663081,"oneLine":"28 Rue De Charenton","addressLine1":"28 Rue De Charenton","addressLine2":"","addressLine3":"","addressLine4":"","city":"Paris","postcode":"75012","country":2012,"countryName":"France"},"phone":"0033140021460","email":"jfgirmens@15-20.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100009504"},"personInfo":{"id":1750508,"firstName":"Jean François","lastName":"Girmens","telephone":"0033140021460","email":"jfgirmens@15-20.fr","title":"1"},"departmentName":"Centre d ’Investigation Clinique  1423"},{"id":1574077,"organisationAddressInfo":{"id":613558,"organisation":{"id":651232,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Centre Hospitalier Universitaire De Dijon","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100007304","organisationLocationStatus":"Active"},"address":{"addressId":663039,"oneLine":"2 Boulevard Mal De Lattre De Tassigny","addressLine1":"2 Boulevard Mal De Lattre De Tassigny","addressLine2":"","addressLine3":"","addressLine4":"","city":"Dijon","postcode":"21000","country":2012,"countryName":"France"},"phone":"0033380669468","email":"catherine.creuzot-garcher@chu-dijon.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100007304"},"personInfo":{"id":1750513,"firstName":"Catherine","lastName":"Creuzot-Garcher","telephone":"0033380669468","email":"catherine.creuzot-garcher@chu-dijon.fr","title":"2"},"departmentName":"Ophthalmology Department"},{"id":1574081,"organisationAddressInfo":{"id":613876,"organisation":{"id":651707,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Centre Hospitalier Universitaire De Bordeaux","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008602","organisationLocationStatus":"Active"},"address":{"addressId":663387,"oneLine":"Place Amelie Raba Leon","addressLine1":"Place Amelie Raba Leon","addressLine2":"","addressLine3":"","addressLine4":"","city":"Bordeaux","postcode":"33000","country":2012,"countryName":"France"},"phone":"0033557821216","email":"marie-noelle.delyfer@chu-bordeaux.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100008602"},"personInfo":{"id":1750517,"firstName":"Marie-Noëlle","lastName":"Delyfer","telephone":"0033557821216","email":"marie-noelle.delyfer@chu-bordeaux.fr","title":"2"},"departmentName":"Ophthalmology Department"},{"id":1574078,"organisationAddressInfo":{"id":720779,"organisation":{"id":759042,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Hospices Civils De Lyon","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100006597","organisationLocationStatus":"Active"},"address":{"addressId":790063,"oneLine":"103 Grande Rue De La Croix Rousse","addressLine1":"103 Grande Rue De La Croix Rousse","addressLine2":"","addressLine3":"","addressLine4":"","city":"Lyon Cedex 04","postcode":"69317","country":2012,"countryName":"France"},"phone":"+330426109321","email":"laurent.kodjikian@chu-lyon.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100006597"},"personInfo":{"id":1750514,"firstName":"Laurent","lastName":"Kodjikian","telephone":"+330426109321","email":"laurent.kodjikian@chu-lyon.fr","title":"2"},"departmentName":"Ophtalmologie"},{"id":1574074,"organisationAddressInfo":{"id":613530,"organisation":{"id":651204,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Centre Hospitalier Intercommunal Creteil","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100042860","organisationLocationStatus":"Active"},"address":{"addressId":663007,"oneLine":"40 Avenue De Verdun","addressLine1":"40 Avenue De Verdun","addressLine2":"","addressLine3":"","addressLine4":"","city":"Creteil","postcode":"94000","country":2012,"countryName":"France"},"phone":"0033145175908","email":"eric.souied@chicreteil.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100042860"},"personInfo":{"id":1750510,"firstName":"Eric","lastName":"Souied","telephone":"0033145175908","email":"eric.souied@chicreteil.fr","title":"1"},"departmentName":"Ophthalmology Department"}],"applicationStatusCode":"Authorised"},{"id":237961,"mscId":39613,"mscInfo":{"id":39613,"clinicalTrialId":15935,"countryOrganisationId":2000,"reportingStatusCode":"Authorised","fromDate":"2025-01-15","toDate":"2025-01-15","isProposedRms":false,"expressDecision":"unwilling","countryName":"Austria","organisationInfo":{},"firstDecisionDate":"2025-02-17","trialStatus":"Authorised","trialPeriod":[{"id":56163,"trialStartDate":"2025-04-23","fromDate":"2025-05-07"},{"id":56088,"trialStartDate":"2025-04-23","fromDate":"2025-05-06"}],"trialRecruitmentPeriod":[{"id":75693,"recruitmentStartDate":"2025-04-23","fromDate":"2025-05-07"},{"id":75694,"recruitmentStartDate":"2025-04-23","fromDate":"2025-05-07"},{"id":75662,"recruitmentStartDate":"2025-04-23","fromDate":"2025-05-07"},{"id":82059,"recruitmentStartDate":"2025-04-23","recruitmentEndDate":"2025-06-25","fromDate":"2025-07-10"},{"id":82060,"recruitmentStartDate":"2025-04-23","recruitmentEndDate":"2025-06-25","fromDate":"2025-07-10"},{"id":82004,"recruitmentStartDate":"2025-04-23","recruitmentEndDate":"2025-06-25","fromDate":"2025-07-10"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":81510,"trialStartDate":"2025-04-23","fromDate":"2025-05-07"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2025-04-23","recruitmentEndDate":"2025-06-25"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":55155,"mscId":39613,"trialStatus":"Under evaluation","trialStatusDate":"2024-10-03T20:03:11.567"},{"id":76613,"mscId":39613,"trialStatus":"Authorised","trialStatusDate":"2025-02-17T15:24:12.699"}],"applicationTypeMsc":"1","mscName":"Austria","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-09-22","decision":"authorized","decisionDate":"2025-02-17"},"decisionDate":"2025-02-17","recruitmentSubjectCount":8,"trialSites":[{"id":1615521,"organisationAddressInfo":{"id":612883,"organisation":{"id":650555,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Landeskrankenanstalten-Betriebsgesellschaft Kabeg","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100029233","organisationLocationStatus":"Active"},"address":{"addressId":662274,"oneLine":"Feschnigstrasse 11, Klagenfurt,09.Bez.:Annabichl","addressLine1":"Feschnigstrasse 11","addressLine2":"Klagenfurt,09.Bez.:Annabichl","addressLine3":"","addressLine4":"","city":"Klagenfurt Am Woerthersee","postcode":"9020","country":2000,"countryName":"Austria"},"phone":"+4346353832400","email":"yosuf.el-shabrawi@kabeg.at","isBusinessKeyValidated":true,"businessKey":"ORG-100029233"},"personInfo":{"id":1796330,"firstName":"Yosuf","lastName":"El-Shabrawi","telephone":"+4346353832400","email":"yosuf.el-shabrawi@kabeg.at","title":"2"},"departmentName":"Department of Ophthalmology and Optometry"},{"id":1615520,"organisationAddressInfo":{"id":612881,"organisation":{"id":650553,"type":"Educational Institution","typeCode":"1","name":"Johannes Kepler University Linz","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100038960","organisationLocationStatus":"Active"},"address":{"addressId":662272,"oneLine":"Med Campus III, Krankenhausstrasse 9","addressLine1":"Med Campus III","addressLine2":"Krankenhausstrasse 9","addressLine3":"","addressLine4":"","city":"Linz","postcode":"4020","country":2000,"countryName":"Austria"},"phone":"+4357680831050","email":"matthias.bolz@kepleruniklinikum.at","isBusinessKeyValidated":true,"businessKey":"ORG-100038960"},"personInfo":{"id":1796329,"firstName":"Matthias","lastName":"Bolz","telephone":"+4357680831050","email":"matthias.bolz@kepleruniklinikum.at","title":"2"},"departmentName":"Kepler University Clinic Linz,  University Clinic for Ophthalmology and  Optometry"}],"applicationStatusCode":"Authorised"},{"id":238180,"mscId":39617,"mscInfo":{"id":39617,"clinicalTrialId":15935,"countryOrganisationId":2018,"reportingStatusCode":"Authorised","fromDate":"2025-01-13","toDate":"2025-01-13","isProposedRms":false,"expressDecision":"unwilling","countryName":"Italy","organisationInfo":{},"firstDecisionDate":"2025-02-12","trialStatus":"Authorised","trialPeriod":[{"id":55854,"trialStartDate":"2025-04-29","fromDate":"2025-05-01"},{"id":56008,"trialStartDate":"2025-04-29","fromDate":"2025-05-05"}],"trialRecruitmentPeriod":[{"id":75473,"recruitmentStartDate":"2025-04-29","fromDate":"2025-05-06"},{"id":75474,"recruitmentStartDate":"2025-04-29","fromDate":"2025-05-06"},{"id":75350,"recruitmentStartDate":"2025-04-29","fromDate":"2025-05-05"},{"id":82003,"recruitmentStartDate":"2025-04-29","recruitmentEndDate":"2025-06-27","fromDate":"2025-07-10"},{"id":82053,"recruitmentStartDate":"2025-04-29","recruitmentEndDate":"2025-06-27","fromDate":"2025-07-10"},{"id":82054,"recruitmentStartDate":"2025-04-29","recruitmentEndDate":"2025-06-27","fromDate":"2025-07-10"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":81047,"trialStartDate":"2025-04-29","fromDate":"2025-05-01"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2025-04-29","recruitmentEndDate":"2025-06-27"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":55160,"mscId":39617,"trialStatus":"Under evaluation","trialStatusDate":"2024-10-03T20:03:11.629"},{"id":76264,"mscId":39617,"trialStatus":"Authorised","trialStatusDate":"2025-02-12T19:13:26.205"}],"applicationTypeMsc":"1","mscName":"Italy","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-09-27","decision":"authorized","decisionDate":"2025-02-12"},"decisionDate":"2025-02-12","recruitmentSubjectCount":39,"trialSites":[{"id":1617034,"organisationAddressInfo":{"id":612023,"organisation":{"id":649591,"type":"Patient organisation/association","typeCode":"6","name":"Fondazione G.B.Bietti Per Lo Studio E La Ricerca In Oftalmologia","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100046577","organisationLocationStatus":"Active"},"address":{"addressId":661299,"oneLine":"Via Di Santo Stefano Rotondo 6","addressLine1":"Via Di Santo Stefano Rotondo 6","addressLine2":"","addressLine3":"","addressLine4":"","city":"Rome","postcode":"00184","country":2018,"countryName":"Italy"},"phone":"+393395249399","email":"monica.varano@fondazionebietti.it","isBusinessKeyValidated":true,"businessKey":"ORG-100046577"},"personInfo":{"id":1798031,"firstName":"Monica","lastName":"Varano","telephone":"+393395249399","email":"monica.varano@fondazionebietti.it","title":"1"},"departmentName":"U.O.C Retina Medica"},{"id":1617027,"organisationAddressInfo":{"id":612016,"organisation":{"id":649584,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Azienda Ospedaliera Policlinico Universitario Tor Vergata","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100030361","organisationLocationStatus":"Active"},"address":{"addressId":661291,"oneLine":"Viale Oxford 81","addressLine1":"Viale Oxford 81","addressLine2":"","addressLine3":"","addressLine4":"","city":"Rome","postcode":"00133","country":2018,"countryName":"Italy"},"phone":"+390620903348","email":"federico.ricci@uniroma2.it","isBusinessKeyValidated":true,"businessKey":"ORG-100030361"},"personInfo":{"id":1798024,"firstName":"Federico","lastName":"Ricci","telephone":"+390620903348","email":"federico.ricci@uniroma2.it","title":"1"},"departmentName":"Unit Patologie Retiniche -  4° piano - Torre 6"},{"id":1617028,"organisationAddressInfo":{"id":612021,"organisation":{"id":649589,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100014358","organisationLocationStatus":"Active"},"address":{"addressId":661297,"oneLine":"Largo Francesco Vito 1","addressLine1":"Largo Francesco Vito 1","addressLine2":"","addressLine3":"","addressLine4":"","city":"Rome","postcode":"00168","country":2018,"countryName":"Italy"},"phone":"+390630154929","email":"angelomaria.minnella@unicatt.it","isBusinessKeyValidated":true,"businessKey":"ORG-100014358"},"personInfo":{"id":1798025,"firstName":"Angelo Maria","lastName":"Minnella","telephone":"+390630154929","email":"angelomaria.minnella@unicatt.it","title":"1"},"departmentName":"UOC Oculistica"},{"id":1617029,"organisationAddressInfo":{"id":612006,"organisation":{"id":649574,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Careggi University Hospital","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100010591","organisationLocationStatus":"Active"},"address":{"addressId":661281,"oneLine":"Largo Giovanni Alessandro Brambilla 3","addressLine1":"Largo Giovanni Alessandro Brambilla 3","addressLine2":"","addressLine3":"","addressLine4":"","city":"Florence","postcode":"50134","country":2018,"countryName":"Italy"},"phone":"+390557946992","email":"daniela.bacherini@unifi.com","isBusinessKeyValidated":true,"businessKey":"ORG-100010591"},"personInfo":{"id":1798026,"firstName":"Daniela","lastName":"Bacherini","telephone":"+390557946992","email":"daniela.bacherini@unifi.com","title":"1"},"departmentName":"SOD Oculistica"},{"id":1617030,"organisationAddressInfo":{"id":611837,"organisation":{"id":649403,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Ospedale San Raffaele S.r.l.","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100006123","organisationLocationStatus":"Active"},"address":{"addressId":661094,"oneLine":"Via Olgettina 60","addressLine1":"Via Olgettina 60","addressLine2":"","addressLine3":"","addressLine4":"","city":"Milan","postcode":"20132","country":2018,"countryName":"Italy"},"phone":"+390226432641","email":"bandello.francesco@hsr.it","isBusinessKeyValidated":true,"businessKey":"ORG-100006123"},"personInfo":{"id":1798027,"firstName":"Francesco","lastName":"Bandello","telephone":"+390226432641","email":"bandello.francesco@hsr.it","title":"1"},"departmentName":"Unità Operativa di Oculistica - Settore A / Piano -1"},{"id":1617026,"organisationAddressInfo":{"id":611995,"organisation":{"id":649563,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Multimedica S.p.A.","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100045824","organisationLocationStatus":"Active"},"address":{"addressId":661269,"oneLine":"Via San Vittore 12","addressLine1":"Via San Vittore 12","addressLine2":"","addressLine3":"","addressLine4":"","city":"Milan","postcode":"20123","country":2018,"countryName":"Italy"},"phone":"+393389187604","email":"stela.vujosevic@unimi.it","isBusinessKeyValidated":true,"businessKey":"ORG-100045824"},"personInfo":{"id":1798023,"firstName":"Stela","lastName":"Vujosevic","telephone":"+393389187604","email":"stela.vujosevic@unimi.it","title":"1"},"departmentName":"U.O. Oculistica"},{"id":1617033,"organisationAddressInfo":{"id":637788,"organisation":{"id":675725,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"ASST Fatebenefratelli Sacco","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100009926","organisationLocationStatus":"Active"},"address":{"addressId":690765,"oneLine":"Via Giovanni Battista Grassi 74","addressLine1":"Via Giovanni Battista Grassi 74","addressLine2":"","addressLine3":"","addressLine4":"","city":"Milan","postcode":"20157","country":2018,"countryName":"Italy"},"phone":"+390239042666","email":"chiararosina@gmail.com","isBusinessKeyValidated":true,"businessKey":"ORG-100009926"},"personInfo":{"id":1798030,"firstName":"Chiara","lastName":"Rosina","telephone":"+390239042666","email":"chiararosina@gmail.com","title":"1"},"departmentName":"Clinica Oculistica"},{"id":1617031,"organisationAddressInfo":{"id":611952,"organisation":{"id":649520,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100006307","organisationLocationStatus":"Active"},"address":{"addressId":661224,"oneLine":"Via Francesco Sforza 28","addressLine1":"Via Francesco Sforza 28","addressLine2":"","addressLine3":"","addressLine4":"","city":"Milan","postcode":"20122","country":2018,"countryName":"Italy"},"phone":"+390255033918","email":"francesco.viola@unimi.it","isBusinessKeyValidated":true,"businessKey":"ORG-100006307"},"personInfo":{"id":1798028,"firstName":"Francesco","lastName":"Viola","telephone":"+390255033918","email":"francesco.viola@unimi.it","title":"1"},"departmentName":"SC Oculistica - Padiglione Regina Elena"}],"applicationStatusCode":"Authorised"},{"id":247619,"mscId":39622,"mscInfo":{"id":39622,"clinicalTrialId":15935,"countryOrganisationId":2008,"reportingStatusCode":"Authorised","fromDate":"2025-01-07","toDate":"2025-01-07","isProposedRms":false,"expressDecision":"unwilling","countryName":"Czechia","organisationInfo":{},"firstDecisionDate":"2025-02-12","trialStatus":"Authorised","trialPeriod":[{"id":54941,"trialStartDate":"2025-04-15","fromDate":"2025-04-15"},{"id":54942,"trialStartDate":"2025-04-15","fromDate":"2025-04-15"}],"trialRecruitmentPeriod":[{"id":73923,"recruitmentStartDate":"2025-04-15","fromDate":"2025-04-15"},{"id":73924,"recruitmentStartDate":"2025-04-15","fromDate":"2025-04-15"},{"id":81625,"recruitmentStartDate":"2025-04-15","recruitmentEndDate":"2025-06-26","fromDate":"2025-07-08"},{"id":81626,"recruitmentStartDate":"2025-04-15","recruitmentEndDate":"2025-06-26","fromDate":"2025-07-08"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":79300,"trialStartDate":"2025-04-15","fromDate":"2025-04-15"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2025-04-15","recruitmentEndDate":"2025-06-26"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":55156,"mscId":39622,"trialStatus":"Under evaluation","trialStatusDate":"2024-10-03T20:03:11.582"},{"id":76236,"mscId":39622,"trialStatus":"Authorised","trialStatusDate":"2025-02-12T15:47:08.989"}],"applicationTypeMsc":"1","mscName":"Czechia","decision":"authorized","decisionDate":"2025-02-12"},"decisionDate":"2025-02-12","recruitmentSubjectCount":5,"trialSites":[{"id":1685266,"organisationAddressInfo":{"id":613775,"organisation":{"id":651606,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Vseobecna Fakultni Nemocnice V Praze","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100031413","organisationLocationStatus":"Active"},"address":{"addressId":663282,"oneLine":"U Nemocnice 499/2, Nove Mesto","addressLine1":"U Nemocnice 499/2","addressLine2":"Nove Mesto","addressLine3":"","addressLine4":"","city":"Prague","postcode":"128 00","country":2008,"countryName":"Czechia"},"phone":"+420224962985","email":"bohdan.kousal@vfn.cz","isBusinessKeyValidated":true,"businessKey":"ORG-100031413"},"personInfo":{"id":1873570,"firstName":"Bohdan","lastName":"Kousal","telephone":"+420224962985","email":"bohdan.kousal@vfn.cz","title":"1"},"departmentName":"Oční klinika"},{"id":1685267,"organisationAddressInfo":{"id":613772,"organisation":{"id":651603,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Fakultni Nemocnice Kralovske Vinohrady","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100029480","organisationLocationStatus":"Active"},"address":{"addressId":663278,"oneLine":"Srobarova 1150/50, Vinohrady","addressLine1":"Srobarova 1150/50","addressLine2":"Vinohrady","addressLine3":"","addressLine4":"","city":"Prague","postcode":"100 00","country":2008,"countryName":"Czechia"},"phone":"+420776779799","email":"hamouz@gmail.com","isBusinessKeyValidated":true,"businessKey":"ORG-100029480"},"personInfo":{"id":1873571,"firstName":"Jan","lastName":"Hamouz","telephone":"+420776779799","email":"hamouz@gmail.com","title":"1"},"departmentName":"Oftalmologická klinika"},{"id":1685268,"organisationAddressInfo":{"id":613770,"organisation":{"id":651601,"type":"Laboratory/Research/Testing facility","typeCode":"9","name":"Axon Clinical s.r.o.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100044414","organisationLocationStatus":"Active"},"address":{"addressId":663276,"oneLine":"Ostrovskeho 253/3, Smichov","addressLine1":"Ostrovskeho 253/3","addressLine2":"Smichov","addressLine3":"","addressLine4":"","city":"Prague 5","postcode":"150 00","country":2008,"countryName":"Czechia"},"phone":"+420602550843","email":"jan.ernest@axon-clinical.com","isBusinessKeyValidated":true,"businessKey":"ORG-100044414"},"personInfo":{"id":1873572,"firstName":"Jan","lastName":"Ernest","telephone":"+420602550843","email":"jan.ernest@axon-clinical.com","title":"1"},"departmentName":"n/a"}],"applicationStatusCode":"Authorised"},{"id":249214,"mscId":39619,"mscInfo":{"id":39619,"clinicalTrialId":15935,"countryOrganisationId":2027,"reportingStatusCode":"Authorised","fromDate":"2025-01-13","toDate":"2025-01-13","isProposedRms":false,"expressDecision":"unwilling","countryName":"Spain","organisationInfo":{},"firstDecisionDate":"2025-02-11","trialStatus":"Authorised","trialPeriod":[{"id":52756,"trialStartDate":"2025-03-03","fromDate":"2025-03-17"},{"id":52778,"trialStartDate":"2025-03-03","fromDate":"2025-03-17"}],"trialRecruitmentPeriod":[{"id":70696,"recruitmentStartDate":"2025-03-03","fromDate":"2025-03-17"},{"id":70697,"recruitmentStartDate":"2025-03-03","fromDate":"2025-03-17"},{"id":70698,"recruitmentStartDate":"2025-03-03","fromDate":"2025-03-17"},{"id":82000,"recruitmentStartDate":"2025-03-03","recruitmentEndDate":"2025-07-03","fromDate":"2025-07-10"},{"id":82051,"recruitmentStartDate":"2025-03-03","recruitmentEndDate":"2025-07-03","fromDate":"2025-07-10"},{"id":82052,"recruitmentStartDate":"2025-03-03","recruitmentEndDate":"2025-07-03","fromDate":"2025-07-10"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":75165,"trialStartDate":"2025-03-03","fromDate":"2025-03-17"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2025-03-03","recruitmentEndDate":"2025-07-03"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":55161,"mscId":39619,"trialStatus":"Under evaluation","trialStatusDate":"2024-10-03T20:03:11.642"},{"id":76076,"mscId":39619,"trialStatus":"Authorised","trialStatusDate":"2025-02-11T12:15:08.024"}],"applicationTypeMsc":"1","mscName":"Spain","decision":"authorized","decisionDate":"2025-02-11"},"decisionDate":"2025-02-11","recruitmentSubjectCount":27,"trialSites":[{"id":1697661,"organisationAddressInfo":{"id":612751,"organisation":{"id":650321,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Hospital Universitario Miguel Servet","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100041170","organisationLocationStatus":"Active"},"address":{"addressId":662124,"oneLine":"Paseo De Isabel La Catolica 1-3","addressLine1":"Paseo De Isabel La Catolica 1-3","addressLine2":"","addressLine3":"","addressLine4":"","city":"Zaragoza","postcode":"50009","country":2027,"countryName":"Spain"},"phone":"+34976765500","email":"lpablo@unizar.es","isBusinessKeyValidated":true,"businessKey":"ORG-100041170"},"personInfo":{"id":1887302,"firstName":"Luis","lastName":"Pablo Julvez","telephone":"+34976765500","email":"lpablo@unizar.es","title":"1"},"departmentName":"Ophtalmology"},{"id":1697654,"organisationAddressInfo":{"id":612789,"organisation":{"id":650461,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Metavision Arruzafa S.L.","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100051262","organisationLocationStatus":"Active"},"address":{"addressId":662166,"oneLine":"Avenida De La Arruzafa 9","addressLine1":"Avenida De La Arruzafa 9","addressLine2":"","addressLine3":"","addressLine4":"","city":"Cordoba","postcode":"14012","country":2027,"countryName":"Spain"},"phone":"+3495734018","email":"jmcubero@hospitalarruzafa.com","isBusinessKeyValidated":true,"businessKey":"ORG-100051262"},"personInfo":{"id":1887295,"firstName":"Juan Manuel","lastName":"Cubero Parra","telephone":"+3495734018","email":"jmcubero@hospitalarruzafa.com","title":"1"},"departmentName":"Ophtalmology"},{"id":1697662,"organisationAddressInfo":{"id":612750,"organisation":{"id":650320,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Hospital Universitario Virgen De La Macarena","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100041183","organisationLocationStatus":"Active"},"address":{"addressId":662123,"oneLine":"Avenida Del Doctor Fedriani 3","addressLine1":"Avenida Del Doctor Fedriani 3","addressLine2":"","addressLine3":"","addressLine4":"","city":"Sevilla","postcode":"41009","country":2027,"countryName":"Spain"},"phone":"+34650499239","email":"esgusan@hotmail.com","isBusinessKeyValidated":true,"businessKey":"ORG-100041183"},"personInfo":{"id":1887303,"firstName":"Estanislao","lastName":"Gutierrez Sanchez","telephone":"+34650499239","email":"esgusan@hotmail.com","title":"1"},"departmentName":"Ophtalmology"},{"id":1697663,"organisationAddressInfo":{"id":612788,"organisation":{"id":650460,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Bellvitge University Hospital","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100028921","organisationLocationStatus":"Active"},"address":{"addressId":662164,"oneLine":"Carrer De La Feixa Llarga S/N","addressLine1":"Carrer De La Feixa Llarga S/N","addressLine2":"","addressLine3":"","addressLine4":"","city":"L'Hospitalet De Llobregat","postcode":"08907","country":2027,"countryName":"Spain"},"phone":"34932607705","email":"larias@bellvitgehospital.cat","isBusinessKeyValidated":true,"businessKey":"ORG-100028921"},"personInfo":{"id":1887304,"firstName":"Luis","lastName":"Arias Barquet","telephone":"34932607705","email":"larias@bellvitgehospital.cat","title":"1"},"departmentName":"Ophtalmology"},{"id":1697664,"organisationAddressInfo":{"id":612754,"organisation":{"id":650426,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Valles Ophthalmology Research S.L.","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100044368","organisationLocationStatus":"Active"},"address":{"addressId":662127,"oneLine":"Carrer Pedro I Pons 1","addressLine1":"Carrer Pedro I Pons 1","addressLine2":"","addressLine3":"","addressLine4":"","city":"Sant Cugat Del Valles","postcode":"08195","country":2027,"countryName":"Spain"},"phone":"+34937071936","email":"lsararols@omiq.es","isBusinessKeyValidated":true,"businessKey":"ORG-100044368"},"personInfo":{"id":1887305,"firstName":"Laura","lastName":"Sararols Ramsay","telephone":"+34937071936","email":"lsararols@omiq.es","title":"1"},"departmentName":"Ophtalmology"},{"id":1697665,"organisationAddressInfo":{"id":612798,"organisation":{"id":650470,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Clinica Baviera S.A.","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100044889","organisationLocationStatus":"Active"},"address":{"addressId":662178,"oneLine":"Paseo De La Castellana 20","addressLine1":"Paseo De La Castellana 20","addressLine2":"","addressLine3":"","addressLine4":"","city":"Madrid","postcode":"28046","country":2027,"countryName":"Spain"},"phone":"+34911102109","email":"figueroa.marta@outlook.es","isBusinessKeyValidated":true,"businessKey":"ORG-100044889"},"personInfo":{"id":1887306,"firstName":"Marta","lastName":"Suarez de Figueroa","telephone":"+34911102109","email":"figueroa.marta@outlook.es","title":"1"},"departmentName":"Ophtalmology"},{"id":1697658,"organisationAddressInfo":{"id":612784,"organisation":{"id":650456,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Oftalmologia Vistahermosa S.L.","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100044741","organisationLocationStatus":"Active"},"address":{"addressId":662160,"oneLine":"Avenida De La Ilustracion 1, Poligono Industrial De Burjassot","addressLine1":"Avenida De La Ilustracion 1","addressLine2":"Poligono Industrial De Burjassot","addressLine3":"","addressLine4":"","city":"Burjassot","postcode":"46100","country":2027,"countryName":"Spain"},"phone":"+34674757868","email":"robertogallegopinazo@gmail.com","isBusinessKeyValidated":true,"businessKey":"ORG-100044741"},"personInfo":{"id":1887299,"firstName":"Roberto","lastName":"Gallego Pinazo","telephone":"+34674757868","email":"robertogallegopinazo@gmail.com","title":"1"},"departmentName":"Ophtalmology"},{"id":1697656,"organisationAddressInfo":{"id":612787,"organisation":{"id":650459,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Complexo Hospitalario Universitario De Santiago","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100041171","organisationLocationStatus":"Active"},"address":{"addressId":662163,"oneLine":"Calle Choupana Da S/n","addressLine1":"Calle Choupana Da S/n","addressLine2":"","addressLine3":"","addressLine4":"","city":"Santiago De Compostela","postcode":"15706","country":2027,"countryName":"Spain"},"phone":"+34981951757","email":"maria.isabel.fernandez.rodriguez@sergas.es","isBusinessKeyValidated":true,"businessKey":"ORG-100041171"},"personInfo":{"id":1887297,"firstName":"María Isabel","lastName":"Fernández Rodríguez","telephone":"+34981951757","email":"maria.isabel.fernandez.rodriguez@sergas.es","title":"1"},"departmentName":"Ophtalmology"},{"id":1697655,"organisationAddressInfo":{"id":612757,"organisation":{"id":650429,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Hospital Clinico Universitario Lozano Blesa","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100041561","organisationLocationStatus":"Active"},"address":{"addressId":662130,"oneLine":"Avenida De San Juan Bosco 15","addressLine1":"Avenida De San Juan Bosco 15","addressLine2":"","addressLine3":"","addressLine4":"","city":"Zaragoza","postcode":"50009","country":2027,"countryName":"Spain"},"phone":"34976556400","email":"jascaso@gmail.com","isBusinessKeyValidated":true,"businessKey":"ORG-100041561"},"personInfo":{"id":1887296,"firstName":"Francisco Javier","lastName":"Ascaso Puyuelo","telephone":"34976556400","email":"jascaso@gmail.com","title":"1"},"departmentName":"Ophtalmology"},{"id":1697660,"organisationAddressInfo":{"id":612766,"organisation":{"id":650438,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Hospital Universitari Vall D Hebron","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100030781","organisationLocationStatus":"Active"},"address":{"addressId":662140,"oneLine":"Passeig De La Vall D'Hebron 119-129","addressLine1":"Passeig De La Vall D'Hebron 119-129","addressLine2":"","addressLine3":"","addressLine4":"","city":"Barcelona","postcode":"08035","country":2027,"countryName":"Spain"},"phone":"+34674108369","email":"miguelangel.zapata@vallhebron.cat","isBusinessKeyValidated":true,"businessKey":"ORG-100030781"},"personInfo":{"id":1887301,"firstName":"Miguel Angel","lastName":"Zapata Victori","telephone":"+34674108369","email":"miguelangel.zapata@vallhebron.cat","title":"1"},"departmentName":"Ophtalmology"},{"id":1697659,"organisationAddressInfo":{"id":612795,"organisation":{"id":650467,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Institut Catala De Retina S.L.","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100044100","organisationLocationStatus":"Active"},"address":{"addressId":662173,"oneLine":"Calle De La Pau Alcover 67","addressLine1":"Calle De La Pau Alcover 67","addressLine2":"","addressLine3":"","addressLine4":"","city":"Barcelona","postcode":"08017","country":2027,"countryName":"Spain"},"phone":"34932547925","email":"Ignasi.jurgens@icrcat.com","isBusinessKeyValidated":true,"businessKey":"ORG-100044100"},"personInfo":{"id":1887300,"firstName":"Ignasi","lastName":"Jürgens Mestre","telephone":"34932547925","email":"Ignasi.jurgens@icrcat.com","title":"1"},"departmentName":"Ophtalmology"},{"id":1697657,"organisationAddressInfo":{"id":612775,"organisation":{"id":650447,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Hospital Universitario Puerta De Hierro De Majadahonda","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100028532","organisationLocationStatus":"Active"},"address":{"addressId":662149,"oneLine":"Calle De Manuel De Falla 1","addressLine1":"Calle De Manuel De Falla 1","addressLine2":"","addressLine3":"","addressLine4":"","city":"Majadahonda","postcode":"28222","country":2027,"countryName":"Spain"},"phone":"+34911917572","email":"josemaria.ruiz@uclm.es","isBusinessKeyValidated":true,"businessKey":"ORG-100028532"},"personInfo":{"id":1887298,"firstName":"Jose Maria","lastName":"Ruiz Moreno","telephone":"+34911917572","email":"josemaria.ruiz@uclm.es","title":"1"},"departmentName":"Ophtalmology"}],"applicationStatusCode":"Authorised"},{"id":271481,"mscId":39615,"mscInfo":{"id":39615,"clinicalTrialId":15935,"countryOrganisationId":2013,"reportingStatusCode":"Authorised","fromDate":"2025-01-13","toDate":"2025-01-13","isProposedRms":false,"expressDecision":"unwilling","countryName":"Germany","organisationInfo":{},"firstDecisionDate":"2025-04-14","trialStatus":"Authorised","trialPeriod":[{"id":54855,"trialStartDate":"2025-04-09","fromDate":"2025-04-14"},{"id":55018,"trialStartDate":"2025-04-09","fromDate":"2025-04-16"}],"trialRecruitmentPeriod":[{"id":74050,"recruitmentStartDate":"2025-04-09","fromDate":"2025-04-16"},{"id":74068,"recruitmentStartDate":"2025-04-09","fromDate":"2025-04-16"},{"id":74069,"recruitmentStartDate":"2025-04-09","fromDate":"2025-04-16"},{"id":82057,"recruitmentStartDate":"2025-04-09","recruitmentEndDate":"2025-06-25","fromDate":"2025-07-10"},{"id":82058,"recruitmentStartDate":"2025-04-09","recruitmentEndDate":"2025-06-25","fromDate":"2025-07-10"},{"id":81999,"recruitmentStartDate":"2025-04-09","recruitmentEndDate":"2025-06-25","fromDate":"2025-07-10"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":79120,"trialStartDate":"2025-04-09","fromDate":"2025-04-14"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2025-04-09","recruitmentEndDate":"2025-06-25"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":55158,"mscId":39615,"trialStatus":"Under evaluation","trialStatusDate":"2024-10-03T20:03:11.605"},{"id":76175,"mscId":39615,"trialStatus":"Authorised","trialStatusDate":"2025-02-12T09:12:00.759"}],"applicationTypeMsc":"1","mscName":"Germany","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-03-02","decision":"authorized","decisionDate":"2025-04-14"},"decisionDate":"2025-04-14","recruitmentSubjectCount":17,"trialSites":[{"id":1860657,"organisationAddressInfo":{"id":611241,"organisation":{"id":648806,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Universitaetsklinikum Heidelberg AöR","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100013733","organisationLocationStatus":"Active"},"address":{"addressId":660428,"oneLine":"Im Neuenheimer Feld 400, Neuenheim","addressLine1":"Im Neuenheimer Feld 400","addressLine2":"Neuenheim","addressLine3":"","addressLine4":"","city":"Heidelberg","postcode":"69120","country":2013,"countryName":"Germany"},"phone":"+4962215636972","email":"victor.augustin@med.uni-heidelberg.de","isBusinessKeyValidated":true,"businessKey":"ORG-100013733"},"personInfo":{"id":2067780,"firstName":"Victor","lastName":"Augustin","telephone":"+4962215636972","email":"victor.augustin@med.uni-heidelberg.de","title":"1"},"departmentName":"Department für Ophthalmologie"},{"id":1860654,"organisationAddressInfo":{"id":611246,"organisation":{"id":648811,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Augenzentrum Am St Franziskus-Hospital Muenster","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100044485","organisationLocationStatus":"Active"},"address":{"addressId":660433,"oneLine":"Hohenzollernring 74, Herz-Jesu","addressLine1":"Hohenzollernring 74","addressLine2":"Herz-Jesu","addressLine3":"","addressLine4":"","city":"Munster","postcode":"48145","country":2013,"countryName":"Germany"},"phone":"+492519352702","email":"a.lommatzsch@augen-franziskus.de","isBusinessKeyValidated":true,"businessKey":"ORG-100044485"},"personInfo":{"id":2067777,"firstName":"Albrecht","lastName":"Lommatzsch","telephone":"+492519352702","email":"a.lommatzsch@augen-franziskus.de","title":"2"},"departmentName":"N/A"},{"id":1860655,"organisationAddressInfo":{"id":611199,"organisation":{"id":648764,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Diakonie Klinikum Dietrich Bonhoeffer GmbH","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100022351","organisationLocationStatus":"Active"},"address":{"addressId":660381,"oneLine":"Salvador-Allende-Strasse 30, Oststadt","addressLine1":"Salvador-Allende-Strasse 30","addressLine2":"Oststadt","addressLine3":"","addressLine4":"","city":"Neubrandenburg","postcode":"17036","country":2013,"countryName":"Germany"},"phone":"+493957753469","email":"BrinkmannC@dbknb.de","isBusinessKeyValidated":true,"businessKey":"ORG-100022351"},"personInfo":{"id":2067778,"firstName":"Christian Karl","lastName":"Brinkmann","telephone":"+493957753469","email":"BrinkmannC@dbknb.de","title":"1"},"departmentName":"Klinik für Augenheilkunde"},{"id":1860656,"organisationAddressInfo":{"id":611235,"organisation":{"id":648800,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Universitaetsklinikum Bonn AöR","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100009711","organisationLocationStatus":"Active"},"address":{"addressId":660420,"oneLine":"Venusberg-Campus 1, Venusberg","addressLine1":"Venusberg-Campus 1","addressLine2":"Venusberg","addressLine3":"","addressLine4":"","city":"Bonn","postcode":"53127","country":2013,"countryName":"Germany"},"phone":"+4922828715808","email":"frank.holz@ukbonn.de","isBusinessKeyValidated":true,"businessKey":"ORG-100009711"},"personInfo":{"id":2067779,"firstName":"Frank","lastName":"Holz","telephone":"+4922828715808","email":"frank.holz@ukbonn.de","title":"2"},"departmentName":"N/A"},{"id":1860653,"organisationAddressInfo":{"id":611186,"organisation":{"id":648751,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Universitaetsklinikum Tuebingen AöR","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100007980","organisationLocationStatus":"Active"},"address":{"addressId":660368,"oneLine":"Elfriede-Aulhorn-Strasse 7, Nordstadt","addressLine1":"Elfriede-Aulhorn-Strasse 7","addressLine2":"Nordstadt","addressLine3":"","addressLine4":"","city":"Tuebingen","postcode":"72076","country":2013,"countryName":"Germany"},"phone":"+4970712988088","email":"felix.reichel@med.uni-tuebingen.de","isBusinessKeyValidated":true,"businessKey":"ORG-100007980"},"personInfo":{"id":2067776,"firstName":"Felix","lastName":"Reichel","telephone":"+4970712988088","email":"felix.reichel@med.uni-tuebingen.de","title":"1"},"departmentName":"Department für Augenheilkunde"}],"applicationStatusCode":"Authorised"}],"applicationInfo":[{"id":27470,"type":"INITIAL","status":"Authorised","ctNumber":"2024-515022-88-00","trialStatus":"Authorised","submissionDate":"2024-10-03","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-02-10"},"partIIInfo":[{"id":172163,"mscId":39613,"mscInfo":{"id":39613,"mscName":"Austria","countryOrganisationId":2000,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-02-03","decision":"authorized","decisionDate":"2025-02-17","reportingStatusCode":"Authorised","countryName":"Austria","trialStatus":"Authorised","firstDecisionDate":"2025-02-17"},"applicationStatusCode":"Authorised"},{"id":171058,"mscId":39615,"mscInfo":{"id":39615,"mscName":"Germany","countryOrganisationId":2013,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-02-04","decision":"authorized","decisionDate":"2025-04-14","reportingStatusCode":"Authorised","countryName":"Germany","trialStatus":"Authorised","firstDecisionDate":"2025-04-14"},"applicationStatusCode":"Authorised"},{"id":169629,"mscId":39616,"mscInfo":{"id":39616,"mscName":"Hungary","countryOrganisationId":2015,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-02-03","decision":"authorized","decisionDate":"2025-02-13","reportingStatusCode":"Authorised","countryName":"Hungary","trialStatus":"Authorised","firstDecisionDate":"2025-02-13"},"applicationStatusCode":"Authorised"},{"id":171138,"mscId":39617,"mscInfo":{"id":39617,"mscName":"Italy","countryOrganisationId":2018,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-02-03","decision":"authorized","decisionDate":"2025-02-12","reportingStatusCode":"Authorised","countryName":"Italy","trialStatus":"Authorised","firstDecisionDate":"2025-02-12"},"applicationStatusCode":"Authorised"},{"id":171254,"mscId":39619,"mscInfo":{"id":39619,"mscName":"Spain","countryOrganisationId":2027,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-01-21","decision":"authorized","decisionDate":"2025-02-11","reportingStatusCode":"Authorised","countryName":"Spain","trialStatus":"Authorised","firstDecisionDate":"2025-02-11"},"applicationStatusCode":"Authorised"},{"id":172352,"mscId":39620,"mscInfo":{"id":39620,"mscName":"Netherlands","countryOrganisationId":2029,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-02-03","decision":"authorized","decisionDate":"2025-02-10","reportingStatusCode":"Authorised","countryName":"Netherlands","trialStatus":"Authorised","firstDecisionDate":"2025-02-10"},"applicationStatusCode":"Authorised"},{"id":170964,"mscId":39621,"mscInfo":{"id":39621,"mscName":"Poland","countryOrganisationId":2031,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-02-04","decision":"authorized","decisionDate":"2025-02-17","reportingStatusCode":"Authorised","countryName":"Poland","trialStatus":"Authorised","firstDecisionDate":"2025-02-17"},"applicationStatusCode":"Authorised"},{"id":169570,"mscId":39622,"mscInfo":{"id":39622,"mscName":"Czechia","countryOrganisationId":2008,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-02-04","decision":"authorized","decisionDate":"2025-02-12","reportingStatusCode":"Authorised","countryName":"Czechia","trialStatus":"Authorised","firstDecisionDate":"2025-02-12"},"applicationStatusCode":"Authorised"},{"id":164516,"mscId":39623,"mscInfo":{"id":39623,"mscName":"France","countryOrganisationId":2012,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-12-11","decision":"authorized","decisionDate":"2025-03-31","reportingStatusCode":"Authorised","countryName":"France","trialStatus":"Authorised","firstDecisionDate":"2025-03-31"},"applicationStatusCode":"Authorised"}],"decisionDate":"2025-02-10","ctMSCsByApplication":[{"id":39613,"mscName":"Austria","reportingStatusCode":"Authorised"},{"id":39615,"mscName":"Germany","reportingStatusCode":"Authorised"},{"id":39616,"mscName":"Hungary","reportingStatusCode":"Authorised"},{"id":39617,"mscName":"Italy","reportingStatusCode":"Authorised"},{"id":39619,"mscName":"Spain","reportingStatusCode":"Authorised"},{"id":39620,"mscName":"Netherlands","reportingStatusCode":"Authorised"},{"id":39621,"mscName":"Poland","reportingStatusCode":"Authorised"},{"id":39622,"mscName":"Czechia","reportingStatusCode":"Authorised"},{"id":39623,"mscName":"France","reportingStatusCode":"Authorised"}],"businessKey":"IN","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":57705,"applicationId":27470,"mscId":39617,"mscName":"Italy","decisionDate":"2025-02-12T19:13:28.273","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":171138,"part1Id":72165,"applicationType":"INITIAL","isRMS":false},{"id":57871,"applicationId":27470,"mscId":39623,"mscName":"France","decisionDate":"2025-02-13T15:55:29.732","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":164516,"part1Id":72165,"applicationType":"INITIAL","isRMS":true},{"id":58253,"applicationId":27470,"mscId":39621,"mscName":"Poland","decisionDate":"2025-02-17T14:19:08.049","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":170964,"part1Id":72165,"applicationType":"INITIAL","isRMS":false},{"id":57512,"applicationId":27470,"mscId":39615,"mscName":"Germany","decisionDate":"2025-02-12T09:12:02.233","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":171058,"part1Id":72165,"applicationType":"INITIAL","isRMS":false},{"id":57845,"applicationId":27470,"mscId":39616,"mscName":"Hungary","decisionDate":"2025-02-13T14:44:44.916","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":169629,"part1Id":72165,"applicationType":"INITIAL","isRMS":false},{"id":57365,"applicationId":27470,"mscId":39619,"mscName":"Spain","decisionDate":"2025-02-11T12:15:10.203","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":171254,"part1Id":72165,"applicationType":"INITIAL","isRMS":false},{"id":57145,"applicationId":27470,"mscId":39620,"mscName":"Netherlands","decisionDate":"2025-02-10T15:44:41.236","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":172352,"part1Id":72165,"applicationType":"INITIAL","isRMS":false},{"id":57653,"applicationId":27470,"mscId":39622,"mscName":"Czechia","decisionDate":"2025-02-12T15:47:11.948","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":169570,"part1Id":72165,"applicationType":"INITIAL","isRMS":false},{"id":58313,"applicationId":27470,"mscId":39613,"mscName":"Austria","decisionDate":"2025-02-17T15:24:14.979","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":172163,"part1Id":72165,"applicationType":"INITIAL","isRMS":false}]},{"id":50185,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-515022-88-00","trialStatus":"Authorised","submissionDate":"2025-03-07","partI":{"assessmentOutcome":"acceptable"},"partIIInfo":[{"id":188282,"mscId":39615,"mscInfo":{"id":39615,"mscName":"Germany","countryOrganisationId":2013,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-04-11","decision":"authorized","decisionDate":"2025-04-14","reportingStatusCode":"Authorised","countryName":"Germany","trialStatus":"Authorised","firstDecisionDate":"2025-04-14"},"applicationStatusCode":"Authorised"}],"decisionDate":"2025-04-14","ctMSCsByApplication":[{"id":39615,"mscName":"Germany","reportingStatusCode":"Authorised"}],"businessKey":"SM-1","modScope":"PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":66760,"applicationId":50185,"mscId":39615,"mscName":"Germany","decisionDate":"2025-04-14T15:53:55.125","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":188282,"part1Id":77317,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false}]},{"id":50189,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-515022-88-00","trialStatus":"Authorised","submissionDate":"2025-03-07","partI":{"assessmentOutcome":"acceptable"},"partIIInfo":[{"id":188292,"mscId":39616,"mscInfo":{"id":39616,"mscName":"Hungary","countryOrganisationId":2015,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-04-14","decision":"authorized","decisionDate":"2025-02-13","reportingStatusCode":"Authorised","countryName":"Hungary","trialStatus":"Authorised","firstDecisionDate":"2025-02-13"},"applicationStatusCode":"Authorised"}],"decisionDate":"2025-04-16","ctMSCsByApplication":[{"id":39616,"mscName":"Hungary","reportingStatusCode":"Authorised"}],"businessKey":"SM-2","modScope":"PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":67206,"applicationId":50189,"mscId":39616,"mscName":"Hungary","decisionDate":"2025-04-16T09:40:11.115","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":188292,"part1Id":77324,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false}]},{"id":50242,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-515022-88-00","trialStatus":"Authorised","submissionDate":"2025-03-07","partI":{"assessmentOutcome":"acceptable"},"partIIInfo":[{"id":188503,"mscId":39623,"mscInfo":{"id":39623,"mscName":"France","countryOrganisationId":2012,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-03-31","decision":"authorized","decisionDate":"2025-03-31","reportingStatusCode":"Authorised","countryName":"France","trialStatus":"Authorised","firstDecisionDate":"2025-03-31"},"applicationStatusCode":"Authorised"}],"decisionDate":"2025-03-31","ctMSCsByApplication":[{"id":39623,"mscName":"France","reportingStatusCode":"Authorised"}],"businessKey":"SM-3","modScope":"PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":64440,"applicationId":50242,"mscId":39623,"mscName":"France","decisionDate":"2025-03-31T14:30:41.309","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":188503,"part1Id":77419,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true}]},{"id":57987,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-515022-88-00","trialStatus":"Authorised","submissionDate":"2025-06-25","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-09-22"},"partIIInfo":[{"id":238639,"mscId":39620,"mscInfo":{"id":39620,"mscName":"Netherlands","countryOrganisationId":2029,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-09-29","decision":"authorized","decisionDate":"2025-02-10","reportingStatusCode":"Authorised","countryName":"Netherlands","trialStatus":"Authorised","firstDecisionDate":"2025-02-10"},"applicationStatusCode":"Authorised"},{"id":233921,"mscId":39622,"mscInfo":{"id":39622,"mscName":"Czechia","countryOrganisationId":2008,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-09-29","decision":"authorized","decisionDate":"2025-02-12","reportingStatusCode":"Authorised","countryName":"Czechia","trialStatus":"Authorised","firstDecisionDate":"2025-02-12"},"applicationStatusCode":"Authorised"},{"id":233558,"mscId":39615,"mscInfo":{"id":39615,"mscName":"Germany","countryOrganisationId":2013,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-09-24","decision":"authorized","decisionDate":"2025-04-14","reportingStatusCode":"Authorised","countryName":"Germany","trialStatus":"Authorised","firstDecisionDate":"2025-04-14"},"applicationStatusCode":"Authorised"},{"id":224042,"mscId":39619,"mscInfo":{"id":39619,"mscName":"Spain","countryOrganisationId":2027,"assessmentOutcome":"no_conclusion","assessmentOutcomeDate":"2025-08-26","decision":"authorized","decisionDate":"2025-02-11","reportingStatusCode":"Authorised","countryName":"Spain","trialStatus":"Authorised","firstDecisionDate":"2025-02-11"},"applicationStatusCode":"Authorised"},{"id":236365,"mscId":39621,"mscInfo":{"id":39621,"mscName":"Poland","countryOrganisationId":2031,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-09-27","decision":"authorized","decisionDate":"2025-02-17","reportingStatusCode":"Authorised","countryName":"Poland","trialStatus":"Authorised","firstDecisionDate":"2025-02-17"},"applicationStatusCode":"Authorised"},{"id":233559,"mscId":39616,"mscInfo":{"id":39616,"mscName":"Hungary","countryOrganisationId":2015,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-09-29","decision":"authorized","decisionDate":"2025-02-13","reportingStatusCode":"Authorised","countryName":"Hungary","trialStatus":"Authorised","firstDecisionDate":"2025-02-13"},"applicationStatusCode":"Authorised"},{"id":232320,"mscId":39623,"mscInfo":{"id":39623,"mscName":"France","countryOrganisationId":2012,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-08-14","decision":"authorized","decisionDate":"2025-03-31","reportingStatusCode":"Authorised","countryName":"France","trialStatus":"Authorised","firstDecisionDate":"2025-03-31"},"applicationStatusCode":"Authorised"},{"id":237961,"mscId":39613,"mscInfo":{"id":39613,"mscName":"Austria","countryOrganisationId":2000,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-09-22","decision":"authorized","decisionDate":"2025-02-17","reportingStatusCode":"Authorised","countryName":"Austria","trialStatus":"Authorised","firstDecisionDate":"2025-02-17"},"applicationStatusCode":"Authorised"},{"id":238180,"mscId":39617,"mscInfo":{"id":39617,"mscName":"Italy","countryOrganisationId":2018,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-09-27","decision":"authorized","decisionDate":"2025-02-12","reportingStatusCode":"Authorised","countryName":"Italy","trialStatus":"Authorised","firstDecisionDate":"2025-02-12"},"applicationStatusCode":"Authorised"}],"decisionDate":"2025-09-23","ctMSCsByApplication":[{"id":39620,"mscName":"Netherlands","reportingStatusCode":"Authorised"},{"id":39622,"mscName":"Czechia","reportingStatusCode":"Authorised"},{"id":39615,"mscName":"Germany","reportingStatusCode":"Authorised"},{"id":39619,"mscName":"Spain","reportingStatusCode":"Authorised"},{"id":39621,"mscName":"Poland","reportingStatusCode":"Authorised"},{"id":39616,"mscName":"Hungary","reportingStatusCode":"Authorised"},{"id":39623,"mscName":"France","reportingStatusCode":"Authorised"},{"id":39613,"mscName":"Austria","reportingStatusCode":"Authorised"},{"id":39617,"mscName":"Italy","reportingStatusCode":"Authorised"}],"businessKey":"SM-4","modScope":"PART_I_AND_PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":91871,"applicationId":57987,"mscId":39620,"mscName":"Netherlands","decisionDate":"2025-10-02T13:54:46.608","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":238639,"part1Id":98822,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":90964,"applicationId":57987,"mscId":39615,"mscName":"Germany","decisionDate":"2025-09-26T13:10:43.872","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":233558,"part1Id":98822,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":90597,"applicationId":57987,"mscId":39623,"mscName":"France","decisionDate":"2025-09-24T12:32:33.442","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":232320,"part1Id":98822,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true},{"id":91696,"applicationId":57987,"mscId":39621,"mscName":"Poland","decisionDate":"2025-10-01T13:47:39.587","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":236365,"part1Id":98822,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":91745,"applicationId":57987,"mscId":39616,"mscName":"Hungary","decisionDate":"2025-10-01T15:48:15.828","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":233559,"part1Id":98822,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":91366,"applicationId":57987,"mscId":39617,"mscName":"Italy","decisionDate":"2025-09-29T19:48:10.408","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":238180,"part1Id":98822,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":91628,"applicationId":57987,"mscId":39622,"mscName":"Czechia","decisionDate":"2025-10-01T10:26:21.502","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":233921,"part1Id":98822,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":90432,"applicationId":57987,"mscId":39613,"mscName":"Austria","decisionDate":"2025-09-23T13:31:31.61","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":237961,"part1Id":98822,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":90734,"applicationId":57987,"mscId":39619,"mscName":"Spain","decisionDate":"2025-09-25T10:01:39.323","decision":"authorized","assessmentOutcome":"no_conclusion","eventType":"decision","part2Id":224042,"part1Id":98822,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false}]},{"id":66956,"type":"NON SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-515022-88-00","trialStatus":"Authorised","submissionDate":"2025-10-09","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-09-22"},"partIIInfo":[{"id":247619,"mscId":39622,"mscInfo":{"id":39622,"mscName":"Czechia","countryOrganisationId":2008,"decision":"authorized","decisionDate":"2025-02-12","reportingStatusCode":"Authorised","countryName":"Czechia","trialStatus":"Authorised","firstDecisionDate":"2025-02-12"},"applicationStatusCode":"Authorised"}],"decisionDate":"2025-10-09","ctMSCsByApplication":[{"id":39622,"mscName":"Czechia","reportingStatusCode":"Authorised"}],"businessKey":"NSM-1","modScope":"PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":92927,"applicationId":66956,"mscId":39622,"mscName":"Czechia","decisionDate":"2025-10-09T09:37:57.1","decision":"authorized","eventType":"decision","part2Id":247619,"part1Id":103190,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false}]},{"id":67504,"type":"NON SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-515022-88-00","trialStatus":"Authorised","submissionDate":"2025-10-15","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-09-22"},"partIIInfo":[{"id":249214,"mscId":39619,"mscInfo":{"id":39619,"mscName":"Spain","countryOrganisationId":2027,"decision":"authorized","decisionDate":"2025-02-11","reportingStatusCode":"Authorised","countryName":"Spain","trialStatus":"Authorised","firstDecisionDate":"2025-02-11"},"applicationStatusCode":"Authorised"}],"decisionDate":"2025-10-15","ctMSCsByApplication":[{"id":39619,"mscName":"Spain","reportingStatusCode":"Authorised"}],"businessKey":"NSM-2","modScope":"PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":93910,"applicationId":67504,"mscId":39619,"mscName":"Spain","decisionDate":"2025-10-15T19:52:35.578","decision":"authorized","eventType":"decision","part2Id":249214,"part1Id":103986,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false}]},{"id":72593,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-515022-88-00","trialStatus":"Authorised","submissionDate":"2025-12-19","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-03-31"},"partIIInfo":[{"id":271481,"mscId":39615,"mscInfo":{"id":39615,"mscName":"Germany","countryOrganisationId":2013,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-03-02","decision":"authorized","decisionDate":"2025-04-14","reportingStatusCode":"Authorised","countryName":"Germany","trialStatus":"Authorised","firstDecisionDate":"2025-04-14"},"applicationStatusCode":"Authorised"}],"decisionDate":"2026-03-31","ctMSCsByApplication":[{"id":39615,"mscName":"Germany","reportingStatusCode":"Authorised"}],"businessKey":"SM-5","modScope":"PART_I_AND_PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":117480,"applicationId":72593,"mscId":39621,"mscName":"Poland","decisionDate":"2026-04-03T11:31:37.613","decision":"authorized","eventType":"decision","part1Id":121625,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":117006,"applicationId":72593,"mscId":39617,"mscName":"Italy","decisionDate":"2026-03-31T18:15:59.013","decision":"authorized","eventType":"decision","part1Id":121625,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":117086,"applicationId":72593,"mscId":39622,"mscName":"Czechia","decisionDate":"2026-04-01T10:01:00.302","decision":"authorized","eventType":"decision","part1Id":121625,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":117290,"applicationId":72593,"mscId":39615,"mscName":"Germany","decisionDate":"2026-04-02T10:31:12.955","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":271481,"part1Id":121625,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":116959,"applicationId":72593,"mscId":39620,"mscName":"Netherlands","decisionDate":"2026-03-31T15:51:57.294","decision":"authorized","eventType":"decision","part1Id":121625,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":117612,"applicationId":72593,"mscId":39619,"mscName":"Spain","decisionDate":"2026-04-07T08:52:25.414","decision":"authorized","eventType":"decision","part1Id":121625,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":117278,"applicationId":72593,"mscId":39616,"mscName":"Hungary","decisionDate":"2026-04-02T10:02:24.248","decision":"authorized","eventType":"decision","part1Id":121625,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":117430,"applicationId":72593,"mscId":39623,"mscName":"France","decisionDate":"2026-04-02T18:55:34.091","decision":"authorized","eventType":"decision","part1Id":121625,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true},{"id":117599,"applicationId":72593,"mscId":39613,"mscName":"Austria","decisionDate":"2026-04-06T21:07:20.706","decision":"authorized","eventType":"decision","part1Id":121625,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false}]},{"id":93337,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-515022-88-00","trialStatus":"Authorised","submissionDate":"2026-09-02","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-11-09"},"partIIInfo":[],"decisionDate":"2026-11-09","ctMSCsByApplication":[{"id":39620,"mscName":"Netherlands","reportingStatusCode":"Authorised"},{"id":39621,"mscName":"Poland","reportingStatusCode":"Authorised"},{"id":39616,"mscName":"Hungary","reportingStatusCode":"Authorised"},{"id":39623,"mscName":"France","reportingStatusCode":"Authorised"},{"id":39613,"mscName":"Austria","reportingStatusCode":"Authorised"},{"id":39617,"mscName":"Italy","reportingStatusCode":"Authorised"},{"id":39622,"mscName":"Czechia","reportingStatusCode":"Authorised"},{"id":39619,"mscName":"Spain","reportingStatusCode":"Authorised"},{"id":39615,"mscName":"Germany","reportingStatusCode":"Authorised"}],"businessKey":"SM-6","modScope":"PART_I","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":150219,"applicationId":93337,"mscId":39616,"mscName":"Hungary","decisionDate":"2026-11-10T09:50:40.545","decision":"authorized","eventType":"decision","part1Id":142543,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":150647,"applicationId":93337,"mscId":39615,"mscName":"Germany","decisionDate":"2026-11-12T11:20:41.898","decision":"authorized","eventType":"decision","part1Id":142543,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":151014,"applicationId":93337,"mscId":39621,"mscName":"Poland","decisionDate":"2026-11-13T20:00:51.353","decision":"authorized","eventType":"decision","part1Id":142543,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":151048,"applicationId":93337,"mscId":39613,"mscName":"Austria","decisionDate":"2026-11-15T12:45:10.013","decision":"authorized","eventType":"decision","part1Id":142543,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":150081,"applicationId":93337,"mscId":39617,"mscName":"Italy","decisionDate":"2026-11-09T14:31:52.279","decision":"authorized","eventType":"decision","part1Id":142543,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":150064,"applicationId":93337,"mscId":39620,"mscName":"Netherlands","decisionDate":"2026-11-09T13:58:29.405","decision":"authorized","eventType":"decision","part1Id":142543,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":150299,"applicationId":93337,"mscId":39622,"mscName":"Czechia","decisionDate":"2026-11-10T12:37:26.616","decision":"authorized","eventType":"decision","part1Id":142543,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":151241,"applicationId":93337,"mscId":39619,"mscName":"Spain","decisionDate":"2026-11-16T15:26:53.142","decision":"authorized","eventType":"decision","part1Id":142543,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":150011,"applicationId":93337,"mscId":39623,"mscName":"France","decisionDate":"2026-11-09T11:46:32.453","decision":"authorized","eventType":"decision","part1Id":142543,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true}]}],"trialGlobalEnd":[],"memberStatesConcerned":[{"mscName":"Italy","mscId":39617,"firstDecisionDate":"2025-02-12T19:13:28.273","lastDecisionDate":"2026-03-31T18:15:59.013","mscPublicStatusCode":5},{"mscName":"France","mscId":39623,"firstDecisionDate":"2025-02-13T15:55:29.732","lastDecisionDate":"2026-04-02T18:55:34.091","mscPublicStatusCode":5},{"mscName":"Poland","mscId":39621,"firstDecisionDate":"2025-02-17T14:19:08.049","lastDecisionDate":"2026-04-03T11:31:37.613","mscPublicStatusCode":5},{"mscName":"Germany","mscId":39615,"firstDecisionDate":"2025-02-12T09:12:02.233","lastDecisionDate":"2026-04-02T10:31:12.955","mscPublicStatusCode":5},{"mscName":"Hungary","mscId":39616,"firstDecisionDate":"2025-02-13T14:44:44.916","lastDecisionDate":"2026-04-02T10:02:24.248","mscPublicStatusCode":5},{"mscName":"Spain","mscId":39619,"firstDecisionDate":"2025-02-11T12:15:10.203","lastDecisionDate":"2026-04-07T08:52:25.414","mscPublicStatusCode":5},{"mscName":"Netherlands","mscId":39620,"firstDecisionDate":"2025-02-10T15:44:41.236","lastDecisionDate":"2026-03-31T15:51:57.294","mscPublicStatusCode":5},{"mscName":"Czechia","mscId":39622,"firstDecisionDate":"2025-02-12T15:47:11.948","lastDecisionDate":"2026-04-01T10:01:00.302","mscPublicStatusCode":5},{"mscName":"Austria","mscId":39613,"firstDecisionDate":"2025-02-17T15:24:14.979","lastDecisionDate":"2026-04-06T21:07:20.706","mscPublicStatusCode":5}],"eudraCt":{"isTransitioned":false}},"events":{"temporaryHaltList":[],"trialEvents":[{"mscId":39613,"mscName":"Austria","events":[{"notificationType":"START_OF_TRIAL","date":"2025-04-23"},{"notificationType":"START_OF_RECRUITMENT","date":"2025-04-23"},{"notificationType":"END_OF_RECRUITMENT","date":"2025-06-25"}]},{"mscId":39615,"mscName":"Germany","events":[{"notificationType":"START_OF_TRIAL","date":"2025-04-09"},{"notificationType":"START_OF_RECRUITMENT","date":"2025-04-09"},{"notificationType":"END_OF_RECRUITMENT","date":"2025-06-25"}]},{"mscId":39616,"mscName":"Hungary","events":[{"notificationType":"START_OF_TRIAL","date":"2025-04-01"},{"notificationType":"START_OF_RECRUITMENT","date":"2025-04-01"},{"notificationType":"END_OF_RECRUITMENT","date":"2025-06-26"}]},{"mscId":39617,"mscName":"Italy","events":[{"notificationType":"START_OF_TRIAL","date":"2025-04-29"},{"notificationType":"START_OF_RECRUITMENT","date":"2025-04-29"},{"notificationType":"END_OF_RECRUITMENT","date":"2025-06-27"}]},{"mscId":39619,"mscName":"Spain","events":[{"notificationType":"START_OF_TRIAL","date":"2025-03-03"},{"notificationType":"START_OF_RECRUITMENT","date":"2025-03-03"},{"notificationType":"END_OF_RECRUITMENT","date":"2025-07-03"}]},{"mscId":39620,"mscName":"Netherlands","events":[{"notificationType":"START_OF_TRIAL","date":"2025-05-21"},{"notificationType":"START_OF_RECRUITMENT","date":"2025-05-21"},{"notificationType":"END_OF_RECRUITMENT","date":"2025-06-25"}]},{"mscId":39621,"mscName":"Poland","events":[{"notificationType":"START_OF_TRIAL","date":"2025-04-07"},{"notificationType":"START_OF_RECRUITMENT","date":"2025-04-07"},{"notificationType":"END_OF_RECRUITMENT","date":"2025-06-25"}]},{"mscId":39622,"mscName":"Czechia","events":[{"notificationType":"START_OF_TRIAL","date":"2025-04-15"},{"notificationType":"START_OF_RECRUITMENT","date":"2025-04-15"},{"notificationType":"END_OF_RECRUITMENT","date":"2025-06-26"}]},{"mscId":39623,"mscName":"France","events":[{"notificationType":"START_OF_TRIAL","date":"2025-04-28"},{"notificationType":"START_OF_RECRUITMENT","date":"2025-04-28"},{"notificationType":"END_OF_RECRUITMENT","date":"2025-06-26"}]}],"unexpectedEvents":[],"seriousBreaches":[],"urgentSafetyMeasures":[]},"results":{},"documents":[{"title":"K1_ANX007-GA-02_Recruitment-arrangements_NL_English","uuid":"c67274bf-a2bc-4a00-bdd3-7dbcd9294016","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":238639,"manualVersion":"n/a","systemVersion":"2"},{"title":"K2_ANX007-GA-02_Dear-Patient-recruitment-letter_NL_Dutch_Public","uuid":"8a0b25d0-8800-42d8-ae8f-b7fe1bb95e34","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":37,"fileType":"PDF","associatedEntityId":238639,"manualVersion":"1.0","systemVersion":"1"},{"title":"L1_ANX007-GA-02_Imaging-Certification-Volunteer-Participant-ICF_NL_Dutch_Public","uuid":"89b01237-7ab6-48a3-b9f7-a1f6f69b346e","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":37,"fileType":"PDF","associatedEntityId":238639,"manualVersion":"1.0","systemVersion":"2"},{"title":"L1_ANX007-GA-02_Pregnancy-ICF_NL_Dutch_Public","uuid":"b139b368-0e0b-4b6b-8604-88fdd56fcc07","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":37,"fileType":"PDF","associatedEntityId":238639,"manualVersion":"3.0","systemVersion":"4"},{"title":"L1_ANX007-GA-02_SIS-and-ICF_Adults_NL_Dutch_Public","uuid":"b9baa0ad-ab33-4389-9268-b9e901bde100","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":37,"fileType":"PDF","associatedEntityId":238639,"manualVersion":"4.0","systemVersion":"4"},{"title":"K1_ANX007-GA-02_Recruitment-Arrangement_PL_Polish_Public","uuid":"86ffd065-862c-4811-bc25-5ef46a7415ab","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":236365,"manualVersion":"n/a","systemVersion":"3"},{"title":"L1_ANX007-GA-02_Main-ICF_PL_Polish_Public","uuid":"8b87e247-2403-41ee-9ffe-af558374ab5e","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":236365,"manualVersion":"4.0","systemVersion":"4"},{"title":"L2_ANX007-GA-02_Imaging-Certification-Volunteer-ICF_PL_Polish_Public","uuid":"db85d01c-8692-4dbe-893b-f0a407a962ac","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":236365,"manualVersion":"1.0","systemVersion":"1"},{"title":"L2_ANX007-GA-02_PP-ICF_PL_Polish_Public","uuid":"dfa867a8-8254-4dc8-8975-55246c3c9fe3","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":236365,"manualVersion":"3.0","systemVersion":"2"},{"title":"K_ANX007-GA-02_Recruitment Arrangements_Hungary","uuid":"ba6f4eb1-ffe8-4716-a739-8976da2b764e","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":233559,"manualVersion":"n/a","systemVersion":"2"},{"title":"K1_ANX007-GA-02_Dear_Patient_recruitment_letter_HU_Hungarian_clean","uuid":"a718b19f-e944-4824-8b6b-0c24a0f6b2e4","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":13,"fileType":"PDF","associatedEntityId":233559,"manualVersion":"1.0","systemVersion":"1"},{"title":"L1_ANX007-GA-02_Main_ICF_HU_Hungarian_Public","uuid":"ebf31640-0543-4cbd-a7a1-3dfecd6b6f7d","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":13,"fileType":"PDF","associatedEntityId":233559,"manualVersion":"4.0","systemVersion":"5"},{"title":"L2_ANX007-GA-02_List of Part II Documents_HUN_Hungarian_Public","uuid":"8e6f1356-c5d7-4cc3-9492-450de93bb071","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":13,"fileType":"PDF","associatedEntityId":233559,"manualVersion":"n/a","systemVersion":"1"},{"title":"L2_ANX007-GA-02_NtF_PC_HU_Hungarian_Public","uuid":"720926ae-8099-4006-af34-9eb867546cd0","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":13,"fileType":"PDF","associatedEntityId":233559,"manualVersion":"1.0.0","systemVersion":"1"},{"title":"L1_ANX007-GA-02_Pregnant_Particpant_ICF_HU_Hungarian_Public","uuid":"59c2b2f6-5c7f-4402-8d60-8a2c79782423","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":13,"fileType":"PDF","associatedEntityId":233559,"manualVersion":"3.0","systemVersion":"2"},{"title":"L1_ANX007-GA-02_Genetic_ICF_HU_Hungarian_Public","uuid":"82e0eecb-2666-41c6-866b-e2db51d17a2c","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":13,"fileType":"PDF","associatedEntityId":233559,"manualVersion":"2.0","systemVersion":"1"},{"title":"L1_ANX007-GA-02_Imaging_Cert_Volunteer_ICF_HU_Hungarian_Public","uuid":"6ee70e29-38d7-4f7f-99c6-0acd86274d1f","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":13,"fileType":"PDF","associatedEntityId":233559,"manualVersion":"1.0","systemVersion":"2"},{"title":"L1_ANX007-GA-02_Protocol_V2_0_Memo_Procedures_not_applicable_in_Hungary_Public","uuid":"f7398ca4-0812-456e-bd3d-58e2f1ef588a","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":233559,"manualVersion":"n/a","systemVersion":"1"},{"title":"K1_ANX007-GA-02_Recruitment-Arrangements_FR_French_Public","uuid":"056180d4-3701-4920-917f-b3811520e87e","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":232320,"manualVersion":"N/A","systemVersion":"3"},{"title":"K1_ANX007-GA-02_Dear Patient recruitment letter_FR_French_Public","uuid":"47ced5f1-38db-4cf9-b33e-a75f41b60f49","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":232320,"manualVersion":"1.0","systemVersion":"1"},{"title":"L1_ANX007-GA-02_Imaging_Certification_Volunteer_Participant_ICF_FR_French_Public","uuid":"cf5f8fb5-cb62-4a91-8d75-f37f39109386","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":232320,"manualVersion":"1.0","systemVersion":"1"},{"title":"L1_ANX007-GA-02_Main-ICF_FR_French_Public","uuid":"996a1312-8f0e-4f19-b325-9ec52055ce72","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":232320,"manualVersion":"4.0","systemVersion":"4"},{"title":"L1_ANX007-GA-02_Preg-Participant_ICF_FR_French_Public","uuid":"629d8484-cc51-4d2b-8185-5b1e778ac20b","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":232320,"manualVersion":"3.0","systemVersion":"2"},{"title":"L1_ANX007-GA-02_Preg-Partner_ICF_FR_French_Public","uuid":"6041a68e-6049-447d-b8c0-fea51c831f53","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":232320,"manualVersion":"2.0","systemVersion":"1"},{"title":"L2_ANX007-GA-02_Patient_Card_FR_French_Public","uuid":"c86f6735-4cc7-4028-ac4b-fa23db180f69","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":232320,"manualVersion":"1.0.0","systemVersion":"1"},{"title":"K1_ANX007-GA-02_Recruitment-Arrangements_AT_Public","uuid":"9e44ad8e-aba0-4673-b016-af1989864240","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":237961,"manualVersion":"n/a","systemVersion":"3"},{"title":"K1_ANX007-GA-02_Dear-Patient-recruitment-letter_Austria_German_Public","uuid":"f8160cfa-3690-4299-bd25-bacea1ca54e8","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":27,"fileType":"PDF","associatedEntityId":237961,"manualVersion":"1.0","systemVersion":"1"},{"title":"L1_ANX007-GA-02_Imaging Certification Volunteer Participant ICF_Austria_German_Public","uuid":"47c3bd1d-bd1a-4e13-a9c2-fdffed75e61a","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":27,"fileType":"PDF","associatedEntityId":237961,"manualVersion":"1.0","systemVersion":"2"},{"title":"L1_ANX007-GA-02_Main-ICF_AT_German_Clean_Public","uuid":"ccc68c34-990a-4a28-b1be-42b6700205a8","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":27,"fileType":"PDF","associatedEntityId":237961,"manualVersion":"4.0","systemVersion":"4"},{"title":"L1_ANX007-GA-02_Optional-Future-Research-ICF_AT_German_Public","uuid":"607012f6-d661-48a3-9b1a-4815800c0cfc","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":27,"fileType":"PDF","associatedEntityId":237961,"manualVersion":"4.0","systemVersion":"3"},{"title":"L1_ANX007-GA-02_Optional-Genetic-Testing-ICF_AT_German_Public","uuid":"d090ab20-5179-4123-a16a-000b781eb13a","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":27,"fileType":"PDF","associatedEntityId":237961,"manualVersion":"4.0","systemVersion":"3"},{"title":"L1_ANX007-GA-02_Pregnant Participant ICF_AT_German_Clean_Public","uuid":"dc739f5e-ccee-4354-ab7f-763777f09225","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":27,"fileType":"PDF","associatedEntityId":237961,"manualVersion":"3.0","systemVersion":"3"},{"title":"L1_ANX007-GA-02_Reimbursement-ICF_AT_German_Public","uuid":"c8a20cc3-ec01-4556-9217-896306fba8fe","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":27,"fileType":"PDF","associatedEntityId":237961,"manualVersion":"4.0","systemVersion":"3"},{"title":"L2_ANX007-GA-02_SitePatient advocacy_Contact List for ICF_AT_Public","uuid":"a428e5f8-0542-4ae4-900e-9ea100ca4d0a","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":237961,"manualVersion":"n/a","systemVersion":"1"},{"title":"K2_ANX007-GA-02_Recruitment-Procedure_IT_Public","uuid":"7927a1c1-ef9b-4fcb-b42e-c3ccd0ef01d4","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":238180,"manualVersion":"N/A","systemVersion":"2"},{"title":"K2_ANX007-GA-02_GP-letter_IT_Italian_Public","uuid":"7bc113a4-b43b-4e30-92dc-3d3d0c443f33","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":238180,"manualVersion":"2.0","systemVersion":"2"},{"title":"K2_ANX007-GA-02_Dear-Patient-Recruitment-Letter_IT_Italian_Public","uuid":"046485c4-5e29-4688-b3f4-9c2f431243a2","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":238180,"manualVersion":"1.1","systemVersion":"1"},{"title":"L1_ANX007-GA-02_Main-ICF_IT_Italian_Public","uuid":"4b8eee18-6c01-44c8-8480-1ae8146d61fa","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":238180,"manualVersion":"4.0","systemVersion":"5"},{"title":"L1_ANX007-GA-02_Optional-Research-ICF_IT_Italian_Public","uuid":"bc8dfc9e-49f3-4839-bbb1-e53a61342c1f","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":238180,"manualVersion":"4.0","systemVersion":"4"},{"title":"L1_ANX007-GA-02_Pregnancy-ICF_IT_Italian_Public","uuid":"598b72e9-33f6-40a8-986d-a29014ae603a","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":238180,"manualVersion":"3.0","systemVersion":"4"},{"title":"L1_ANX007-GA-02_Volunteer-Eye-Imaging-Collection-ICF_IT_Italian_Public","uuid":"a728fe2d-a255-42e5-beac-5f3e3b70d1fe","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":238180,"manualVersion":"1.0","systemVersion":"3"},{"title":"K1_ANX007-GA-02_Recruitment-Informed-Consent-Procedure_CZE_Public","uuid":"83492795-12f6-4a53-96cf-c845857599e0","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":40,"fileType":"PDF","associatedEntityId":247619,"manualVersion":"N/A","systemVersion":"3"},{"title":"K2_ANX007-GA-02_Patient-letter_CZ_Czech_Public","uuid":"295ab69d-9437-4fa2-8458-cae5bbde0dce","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":2,"fileType":"PDF","associatedEntityId":247619,"manualVersion":"1.0","systemVersion":"1"},{"title":"L1_ANX007-GA-02_Future-Research-ICF_CZ_Czech_Public","uuid":"aebe170b-baa5-4a97-863f-7e00f00b2fb1","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":2,"fileType":"PDF","associatedEntityId":247619,"manualVersion":"4.0","systemVersion":"2"},{"title":"L1_ANX007-GA-02_GDPR-Notice_CZ_Czech_Public","uuid":"ed632de7-71d8-404d-acc7-d8d34fced816","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":2,"fileType":"PDF","associatedEntityId":247619,"manualVersion":"4.0","systemVersion":"2"},{"title":"L1_ANX007-GA-02_Genetic-Testing-ICF_CZ_Czech_Public","uuid":"7e1a2c57-5eba-474a-a943-2e69521fe2d2","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":2,"fileType":"PDF","associatedEntityId":247619,"manualVersion":"4.0","systemVersion":"2"},{"title":"L1_ANX007-GA-02_Imaging-Certification-Volunteer-Participant-ICF_CZE_Czech_Public","uuid":"77db7e23-0c06-47ed-a25d-5dc5f4d00bf8","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":2,"fileType":"PDF","associatedEntityId":247619,"manualVersion":"1.0","systemVersion":"1"},{"title":"L1_ANX007-GA-02_Main-ICF_CZ_Czech_Public","uuid":"36e6049b-8111-4d69-a24a-9f21f709782c","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":2,"fileType":"PDF","associatedEntityId":247619,"manualVersion":"4.0","systemVersion":"4"},{"title":"L1_ANX007-GA-02_Pregnancy-Form_CZ_Czech_Public","uuid":"c27db9de-11de-46aa-b2c5-3f0f335718fa","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":2,"fileType":"PDF","associatedEntityId":247619,"manualVersion":"3.0","systemVersion":"2"},{"title":"L1_ANX007-GA-02_Scout-ICF_CZ_Czech_Public","uuid":"f6542b13-192b-4032-89ed-b8233a5229f3","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":2,"fileType":"PDF","associatedEntityId":247619,"manualVersion":"3.0","systemVersion":"2"},{"title":"L2_ANX007-GA-02_Patient-card_CZ_Czech_Public","uuid":"f3444d79-a6d3-45e2-b029-9f6ab7d81ec7","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":2,"fileType":"PDF","associatedEntityId":247619,"manualVersion":"1.0.0","systemVersion":"1"},{"title":"K1_ANX007-GA-02_Recruitment-Arrangements_ES","uuid":"cb8a70bd-a3a5-4e0a-9d84-fbcda17b5066","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":249214,"manualVersion":"2","systemVersion":"2"},{"title":"K2_ANX007-GA-02_Dear-Patient-Recruitment-Letter_ES_Spanish_Public","uuid":"677087c2-914b-4b0f-ba5a-755f47ce6033","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":249214,"manualVersion":"1.0","systemVersion":"1"},{"title":"L1_ANX007-GA-02_Imaging-Certification-Volunteer-Participant-ICF_ES_Spanish_Public","uuid":"8c41ffe3-57bb-4c98-ab3e-d4515257d93f","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":249214,"manualVersion":"1.0","systemVersion":"2"},{"title":"L1_ANX007-GA-02_Main-ICF_ES_Spanish_Public","uuid":"23d43a5f-a541-4235-923e-8500e2ee35e3","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":249214,"manualVersion":"4.1","systemVersion":"3.01"},{"title":"L1_ANX007-GA-02_Pregnant-Partner-ICF_ES_Spanish_Public","uuid":"4e98b5e1-9602-4013-ab8a-c01581da4a67","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":249214,"manualVersion":"2.0","systemVersion":"2"},{"title":"K1_ANX007-GA-02_Recruitment-Arrangements_DE_Public","uuid":"370a2793-134b-413e-a69e-c0ba471cb41d","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":271481,"manualVersion":"2.0","systemVersion":"2"},{"title":"L1_ANX007-GA-02_Main-ICF_DE_German_Public","uuid":"7d7a9b2b-2396-479d-a6bf-11768e5c1b26","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":29,"fileType":"PDF","associatedEntityId":271481,"manualVersion":"4.0","systemVersion":"4"},{"title":"L1_ANX007-GA-02_Pregnant-Participant-ICF_DE_German_Public","uuid":"91ae437b-ca44-4467-b168-c1d9f01b4ace","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":29,"fileType":"PDF","associatedEntityId":271481,"manualVersion":"3.0","systemVersion":"2"},{"title":"L1_ANX007-GA-02_Reimbursement-ICF_DE_German_Public","uuid":"31c7812a-0321-4c69-9682-94c66ccf402d","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":29,"fileType":"PDF","associatedEntityId":271481,"manualVersion":"4.0","systemVersion":"2"},{"title":"L1_ANX007-GA-02_Future-Research-ICF_DE_German_Public","uuid":"8be2ac68-09d9-487e-b3cd-ce5f22364d04","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":29,"fileType":"PDF","associatedEntityId":271481,"manualVersion":"4.0","systemVersion":"3"},{"title":"L1_ANX007-GA-02_Genetic-Testing-ICF_DE_German_Public","uuid":"577c0e50-b355-4078-90ea-ab9ff42a76f3","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":29,"fileType":"PDF","associatedEntityId":271481,"manualVersion":"2.0","systemVersion":"1"},{"title":"L1_ANX007-GA-02_Imaging-Volunteer-Participant-ICF_DE_German_Public","uuid":"6c3cc42e-50de-4710-89b4-b7b5baae954f","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":29,"fileType":"PDF","associatedEntityId":271481,"manualVersion":"1.0","systemVersion":"1"},{"title":"D1_Annexon_ANX007-GA-02_Protocol_2024-515022-88-00_Public","uuid":"d2a75ff6-f820-4543-bd61-d54ad7bfc389","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":142543,"manualVersion":"9.0","systemVersion":"6"},{"title":"D4_Annexon_ANX007-GA-02_NEI VFQ25-IA_PL_Polish_Public","uuid":"31c82cb2-7e65-43c5-b7db-be187fa44a5e","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":142543,"manualVersion":"AU2.0","systemVersion":"1"},{"title":"D4_Annexon_ANX007-GA-02_NEI VFQ25-IA_NL_Dutch_Public","uuid":"ab3dcbcd-bfdc-45bd-a6db-02c722f1f570","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":37,"fileType":"PDF","associatedEntityId":142543,"manualVersion":"AU2.0","systemVersion":"1"},{"title":"D4_Annexon_ANX007-GA-02_NEI VFQ25-IA_IT_Italian_Public","uuid":"95944310-bb48-4d90-8f1d-19f3bde3c891","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":142543,"manualVersion":"AU2.0","systemVersion":"1"},{"title":"D4_Annexon_ANX007-GA-02_NEI VFQ25-IA_HU_Hungarian_Public","uuid":"8ef2cdb0-7410-458a-b9d3-1d59e6916a2d","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":13,"fileType":"PDF","associatedEntityId":142543,"manualVersion":"AU2.0","systemVersion":"1"},{"title":"D4_Annexon_ANX007-GA-02_NEI VFQ25-IA_FR_French_Public","uuid":"4f729e87-f57f-4b30-bd96-60a12f7369ab","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":142543,"manualVersion":"AU2.0","systemVersion":"1"},{"title":"D4_Annexon_ANX007-GA-02_NEI VFQ25-IA_ES_Spanish_Public","uuid":"8631488b-e53a-4932-9ef4-dc88ad2af703","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":142543,"manualVersion":"AU2.0","systemVersion":"1"},{"title":"D4_Annexon_ANX007-GA-02_NEI VFQ25-IA_English_Public","uuid":"7a73b71a-2b35-4397-9480-3c29d14f66b9","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":142543,"manualVersion":"AU2.0","systemVersion":"1"},{"title":"D4_Annexon_ANX007-GA-02_NEI VFQ25-IA_DE_German_Public","uuid":"c3ebb061-eced-46de-ab28-10c11b61e3a7","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":29,"fileType":"PDF","associatedEntityId":142543,"manualVersion":"AU2.0","systemVersion":"1"},{"title":"D4_Annexon_ANX007-GA-02_NEI VFQ25-IA_CZ_Czech_Public","uuid":"69e74c08-2363-42e7-8f9a-1def9fcf04bf","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":2,"fileType":"PDF","associatedEntityId":142543,"manualVersion":"AU2.0","systemVersion":"1"},{"title":"D4_Annexon_ANX007-GA-02_NEI VFQ25-IA_AT_German_Public","uuid":"39d8f4a5-9b3c-432c-9c0f-ae5a7be67309","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":27,"fileType":"PDF","associatedEntityId":142543,"manualVersion":"AU2.0","systemVersion":"1"},{"title":"D1_Annexon_ANX007-GA-02_Protocol Memorandum_Public","uuid":"f21a890d-f2f4-498a-9efe-2cb9143ba0a1","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":142543,"manualVersion":"N/A","systemVersion":"1"},{"title":"D1_Annexon_ANX007-GA-02_Protocol SOC_2024-515022-88-00_Public","uuid":"020eb262-5579-4c24-b95b-65520b9b23c9","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":142543,"manualVersion":"9.0","systemVersion":"1"},{"title":"D1_Annexon_ANX007-GA-02_Protocol-synopsis_2024-515022-88-00_CZ_Czech_Public","uuid":"3498c0c6-1699-4622-ac0e-1f8ddd9b3bdd","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":2,"fileType":"PDF","associatedEntityId":142543,"manualVersion":"9.0","systemVersion":"6"},{"title":"D1_Annexon_ANX007-GA-02_Protocol Synopsis_2024-515022-88-00_PL_Polish_Public","uuid":"81e9c23a-31cb-4f2f-9676-e12c78e055aa","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":142543,"manualVersion":"9.0","systemVersion":"6"},{"title":"D1_Annexon_ANX007-GA-02_Protocol Synopsis_2024-515022-88-00_AT_DEU_Public","uuid":"b50c4505-d79f-4c70-85b3-e4129473b3b5","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":27,"fileType":"PDF","associatedEntityId":142543,"manualVersion":"9.0","systemVersion":"6"},{"title":"D1_Annexon_ANX007-GA-02_Protocol Synopsis_2024-515022-88-00_NL_Dutch_Public","uuid":"e406bf56-d8a1-427d-bb05-8486b59b159f","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":37,"fileType":"PDF","associatedEntityId":142543,"manualVersion":"9.0","systemVersion":"6"},{"title":"D1_Annexon_ANX007-GA-02_Protocol Synopsis_2024-515022-88-00_IT_Italian_Public","uuid":"a015ccbd-fee5-4628-b6e2-3f3e67b188c3","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":142543,"manualVersion":"9.0","systemVersion":"6"},{"title":"D1_Annexon_ANX007-GA-02_Protocol Synopsis_2024-515022-88-00_FR_French_Public","uuid":"eab74abe-3209-435a-961b-076185868c74","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":142543,"manualVersion":"9.0","systemVersion":"6"},{"title":"D1_Annexon_ANX007-GA-02_Protocol Synopsis_2024-515022-88-00_ES_Spanish_Public","uuid":"f264e125-be73-405d-abb6-6348f0e8dae4","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":142543,"manualVersion":"9.0","systemVersion":"6"},{"title":"D1_Annexon_ANX007-GA-02_Protocol Synopsis_2024-515022-88-00_Public","uuid":"63012e24-3e27-4c46-b59c-fb6c8feb1554","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":142543,"manualVersion":"9.0","systemVersion":"6"},{"title":"D1_Annexon_ANX007-GA-02_Protocol Synopsis_2024-515022-88-00_HU_Hungarian_Public","uuid":"4b6652b5-753b-449a-9663-26f578c4b4db","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":13,"fileType":"PDF","associatedEntityId":142543,"manualVersion":"9.0","systemVersion":"6"},{"title":"D1_Annexon_ANX007-GA-02_PLPS_2024-515022-88-00","uuid":"ef8662b2-b85d-4da1-9889-b8d5e25f8e60","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":142543,"manualVersion":"7.0","systemVersion":"6"},{"title":"D1_Annexon_ANX007-GA-02_PLPS_2024-515022-88-00_DEU_AT","uuid":"92b207c8-6957-4180-9729-8d1a92d3ef3b","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":27,"fileType":"PDF","associatedEntityId":142543,"manualVersion":"7.0","systemVersion":"6"},{"title":"D1_Annexon_ANX007-GA-02_PLPS_2024-515022-88-00_DEU_DE","uuid":"5d71c5d2-c9eb-453b-9195-94c0b02cdfb0","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":29,"fileType":"PDF","associatedEntityId":142543,"manualVersion":"7.0","systemVersion":"6"},{"title":"D1_Annexon_ANX007-GA-02_PLPS_2024-515022-88-00_FRA","uuid":"a6dd2333-127a-4db5-bbe6-3e0f782eeaec","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":142543,"manualVersion":"7.0","systemVersion":"6"},{"title":"D1_Annexon_ANX007-GA-02_PLPS_2024-515022-88-00_CZE","uuid":"d060ea33-5268-49c6-9262-e273372da75c","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":2,"fileType":"PDF","associatedEntityId":142543,"manualVersion":"7.0","systemVersion":"6"},{"title":"D1_Annexon_ANX007-GA-02_PLPS_2024-515022-88-00_DUT_NL","uuid":"e28a35d6-8434-48f3-a998-64ce944b9fc8","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":37,"fileType":"PDF","associatedEntityId":142543,"manualVersion":"7.0","systemVersion":"6"},{"title":"D1_Annexon_ANX007-GA-02_PLPS_2024-515022-88-00_HUN","uuid":"e9f58b75-ca7e-4211-87f0-11526c92b250","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":13,"fileType":"PDF","associatedEntityId":142543,"manualVersion":"7.0","systemVersion":"6"},{"title":"D1_Annexon_ANX007-GA-02_PLPS_2024-515022-88-00_ITA","uuid":"cc173ea3-0919-4581-85d6-ab649ce69cb7","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":142543,"manualVersion":"7.0","systemVersion":"6"},{"title":"D1_Annexon_ANX007-GA-02_PLPS_2024-515022-88-00_POL","uuid":"277ad61d-ecde-49d1-9447-dc9c3014bab8","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":142543,"manualVersion":"7.0","systemVersion":"6"},{"title":"D1_Annexon_ANX007-GA-02_PLPS_2024-515022-88-00_SPA","uuid":"a65647a7-9693-4716-bb94-4bb945db1ea6","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":142543,"manualVersion":"7.0","systemVersion":"6"}],"trialRegion":"Both","trialRegionCode":3,"correctiveMeasures":[]}